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ABSTRACT 
 
 Early detection cancer associated biomarker is believed to improve the prognosis 
outcome of oral cancer by allowing for early treatment. However, discovery of potential 
oral cancer biomarkers in sera is like looking for a needle in haystack due to the large 
dynamic range in the concentration of serum protein. Therefore, a study secretome of 
established cell lines is proposed to bypass such obstacle to discover those secreted 
biomarkers from tumor mass. Most oral cancer biomarkers discovery researches on 
secreteome of cell lines lacks normal cell lines as control. In this study, several normal 
primary cultures (316N, 317N, 322N, 326N) were successfully established without 
hTERT immortalization. By comparison the proteomes of cancer cell lines (48T, 153T, 
H400) and normal primary cultures using 2D gel electrophoresis, 31 protein identities 
were recognized have changed in abundance in the cancer cell lines secretome. 
Bioinformatic analysis of these proteins showed that all identified proteins were 
possibly secreted in either a signal dependant pathway or golgi independent pathways. 
The analysis also demonstrated that their expression dynamics were relevant to cancer 
progression. A concomitant qPCR validation of selected proteins transcript levels 
demonstrated that metalloproteinase VII (MMP-7), heterogeneous nuclear 
ribonucleoprotein A2/B1 (HNRNPA2/B1), peroxiredoxin-1 (PRDX1), tissue inhibitor 
metalloproteinase-1 (TIMP1), laminin beta 3 (LAMB3), interleukin-1 receptor 
antagonist (IL1RN), calcium binding protein S100-A8 (S100A8), and Secreted protein, 
acidic, cysteine-rich (SPARC) were significantly differential expressed (p=0.05) and 
worthwhile for further investigation. With further studies, these proteins may be 
developed into potential diagnostic and prognostic marker candidates for oral cancer.  
ii 
ABSTRAK 
 Biopenanda pengesanan barah awal dapat memanjangkan hayat pesakit barah 
mulut kerana rawatan pada peringkat awal barah adalah lebih berkesan. Walaupun 
begitu, penemuan biopenanda barah mulut yang berada di dalam serum adalah amat 
mencabar kerana protein serum wujud dalam julat dinamik yang amat besar. Untuk 
mengatasi masalah tersebut, pengajian rembesan protein sel selanjar dicadangkan 
sebagai pendekatan alternatif bagi meningkatkan kebarangkalian menemui biopenanda 
yang dirembeskan daripada barah mulut. Walaubagaimanapun, kekurangan sel selanjar 
yang sebagai kawalan dihadapi oleh kebanyakan penyelidikan. Oleh itu, beberapa sel 
selanjar normal (316N, 317N, 322N, 326N) dan berjangka hayat pendek tanpa “ hTERT 
immortalization” telah berjaya ditumbuhkan dalam kajian ini. Berdasarkan 
perbandingan gambar gel 2D rembesan protein antara sel selanjar barah mulut (48T, 
153T, H400) dan sel selanjar normal, sebanyak 31 jenis protein telah ditemukan. 
Kuantiti protein sel barah tersebut adalah berbeza daripada sel normal secara ketara. 
Berpandukan kepada analisis bioinformatik, semua protin-protein yang dikenalpastikan 
berkemungkinan dirembeskan mengikut laluan yang berdasarkan isyarat peptida 
ataupun laluan lain yang baru. Analisis tersebut juga menunjukkan perubahan ekspresi 
protein-protein tersebut adalah berkaitan dengan perkembangan barah mulut. 
Pengesahan ekspresi gen telah dilakukan menggunakan “real-time PCR” dan 
pengesahan tersebut telah menunjukkan bahawa “metalloproteinase VII” (MMP-7), 
“heterogeneous nuclear ribonucleoprotein A2/B1” (HNRNPA2/B1), “peroxiredoxin-1” 
(PRDX1), “tissue inhibitor metalloproteinase-1” (TIMP-1), “laminin beta 3” (LAMB3), 
“interleukin-1 receptor antagonist” (IL1RN), “calcium binding protein S100-A8” 
(S100A8), dan “Secreted protein, acidic, cysteine-rich” (SPARC) adalah berbeza 
kuantiti antara normal dan barah secara ketara (p = 0.05) dan bernilai untuk siasatan 
selanjutnya. Dengan kajian yang lebih lanjut, protein-protein ini berpotensi untuk 
iii 
diketengahkan sebagai calon protein biopenanda diagnostik dan prognostik bagi kanser 
mulut.  
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1.1 Introduction: 
Oral cancer is the 16
th
 most common cancer worldwide. The age-standardized 
incidence and mortality in Malaysia are approximately 3.5 and 1.5 per 100,000 people 
annually (Ferlay et al. 2010). No significant improvement of incidence and mortality of 
oral cancer has been observed in Malaysia over several decades since a report by 
Hirayama in 1966 (Hirayama 1966). Inadequate public awareness of enumerated risk 
factors of oral cancer in Malaysia was believed to account for such dismal statistic. 
Exposure to risk factors such as betel quid chewing, tobacco smoking and alcohol 
consumption may increase the odds of oral cancer development in an individual. 
The five-year survival rate of oral cancer is particularly low at stage III and IV 
due to regional lymph node metastasis, local recurrence and secondary cancer 
occurrence which render current therapies ineffective. Unfortunately, most oral cancer 
patients in Malaysia were diagnosed at their advanced stage (Greene et al. 2002). In 
contrast, patients diagnosed at stage I and II have higher survival rate. Thus, an alternate 
strategy to improve prognosis of oral cancer is early detection (Greene et al. 2002; 
Etzioni et al. 2003). 
 In the context of early-detection of oral cancer, precancerous lesions in oral 
cavity namely leukoplakia and erythroplakia are ubiquitously used by dental professions 
as early markers (Kramer et al. 1978). Visual examination of the oral cavity has to be 
performed regularly for early-detection. However, it is impractical and inefficient to 
regularly screen a large group of people. Unaided oral examination also has relatively 
lower sensitivity and specificity compared to other visually accessible cancers such as 
skin melanoma. Low sensitivity and specificity of oral cancer early-detection may lead 
to overdiagnosis and more false-negative findings (Lingen et al. 2008). In addition, 
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mistakes in diagnosis, delays in obtaining biopsy report, and asymptomatic of 
precancerous lesions may cause delays in administering therapies. This may provide 
more time for transformation of indolent tumor into lethal malignant cancer (Khoo et al. 
1996). As a result, there is a pressing need for identifying new diagnostic aids such as 
serological biomarkers to assist dental practitioners in making definitive diagnosis and 
screening efficiently in a non-invasive way.   
Discovery of cancer serological biomarkers are being extensively performed by 
researchers worldwide due to its accessibility and direct reflection of real-time body 
status. Cancer serological biomarker identification works are initiated based on a 
paradigm that these aberrantly expressed protein biomarkers are secreted and shed or 
leaked from tumor masses into bodily fluids or the blood stream (Lescuyer et al. 2007). 
This family of proteins is termed as the cancer secretome. This subproteom 
encompasses extracellular proteins implicated in anti-apoptosis, adhesion and 
deadhesion, migration, extracellular matrix (ECM) remodeling, angiogenesis, immune 
escape and limitless replication which confer plasticity and immortality to tumor cells 
(Xue et al. 2008). As a result, studying the cancer secretome in serum or plasma should 
improve the likelihood to discover cancer associated biomarkers candidates.  
Serum or plasma is a good source of secreted proteins for proteomics study due 
to its accessibility and homogeneity of protein composition. However, serum 
proteomics is made difficult by the large dynamic range of serum protein concentration. 
In other words, secreted proteins of cancerous tissues which are low in quantity will be 
masked by abundant proteins derived from other tissue sources. Such “masking effect” 
render cancer secreted proteins undetectable (Xue et al. 2008). In order to bypass such 
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issues, studying secretome derived from established cancer cell lines is an alternative 
strategy.  
Cancer cell lines originated from different anatomic site have distinct molecular 
expression pattern (Severino et al. 2008). Thus, cancer cell lines and their normal 
counterparts studied by gel-based proteomics in this report were derived from the same 
anatomic site. This selection constraint may improve result consistency and specificity 
of biomarker candidates by minimizing molecular heterogeneity of anatomic sub site. 
Gel-based proteomics used in this project involved two-dimensional gel electrophoresis 
coupled with tandem mass spectrometry. Potential biomarker candidates identified in 
this study will have to be further validated for their accuracy as diagnostic or prognostic 
markers. By understanding their roles in carcinogenesis may help us to gain more 
insight in oral cancer development. It is also important that they may be potential 
therapeutic targets for oral cancer drug discoveries.   
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1.2  Objectives 
 
 The objectives of this project are:  
 Identifying differentially expressed proteins in the secretome of cultured 
oral cancer cell lines.  
 Validating their expression dynamics by real-time PCR.  
 
Those differential expressed proteins are potential to be the oral cancer 
biomarker candidates or therapeutic targets. The study of their expression 
dynamics may eventually improve our understanding of the oral cancer 
progression.  
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2.1 Epidemiology of Oral Cancer in Malaysia 
 There are 3.5 oral cancer patients for every 100,000 Malaysians in a year and 
approximately 1.5 oral cancer patients are deceased within 100,000 Malaysian annually 
(Ferlay et al. 2010). Retrospectively, a study conducted by Hirayama et al reported that 
3.1 new cases were estimated per 100,000 persons in Malaysia for the year 1963 
(Hirayama 1966). Obviously, a downtrend of oral cancer incidence in Malaysia is still 
unseen in over a half century even though numerous researches on oral cancer have 
been carried out worldwide. 
 Between the years from 2003 to 2005, the National Cancer Registry, Malaysia 
documented age-standardized incidence of mouth cancer for Indian male and female at 
Peninsular Malaysia were 4.4 and 14.5 respectively. It is followed by Chinese male and 
female, 1.3 and 0.6 respectively. Malay male and female had the lowest age-
standardized incidence rates that were 0.7 and 0.8 respectively. Furthermore, Indian 
male and female had the highest age-standardized incidences of tongue cancer that were 
6.0 and 4.9 respectively. Chinese and Malays were ranked second and third in the age-
standardized rate of tongue cancer (Lim et al. 2008).  
 For the year 2006, Malaysian Cancer Statistics demonstrated that age-
standardized rate of mouth cancer in Indian male and female groups were still lingering 
higher at 2.4 and 11.5 respectively. Whereas, age-standardized incidence of mouth 
cancer in Malay and Chinese ethnic groups are remain stable as in the previous years. 
The estimated age-standardized incidence of tongue cancer for both sexes was 1.3 cases 
per 100,000 persons.  The Indian ethnic group was still ranked top among other races in 
the incidence of tongue cancer (Ariffin et al. 2010).  
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 In the year 2007, the Malaysian Cancer Statistics categorized lip, tongue and 
mouth cancer under same category, namely oral cancer. Its statistical results indicated 
the Indian male and female ethnic groups were predominantly inflicted by oral cancer 
where their age-standardized incidence rates were 3.8 and 10.2 respectively. The 
National Cancer Registry report 2007 also reported the distribution of diagnosed oral 
cancer patients based on their tumor staging. It demonstrated that the number of stage 
IV oral cancer patients accounted for 44.6% of total oral cancer patients in Malaysia, 
followed by stage II, III, and I, as shown in Figure 2.1 (Ariffin and Saleha 2011).  
 Collectively, oral cancer incidence ratio of male and female groups is 
approximately 1:1. However, it has to be noted that the Indian female group has a 
higher incidence rate of mouth cancer than the male group. This may be associated with 
Indian females more frequently indulging in betel quid chewing (Tan et al. 2000). All 
these statistics and studies substantiate an apparent association between ethnic 
background and prevalence of oral cancer in Malaysia (Ramanathan and Lakshimi 1976; 
Ng et al. 1985).  
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Figure 2.1: Distribution of stage at diagnosis of oral cancer at Malaysia 2007. Source 
of reference: Ariffin, O. Z., & Saleha, I. T. N. (2011) National Cancer Registry Report: 
Malaysia Cancer Statistics - Data and Figure 2007. Ministry of Health, Malaysia. 
 
2.2 Etiology of Oral Cancer 
 With the Indians and the indigenous people of Sabah and Sarawak being the 
most vulnerable group, it is likely that the variation in incidence rates among 
populations is due to differences in predisposing factors such as aging, low intake of 
fruit and vegetable, tobacco smoking, alcohol consumption, and quid chewing 
(R.B.Zain and N.Ghazali 2001).  
 A close association between betel quid chewing and oral cancer has been 
recognized for many years. A cohort study in Taiwan by Shiu M. N. et al demonstrated 
that betel quid chewers were 26 times more likely to develop leukoplakia – a 
precancerous lesion compared to control subjects. Their report also indicated that betel 
quid chewers has a higher likelihood of  malignancy transformation compared to 
individuals exposed to other etiologic factors (Shiu et al. 2000). In a case-control study 
conducted by Hirayama in Kuala Lumpur for the year 1963, it was shown that heavy 
quid chewers in the cancer group were more than the control group. This result 
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suggested that the heavy quid chewers have a higher risk of developing oral cancer 
(Hirayama 1966).  
 In addition, two retrospective studies of case series with a total 1643 cases over 
two time periods 1967 – 1972 and 1978 – 1984 at the Institute of Medical Research 
(IMR), Malaysia further supported the association between prevalence of oral cancer 
and betel-quid chewing. It was also observed that the most prevalent site of oral cancer 
was the buccal mucosa for quid chewers (R.B.Zain and N.Ghazali 2001). A cohort 
study by Tan B. S. at six Malaysian estates showed that the quid chewing habit is 
mainly initiated by family and friends. It also reported that mixing tobacco and lime in 
betel quid are associated with higher occurrences of precancerous lesions (Tan et al. 
2000). With respect to carcinogens, the basic ingredient of betel-tobacco quid areca nut, 
betel-leaf, slaked lime and tobacco has been implicated as the causative agents in oral 
carcinogenesis. The alkaloid and polyphenolic constituents in the areca nut and betel 
leaf are analogous to DNA alkylating agents. Nitrosamine, a notorious carcinogen can 
be produced from the reaction of betel arecoline, nitrites, and thiocyanate in vivo. 
Slaked limes in the quid aid in oral carcinogenesis by promoting the release of free 
alkaloids from the betel quid (Awang 1988).  
 The link between tobacco consumption and oral cancer has been firmly 
established for many decades with substantial epidemiological studies (R.B.Zain 2001). 
Tobacco consumption is widely practiced among Malaysian people. In the years 1993 - 
1994, a nationwide cancer survey reported that a prevalence of 23.2 % of current 
smokers who are aged 25 years old and above. While, a prevalence of 24.8% was 
reported for current smokers aged 18 and above for the year 1996 (R.B.Zain and 
N.Ghazali 2001). The major carcinogenic compounds in cigarette smoke are 
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nitrosamine and benzopyrene which are implicated in DNA adduct formation in a cell 
(Silverman 1998).  
 Alcohol consumption is another etiological factor for oral cancer. However, the 
prevalence of alcohol consumption in Malaysians is relatively low compared to other 
risk factors due to ethnic and religious sensitivities. A survey conducted in 1996 among 
non-Muslims showed a 23% prevalence of alcohol drinkers in Malaysia. The Indians 
accounted for the large proportion of alcohol drinkers in Malaysia (approximately 13%), 
followed by the indigenous people of Sabah and Sarawak; (10%) and the Chinese; 
(7.8%) (R.B.Zain and N.Ghazali 2001). The synergistic effect of alcohol consumption 
and tobacco smoking has been demonstrated in many studies from different countries 
(R.B.Zain 2001). It potentiates the carcinogenic effect of tobacco at every level of 
tobacco use. In this respect, alcohol may render the oral mucosa more vulnerable to 
carcinogens (Silverman 1998). It is further supported by a study using an in-vitro model 
of porcine oral mucosa to demonstrate that ethanol enhanced the penetration of N-
nitrosornonicotine (a tobacco associated carcinogen) across oral mucosa (Du et al. 
2000).  
 Environmental factors are also risk factors in developing oral cancer. These 
include humanpapilloma virus (HPV) infection, Candida species fungal infection, UV 
exposure, poor oral hygiene, medical immunosuppression, and syphilis (Kumar and 
R.B.Zain 2004). Notably, HPV infection has been associated with several anogenital 
and non-anogenital cancers (such as uterine cervix cancer, head and neck squamous cell 
carcinomas). Their cancer inducing ability is largely attributed to their E6/E7 
oncoproteins which are able to disrupt retinoblastoma protein and degrade p53 leading 
to uncontrollable cell growth. Among the hundreds of types of HPV, HPV-16 is the 
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most frequently found in the majority of OSCC followed by HPV-18 (Munoz et al. 
2006). Studies in Malaysia demonstrated that HPV infection is significantly associated 
with oral cancer and there is a low risk of vertical transmission from women with 
cervical cancer to their children (Saini et al. 2010; Saini et al. 2011). Environmental risk 
factors of oral cancer can be avoided by understanding the cancer associated virus 
transmission routes and maintaining personal hygiene. As a result, frequent exposure to 
such risk factors may contribute to a higher chance for oral cancer developing in an 
individual.  
 
2.3  Oral cancer and Prognosis 
 Oral cancer is clinically defined as malignant lesion within oral cavity. The 
mucosal surface of the oral cavity is divided into eight subsites that are the mucosal lip, 
buccal mucosa, lower alveolar ridge, upper alveolar ridge, retromolar gingival, floor of 
the mouth, hard palate, and anterior two-third of the tongue. Most cancerous oral cells 
originate from the oral squamous epithelium cell which is the primary surface structure 
of the lips and mucous membrane of the oral cavity (Sugerman and Savage 1999). 
Furthermore, OSCC has been histologically characterized as irregular nests, columns or 
malignant epithelial cells which was infiltrating subepithelially to surrounding tissue 
such as the subepithelial connective tissue, adipose tissue, muscle, vascular spaces, bone 
or neural bundle (R.B.Zain and N.Ghazali 2001). Abnormalities of oral cancerous cells 
are the result of several consecutive genetic mutations.  
 The genetic progression model of epithelial carcinogenesis is widely adopted to 
demonstrate oral carcinogenesis. It begins with a persistent and stepwise accumulation 
of mutation inside the cells. By clonal selection of viable cells which have accumulated 
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genetic damages, normal mucosa cells ultimately evolve into malignant mucosa cells 
over an indefinite period (Califano et al. 1996b). The developing of malignant oral 
mucosa cells is life-threatening and always lead to a poor prognosis. 
 The prognosis of oral cancer is highly affected by the location, stage, and grade 
of neoplastic tissue. The tumor stage is an important prognosis predictor. According to 
the American Joint Committee on Cancer (AJCC), the 5-year survival rate for oral 
cancer is as follows in descending order of survival rate: stage I, 65 to 70%; stage II, 50 
to 55%; stage III, 38 to 44%; and stage IV, 25 to 29% (Greene et al. 2002). The 
histological grade of oral cancer does have independent prognostic value. Grade I, II, 
and III of tumor mass are termed as well, moderately, and poorly-differentiated. Poorly-
differentiated tumors have a poorer prognosis overall than well-differentiated, with a 
higher propensity of lymph node metastasis. Five-year survival rates of well-
differentiated, moderately differentiated, and poorly differentiated tumors are reported 
as follows: grade I, 54 to 80%; grade II, 41 to 62%; grade III, 29 to 70% (Kademani et 
al. 2005).  
 Besides tumor staging and grade, biomarkers are also emerging as valuable 
prognostic markers. Numerous studies have shown the prognostic significance of 
different biomarkers in tissues, which include p53, p27, Ki-67, and proliferating cell 
nuclear antigen (Bettendorf et al. 2004). Low survival rate of stage III and stage IV oral 
cancer is mostly due to regional lymph node metastasis and high recurrence incidence 
leading to ineffectiveness of current treatment modalities and regimes. As a result, a 
conceivable strategy to eradicate oral cancer is early detection of oral cancer followed 
by effective treatments at its early stage. 
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2.4 Oral Pre-cancer and Malignant Transformation 
  Fortunately, benign oral precancer lesions are visible in the oral cavity. Its good 
visibility offers a chance for early detection of oral cancer. Oral cancer is commonly 
preceded by oral precancer which is defined as „a morphologically altered tissue in 
which cancer is more likely to occur than in its apparently normal counterpart‟ (Kramer 
et al. 1978). Well-recognized oral precancer lesions and conditions that are associated 
with malignant potential include leukoplakia, erythroplakia, lichen planus and 
submucous fibrosis.  
 Oral leukoplakia is defined as a white plaque that cannot be scraped off in the 
oral cavity (Kramer et al. 1978). Oral erythroplakia normally appears as a well-
dermacated red plaque with a soft, bright-red, velvety texture. Oral lichen planus is an 
autoimmune, T-cell mediated condition that gives rise to the accumulation of 
lymphocyte beneath basal keratinocytes and hyperkeratosis (Lodi et al. 2005). Oral 
submucous fibrosis is an irreversible, chronic disease with the earliest symptom being 
burning sensation while eating spicy foods followed by blanching and hardening of the 
mucosa resulting in restriction of mouth opening (Pundir et al. 2010). Oral leukoplakia 
is more common than erythroplakia while erythroplakia is prone to develop into 
invasive carcinoma (Reichart and Philipsen 2005). All types of precancerous lesions 
aforementioned are intermediate steps towards transformation into malignant lesions.  
 Generally, oral precancer malignant transformation rate varied from 14% to 50% 
with weighted average 26.3% in the studies follow-up less than 2 years and more than 
10 years (Reichart and Philipsen 2005). Oral erythroplakia has the highest potential of 
malignant transformation compared to other precancerous lesions and conditions 
(Reichart and Philipsen 2005). A review of recent studies showed that the malignant 
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transformation rate of oral leukoplakia was varied from 8.9 to 17.5% (Neville and Day 
2002). A 7.6% malignant transformation rate of oral submucous fibrosis was observed 
over a 17-year period (Murti et al. 1985). The transformation rate of oral Lichen Planus 
was estimated to be 1% over 5 years (Lodi et al. 2005). Understanding of 
transformation rate of clinically distinct lesions may facilitate clinicians to better weigh 
the benefit and risk of treatments of cancer patients.  
 
2.5  Diagnosis and Early Detection of Pre-malignant Lesions  
 Early detection of any pre-cancerous and early malignant oral lesions by visual 
examination is more clinically feasible and practical. This is because the easy 
accessibility of the oral cavity and the apparent clinical presentation of premalignant 
lesions. However, a tissue biopsy of precancerous lesions with a gold standard 
histopathologic review is strictly required for the evaluation of oral dysplasia or 
invasive carcinoma in order to make a definitive diagnosis.  
 Several adjuvant diagnostic aids have been used to assist in visual recognition 
and detection of oral mucosa precancerous lesion sites in the oral cavity. These aids 
include toludine blue staining, oral brush biopsy (OralCDx), ViziLite, and oral 
autofluorescent. Toludine blue stains the DNA and RNA and therefore dysplastic and 
malignant cells that contain higher quantities of DNA and RNA are preferentially 
stained dark blue. OralCDx enables dentists to obtain exfoliated dysplastic tissues that 
are covered underneath a thick layer of keratin from a suspected site. With the ViziLite 
kit, chemiluminescent light is used to inspect the oral cavity of patients in a dimly lit 
room after mouth washing with acetic acid. Abnormal lesions which are highly 
keratinized will appear white while normal mucosa should appear dark. Oral 
 Literature Reviews 
14 
Chapter 2 
autofluorescent is a novel technology that examines the autofluorescent signals emitted 
from biomolecules in cells particularly NADH and FAD molecules. Dysplastic 
epithelial cells which lack of NADH and FAD activities will emit less autofluorescent 
signal compared to normal cells resulting in abnormal lesions appearing dark (Patton et 
al. 2008; Jerry et al. 2010).  
  With the mentioned early-detection technologies, a declining of incidence and 
mortality rate of oral cancer is still not significantly observed in Malaysia. In addition, 
most patients with oral cancer are diagnosed when they are already at the advanced 
stage where prognosis is generally bad (Ariffin and Saleha 2011). This is perhaps due to 
the delay in diagnosis of oral cancer. The reasons for the delays in diagnosis have been 
studied by Khoo SP. at five specialist centres in Malaysia from 1994 – 1995. The results 
showed that asymptomatic premalignant lesions and delays in obtaining biopsy reports 
are the main reasons for late diagnosis (Khoo et al. 1996). Therefore, it is essential to 
educate people with regards to the characteristics of oral premalignant lesions and 
plausible risk factors of oral cancer (Neville and Day 2002). Furthermore, there is a 
pressing need to identify reliable molecular factors which are able to diagnose oral 
cancer early and requires a shorter time for analysis. These biomarkers has been 
suggested as the risk factors for determining the malignant transformation rate of oral 
premalignant lesions in order to aid clinicians planning the management strategies and 
therapies for their oral precancer patients (Lozada-Nur 2009).  
  However, early detection of cancer may unintentionally lead to overdiagnosis 
which is a diagnosed condition that would not go on to cause death or symptoms 
(depicted in Figure 2.2). Raising diagnostic threshold of cancer screening has been 
proposed to mitigate overdiagnosis (Welch and Black 2010). It is believed that a new 
 Literature Reviews 
15 
Chapter 2 
insight in cancer associated molecular markers will ultimately allow us to accurately 
predict tumor behavior and thus address overdiagnosis.  
 
Figure 2.2: Tumor size increasing along cancer progression timeline. Early detection of 
cancer below tumor size at which cancer causes symptoms may lead to overdiagnosis 
(dotted line). This is because those cancers may grow very slowly till their host death 
from other causes or they never grow to cause cancer symptoms and even regress 
afterward. Source of reference: Welch, H. G., & Black, W. C. (2010). Overdiagnosis in 
cancer. J Natl Cancer Inst 102(9): 605-13. 
 
2.6 Early Cancer Molecular Markers  
 Biomarkers can be derived from DNA, RNA, or proteins. Nucleic acid based 
markers which are freely circulating in bodily fluids are worthwhile for screening. 
Cancer associated gene mutations are primary targets as early cancer markers such as 
TP53 mutation. Mutation of TP53 has been used in tracking the status of head and neck 
cancer lymph node metastasis (Sidransky 2002). Moreover, loss of heterozygosity or 
microsatellite instability was examined in head and neck squamous cell carcinoma 
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(HNSCC) primary tumors and saliva samples and at least one of the alteration markers 
has been detected in  86% of primary tumors and 79% of saliva samples (Nawroz et al. 
1996). DNA methylation which is involved in silencing tumor suppressor genes has also 
been detected in saliva samples of oral cancer (Rosas et al. 2001). HPV infection has 
been shown to be associated with oral cancer initiation as well. Hence, detection of 
HPV DNA provides an alternative strategy for early marking of risky groups (Sidransky 
2002).  
 Although carcinogenesis is always due to genomic mutations, examination of 
the proteome gives more crucial information than analysis of nucleic acids or the 
genome independently (Banks and Selby 2003). Therefore, protein biomarkers may be 
more useful in predicting the invasiveness and occurrence of cancer. In theory, 
differential expression of proteins can be predicted from the analysis of the 
transcriptome or translatome in response to internal and external events due to the fact 
that proteins are translated from mRNA. However, there is a discrepancy when 
comparing the results of transcriptomic and proteomic analyses of human cancer.  
 Due to the fact that proteins are the biologically functional end-units of the 
genome, a study of the proteome should provide more meaningful insights into cell 
interaction and signaling in cancer. Moreover, proteins undergo posttranslational 
modifications and proteolytic cleavage upon translation and transcription from RNA 
and DNA. These modifications are not reflected in the genome and transcriptome. Thus, 
proteomic analysis is more useful in identifying biomarkers (Mlynarek et al. 2007).  
 By proteomic approaches, a number of potential protein biomarkers for oral 
cancer have been identified and they include telomerase, Mac-2 binding protein and 
MAGED4B which were over-expressed in OSCC tissues (Califano et al. 1996a; Weng 
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et al. 2008; Chong et al. 2012). These protein markers may have specific roles in 
carcinogenesis to promote cancer cell growth and survival. Therefore, when a cell is 
aberrantly expressing these protein biomarkers, it would be an omen of cancer 
transformation and initiation.  
 
2.7 Cancer Molecular Biology and Tumor Microenvironment 
 Irreversible genetic mutations induced by carcinogens or viruses in a single cell 
are a cornerstone of cancer initiation. Subsequent cancer proliferation with accumulated 
genetic mutations and more epigenetic changes promote cancer progression and further 
hyperplasia. Ultimately, localized cancer cells evolve into malignant cancer 
endangering the host‟s life. Cancer development and progression are regulated stepwise 
through activating oncogenes and silencing of tumor suppressor genes. Oncogenic 
proteins such as platelet derived growth factor (PDGF), epidermal growth factor 
receptor (EGFR), Ras proteins, c-myc transcription factor, and bcl-2 antiapoptotic 
proteins promote cancer cells to proliferate indefinitely while repress cell senescence 
and apoptosis. Moreover, deregulation of tumor suppressor genes such as hMSH2, RB 
proteins, and p53 resulting in more genetic instability, uncontrolled cell proliferation, 
and evasion of programmed cell death (Wong et al. 1996; Bertram 2001).  
 Cancer cell hyperproliferation and immortalization are fundamental in cancer 
transformation. Loss of cell cycle control is the key step leading to hyperproliferation 
independent of growth signals. Deregulation of cell cycle associated proteins such as 
KIP family (p21, p27, p57), INK4 family (p16, p15, p18, p19), cyclin D1, Ras proteins 
and RB proteins causes cancer cells undergo unlimited mitosis via unguarded restriction 
point (R) of the cell cycle and transit from G1 to S phase rather than rest in G0 phase. 
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Proliferation of cancer cells is also enhanced by over-expression of mitogenic factors 
such as PDGF and epidermal growth factor (EGF) (Roussel 1999; Bertram 2001; 
Greene et al. 2002).  
 As the size of tumor increase due to cancer cells proliferation, size expansion 
may cause the tumor to suffer from a hypoxic condition which can limit the cancer cell 
growth. This condition is especially prominent at the centre of the tumor mass. However, 
oxygen supply can be made available by formation of new blood vessels inside the 
tumor mass. Tumor secretion of angiogenic factors such as vascular endothelial growth 
factor (VEGF) and fibroblast growth factor (FGF) is vital for the stimulation sprouting 
of new blood vessel formation from nearby blood vessels towards the centre of tumor 
mass (Carmeliet and Jain 2000).  
 When the normal cells replication numbers reach a critical limit, they are 
preordained for cell apoptosis or are cell cycle arrested. Such phenotype was first coined 
by Hayflick and thus termed as the “Hayflick limit” (Hayflick 1965). The loss of 
replicative potential of normal cells has been attributed to telomere shortening with each 
subsequent cell doubling. The telomere is a repeated 5‟-TTAGGG-3‟ hexanucleotide 
sequence with a t-loop end at the terminal of chromosomes. This telomeric sequence 
confers protective effects on chromosome ends from being recognized as damaged 
DNA or DNA double-strand breaks which may lead to programmed cell death and 
senescence. In order to preserve the replicative potential of cancer cells, immortalized 
cancer cells have developed a special cellular mechanism to maintain their telomere 
length and chromosome stability by expressing telomerase reverse transcriptase or via 
homologous recombination between chromosome ends (Chiu and Harley 1997). 
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Maintaining telomere length has been proved important in breast and colon cancer cell 
growth (Hahn et al. 1999).  
 Programmed cell death or apoptosis is a fail-safe mechanism to eradicate normal 
cells which have irreparable DNA damage from surviving and transforming into cancer 
cells. One particular tumor suppressor gene, p53 has been intensely studied in its role in 
the activation of apoptosis by inducing mitochondrial release of cytochrome c into the 
cytosolic space. Unleashed cytochrome c molecules cluster to Apaf1-procaspase 9 
complexes resulting in activation of diverse caspase protease family members. These 
caspase proteases degrade all intracellular proteins or activate other apoptotic-associated 
proteins (Amaral et al. 2010). Moreover, a p53-independent apoptosis pathway can be 
initiated via death receptors known as FasR/CD95R , TNF receptor and Trail receptor. 
When their respective ligands bind to receptors, a downstream signaling pathway 
activates caspase 8 which in turn perforate the mitochondria to release cyctochrome c 
into the cytosol. Therefore, most cancer cells lose their wild-type p53 function via gene 
mutation, downregulation of death receptors, and overexpression of decoy death 
receptors to evade apoptosis (Ozoren and El-Deiry 2003). In addition, overexpressed 
apoptosis inhibitors such as Bcl-2 and Mdm-2 show synergistic effect on cancer cells to 
improve their survival and become more apoptosis resistant (Iwakuma and Lozano 2003; 
Amaral et al. 2010).  
 Cancer cells dissemination is a fatal progression. It involves cellular morphology 
alterations and motility enhancements. Initially, cancer cells undergo epithelial to 
messenchymal transition (EMT) to be more invasive and mobile (Huber et al. 2005). 
This is followed by intravasation where the cancer cells penetrate through the basement 
membrane of blood vessels and diffuse into the blood stream for transportation to a 
 Literature Reviews 
20 
Chapter 2 
distinct site. When the cancer cells are arrested in the capillaries of a new site, the 
cancer cells begin to migrate across the slit of endothelial membrane of blood vessel 
into the remote secondary site. Nevertheless, several barriers will be encountered during 
cancer dissemination. Such obstacles are immune surveillance in blood stream and 
blockade of extracellular adhesion molecules leading to inefficiency in cancer 
metastasis. Hence, the tumor microenvironment plays a vital part in facilitating cancer 
metastasis and improving its metastasis efficiency (Chambers et al. 2002).  
 In order to evade T-cell mediated immunity, major histocompatibility complex 
(MHC) membrane proteins of cancer cells are down-regulated. By contrast, expression 
of MHC surrogates in cancer cells are up-regulated to inhibit natural killer cell 
cytotoxicity which is elicited by “missing self” cells phenotype (Igney and Krammer 
2002). Cancer cells and its neighboring cells like fibroblast and stromal cells secrete a 
diverse variety of protease families like matrix metalloproteases (MMPs), a disintegrin 
and metalloproteases (ADAMs), serine proteases, cathepsin cystein proteases into the 
tumor microenvironment. These proteases degrade adhesion molecules and extracellular 
matrix components including laminin, collagen, and fibrin that impede the movement of 
metastatic cancer cells. Additionally, cleaved fragments of extracellular matrix will 
become stimulators of angiogenesis. Degradation of ECM may also lead to liberation of 
trapped growth factors such as FGF and VEGF into the tumor microenvironment for 
sustaining growth and facilitating angiogenesis (Chambers et al. 2002; Bogenrieder and 
Herlyn 2003; Friedl and Alexander 2011). Therefore, studying the proteome of tumor 
microenvironment may provide insights on their roles in cancer metastasis as well as 
discovers any potential diagnostic and therapeutic protein targets.  
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2.8 Secretome-based Proteomics  
 Secretome of cancer cells is an integral part of the tumor microenvironment. The 
term "secretome" was first proposed by Tjalsma et al. in a genome-based survey on 
secreted proteins of Bacillus subtilis (Gronborg et al. 2006). The secretome refers to 
secreted peptides or proteins which include enzymes and the extracellular matrix protein 
components. They are expressed from only about one-tenth of the human genome. 
These extracellular peptides or proteins can be trafficked out via exosome, endosomal 
recycling, actively protein transport, flip-flop mechanism, or classical signal-peptide 
dependent pathway (depicted in Figure 2.3). Shedding of the ectodomain of 
transmembrane protein from cancer cells introduces more complexity into the cancer 
secretome protein profile. This is interesting that some cancer associated intracellular 
proteins are transported out into the cancer secretome while their exact function in 
carcinogenesis remain elusive  (Karagiannis et al. 2010).  
 The cancer secreted proteins are likely growth factors, ECM remodeling 
molecules, cytokines or other bioactive molecules which are vital in the differentiation, 
proliferation, metastasis and angiogenesis of cancers. For example, they may include 
propably osteopontin, galectin-3, transforming growth factor-β (TGF-β), and matrix 
metalloproteinase (Xue et al. 2008; Mbeunkui and Johann 2009). As this group of 
proteins has an essential relationship with carcinogenesis, there will be a high likelihood 
of uncovering novel biomarkers in the cancer secretome.  
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Figure 2.3: Protein secretory pathways. Source of reference: Karagiannis, G. S., 
Pavlou, M. P., & Diamandis, E. P. (2010). Cancer secretomics reveal 
pathophysiological pathways in cancer molecular oncology. Mol Oncol 4(6): 496-510. 
 
2.9 Challenges in Resolving the Cancer Secretome from Plasma 
 Secreted protein biomarkers for cancer proteomic analysis can be obtained from 
a number of sources such as cancer cell lines, human tissues, and body fluids such as 
plasma (Chen and Yates 2007). Plasma proteomics is an attractive approach to discover 
any potential secreted biomarkers which reflects the status of the body instantly. In 
addition, it is also the most accessible sample from patients (Omenn et al. 2005). 
However, plasma is very complex and this creates problems when attempting to 
perform a proteomics based analysis. The large dynamic concentration range of up to 12 
orders of magnitude for plasma proteins, as depicted in Figure 2.4 masks the lower 
Classical signal peptide  
dependent pathway 
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abundance proteins. It is particularly so for secreted proteins which are low abundance 
and are present in below microgram per milliliter concentration. This introduces a major 
challenge in performing a comprehensive plasma proteome analysis (Anderson and 
Anderson 2002). The most widely used proteomics approach, 2D gel electrophoresis 
(2DE) has a range of detection of not more than 3 orders of magnitude. Thus, it is 
unable to resolve low abundance proteins which are located below the lower limit of its 
detectable range (Omenn et al. 2005).  
 As a result, removal of high abundance proteins is an important step to reveal 
the low abundance proteins in the sample. High abundance proteins in plasma can be 
removed through enrichment steps such as the use affinity columns. However, this 
lowers the screening efficiency due to possible nonspecific binding of proteins to the 
column itself (Yocum et al. 2005). Furthermore, albumin (the most abundant protein in 
the plasma) is a carrier protein and thus removal of this protein may cause loss of 
valuable information in the form of proteins that may be removed along with the 
removal of albumin. 
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Figure 2.4: Plasma protein abundance range with reference interval for 70 protein 
analytes. This graph is plotted on a log scale spanning 12 order of magnitude. Source of 
reference: Anderson, N. L., & Anderson, N. G. (2002). The human plasma proteome: 
history, character, and diagnostic prospects. Mol Cell Proteomics 1(11): 845-67. 
 
2.10 Strategy for Bypassing the Problem of Plasma Proteins Dynamic Range in 
Proteomics 
 Due to the limitations of plasma proteomics that has been described here, a 
comparison of secreted protein patterns in human cancer tissue with their normal 
counterparts can be employed to overcome these limitations. However, the amount of 
human tissues and inherent variations among individual patients can be limiting factors 
for clinical proteomic studies. As a result, a study of the secretome using human tissue 
must be carefully manipulated to differentiate true clinical differences in protein 
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expression from variation in sample collection, experimental condition, and normal 
biological variability (Chen and Yates 2007). This makes such a study complex and 
time consuming. 
 Alternatively, cancer cell lines can be used as a surrogate in the study of the 
cancer secretome. Cancer cell lines originated from different anatomic site have distinct 
molecular expression pattern leading to poor therapy outcome (Severino et al. 2008). In 
order to minimize molecular heterogeneity of cell lines from different anatomic sites, 
cancer cell lines from the same anatomic site were selected as studying subjects in this 
project.  As cancer cell lines are cultured under controlled conditions, they exhibit a 
high degree of homogeneity of samples and provide a large amount of sample. However, 
cancer cell lines may undergo genotypic and phenotypic drifts during the process of cell 
culture due to clonal selection. Therefore, it will be necessary to perform validation for 
in vivo physiological relevance. In the validation process, immunoassays which are 
based on specific antibody and antigen reaction are commonly employed. This is due to 
its higher sensitivity and specificity to detect low abundance promising secreted 
biomarkers which may be present in the bloodstream and interstitial fluid of cancer 
tissues (Xue et al. 2008). While, real-time quantitative PCR can be carried out for 
preliminary biomarkers verification due to its lower cost and high sensitivity. 
 The major barriers to this surrogate strategy are difficulties in establishing the 
primary culture of normal epidermal keratinocytes from the resected normal mucosa 
tissues. This is in part due to the unsustainable growth of normal primary culture and 
their limited lifespan. Additionally, it is necessary to limit the degree of cell lysis as the 
cancer cell lines are an in vitro model and contamination of cytosolic proteins during 
cell lysis will contribute towards an inaccurate view of the secretome. Nevertheless, 
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cytosolic and nuclear proteins may also naturally be transported into extracellular space 
from microvesicular bodies (known as exosome), cell leakages and apoptotic blebs 
which exhibit pleiotropic biological functions during cell growth (Mathivanan et al. 
2010). As a result, some cytosolic and nuclear proteins may combine with classical 
secreted proteins giving rise to a distinct version of the secretome. Despite these 
limitations, secretome preliminary studies using cancer cell lines is relatively lower cost, 
easy-to-use, and is an unlimited sample sources compared to using human tissues (Chen 
and Yates 2007).   
 
2.11 Gel-Based Proteomics 
 Gel-based proteomics coupled with mass spectrometry is usually employed in 
the analysis of complex mixtures of secreted proteins from cancer cell lines. Two 
dimensional gel electrophoresis which was developed in mid 1970‟s (O'Farrell 1975) is 
used in resolving hundreds to thousands of heterogeneous proteins in a single 
polyacrylamide gel. It is based on the isoelectric point of proteins to separate them by 
using immobilized pH gel gradients. This is followed by sodium dodecyl sulfate – 
polyacrylamide gel electrophoresis (SDS PAGE) to further separate the proteins on the 
basis of their molecular weight. As a result, a map of protein spots can be visualized in a 
single gel where each spot represents a different protein, different isoforms of the same 
protein, or its post-translational modifications upon staining (Alessandro et al. 2005). 
Subsequently, identification of differentially expressed proteins is performed by tandem 
mass spectrometry. With this technology, tryptic peptides of digested protein spot are 
sorted based on their mass to charge ratio in a mass spectrum. Each detected tryptic 
peptide mass will be subsequently fragmented by collision-induced dissociation (CID) 
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individually. This will generate a fragmented ions mass spectrum which is 
representation for a unique type of protein. The protein identity can be deduced by 
matching this spectrum with theoretical spectrum in a well-established database (Xue et 
al. 2008).    
 However, it has several pitfalls such as potential difficulties in the identification 
of proteins with extreme isoelectric points or molecular weight, and low sensitivity in 
the detection of low abundance proteins and hydrophobic membrane proteins. In 
addition, this technique is time-consuming and labor-intensive (Monteoliva and Albar 
2004). A modified 2DE method, differential in-gel electrophoresis (DIGE) reduces 
experimental variations but it still has several shortcomings such as the fact that it is 
inapplicable for proteins without lysine residues (Xue et al. 2008).  In spite of these 
inherent pitfalls, two-dimensional gel electrophoresis coupled to mass spectrometry is 
still a robust and reliable approach in preliminary discovery of potential biomarkers.  
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3.1 Normal Tissues Collection and Establishment of Normal Primary Culture 
3.1.1  Materials: 
Extraction media (10 mL DMEM-F12 medium, 10% FBS, 200 iu/mL penicillin, 200 
µg/mL streptomycin and fungizone, 5 µg/mL) 
Absolute ethanol 
Phosphate Buffer Saline  
Keratinocyte serum free media (KSFM, Invitrogen) containing 200 iu/ml penicillin, 200 
µg/ml streptomycin, 0.4 ng/ml epithelial growth factors (EGF), 25 µg/ml bovine 
pituitary extract (BPE) and 30 µM calcium chloride 
Trypsin type III (Sigma) 
3.1.2 Methods: 
 Normal tissues were derived from surgically resected tissue specimens from 
different impacted tooth patients at the Dental Faculty and University Malaya Medical 
Centre, Kuala Lumpur Hospital. Informed consent was obtained from all normal tissue 
donors prior to surgery. This project was approved by the Medical Ethics Committee, 
Faculty of Dentistry, University Malaya and endorsed by the Ministry of Health, 
Malaysia (Medical Ethics Clearance no. DF OP1006/0041(P)). Information regarding 
the donors and from which the primary cultures were derived are tabulated in Table 3.1. 
Tissues were collected in 30-mL extraction media immediately upon excision of the 
normal tissues. 
 The tissues were soaked in absolute ethanol for 20~30 seconds followed by 
washing twice with PBS under sterile conditions. It was incubated in 2.5 mL of 1% 
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trypsin type III PBS containing 200 iu/mL penicillin and 200 µg/mL streptomycin at 
4°C for 16 hour and then incubated at 37°C for 30 minutes. Five millliters of DMEM-
F12 with 10% FBS was added and the mixture was pipetted vigorously to disaggregate 
the cells in the tissues. The cells were then pelleted at 3000 rpm and washed in PBS 
twice at 1000 rpm for 10 minutes. Subsequently, the cell pellets were re-suspended in 
KSFM and seeded into 25 cm
2
 culture flasks (Hamid et al. 2007). Epidermal 
keratinoctyes were selectively grown from 4 individual tissues using protocols above. 
Subsequently they were cultured into 4 primary cultures (316N, 317N, 322N, 326N) 
with maximum 4 to 6 passage numbers only for the secretome studies. In addition, they 
are derived from the same anatomic site (mouth gum) to reduce molecular heterogeneity 
among the samples in comparative proteomic studies. 
 
Table 3.1: Details of donors for normal primary cultures 
Normal Primary 
Culture 
Age Gender Race Anatomic site Risk habits 
316N 34 Female Malay Gum None 
317N 26 Female Chinese Gum None 
322N 27 Female Malay Gum None 
326N  26 Male Malay Gum Smoking 
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3.2 MTT Viability Test on Cancer Cell Lines for Treatment of Serum-free 
Media  Over 24 and 48 Hours Incubation 
3.2.1 Materials: 
DMEM-F12 medium (Invitrogen) 
Fetal bovine serum (FBS) 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
Incubator for cell cultures 
Plate reader 
Dimethyl sulfoxide (DMSO) 
3.2.2 Methods: 
 Cancer cell lines were preferred to be studied due to their cell clonal 
homogeneity. Two well-established oral cancer cell lines, 48T and 153T were selected 
from the oral cancer cell lines depository of Cancer Research Initiative Foundation 
(CARIF) as study subjects. Another selected oral cancer cell line, H400 was a kind gift 
from Professor Stephen Prime, University of Bristol. The details for cancer cell lines are 
tabulated in Table 3.2. Cultured cell passage numbers of 48T, 153T, and H400 used for 
this study were 26, 25, and 28 respectively. With such moderately low passage numbers 
of cell lines, genetical or phenotypical drift of cell lines perhaps would be very little and 
negligible.  
 Approximately 5000 cells were seeded in each well of a 96-well plate. All wells 
with seeded cells were incubated in DMEM-F12 medium with 10% fetal bovine serum 
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for 18 hours. The media of each well was then replaced with serum free media and 
incubated for 24 hours and 48 hours respectively. Following the incubation period, 
serum free media was discarded and 20 µL of MTT was added into the well for 4 hours 
in a 5% CO2 incubator. MTT was then removed and 100 µL DMSO subsequently added. 
Absorbance of each well was read using a plate reader at 575 nm. 
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Table 3.2:  Details of cancer cell lines been studied 
Cancer 
cell lines 
(passage 
numbers) 
Age Gender Race 
Anatomic 
site 
Clinical 
TNM 
(stage) 
Pathologic 
TNM 
(stage) 
Risk 
habits 
48T        
(26) 
77 Female Sikh Gum - 
T4N2aMx
a)
 
(IV) 
None 
H400 
(25) 
55 Female Caucasian Gum 
T2N0M0
b)
 
(II) 
-  
*Paan 
Chewer; 
smoking 
153T 
(28) 
36 Male Indian Gum 
T4N2aM0
c)
 
(IV) 
T4N2bM0
d)
 
(IV) 
Smoking 
 
Footnotes of Table 3.2: 
a) Tumor invades adjacent structures; Metastasis in single ipsilateral lymph node; 
Presence of distant metastasis cannot be assessed 
b) Tumor size more than 2 cm and less than 4 cm; No regional lymph node 
metastasis; No distant metastasis 
c) Tumor invades adjacent structures; Metastasis in single ipsilateral lymph node; 
No distant metastasis 
d) Tumor invades adjacent structures; Metastasis in multiple ipsilateral lymph 
nodes; No distant metastasis 
* A kind of preparation of betel leaf combined with areca nut or tobacco 
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3.3 Preparation of Secretome Sample 
3.3.1 Materials: 
DMEM-F12 media (Invitrogen) 
Keratinocyte serum free media (Invitrogen) 
Casy
®
 Model DT cell counter (Innovatis) 
Amicon Ultra-15 (Millipore) 
3.3.2 Methods: 
 Cancer cell lines and normal primary cultures were grown in DMEM-F12 media 
(with 10% FBS) and KSFM respectively until 75% confluency. Old culture media were 
drawn out from culture flask and washed extensively with PBS for 5 times. Both cancer 
cell lines and normal cell lines were then cultured in serum-free DMEM-F12 media for 
24 hours. After 24 hours, approximately 10 mL of conditioned medium was harvested 
and centrifuged at 1000 × g to remove cell debris and floating dead cells. Subsequently, 
living cells were harvested into a microcentrifuge tube by trypsinization and 
centrifugation at 1000 × g. Total cell number and cell death were measured by Casy® 
Model DT cell counter. Conditioned medium was then concentrated and desalted using 
Amicon Ultra-15 ultracentrifuge tube (cut off 3 kDa). 
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3.4  Protein Quantitation - Bradford assay 
3.4.1 Materials: 
Bovine serum albumin (BSA) standard solutions (prepared by using serial dilution):  
Stock solution A (1.00 mg/mL), 
Standard solution B (10.00 µg/mL),  
Standard solution C (5.00 µg/mL),  
Standard solution D (2.50 µg/mL),  
Standard solution E (1.25 µg/mL),  
Standard solution F (0.625 µg/mL) 
Bradford reagent from Biorad 
Ultrospec™ 2100 pro UV/Visible Spectrophotometer from Amersham Bioscience 
3.4.2 Methods: 
 A total volume of 800 µl of each standard solutions B, C, D, E, and F was 
pipetted into a dried and clean test tube. Subsequently, Bradford dye reagent, 200 µl 
was added into each test tube. It was then mixed thoroughly by vortexing. The mixture 
was incubated at room temperature for 5 minutes. Absorbance was read at 595nm for 
each of the standard solutions. A standard curve (absorbance against protein 
concentration) was constructed. The same procedure was performed for samples. 
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3.5   The First Dimension: Isoelectric Focusing of Proteins (pH 3 – 10 Linear) 
3.5.1 Materials: 
Dithiothreitol (DTT) 
24 cm Immobiline Drystrip from GE healthcare 
Immobiline Drystrip Cover Fluid 
Rehydration solution ( 8M urea, 2% w/v CHAPS, 0.5% v/v Pharmalyte or IPG 
buffer  pH 3-10, 0.002% bromophenol blue ) 
2-D Clean-up kit from Amersham Bio-rad 
Ettan IPGphor 3 from GE Heatlhcare 
3.5.2  Methods (rehydration of IPG strips):  
 Samples were thawed and treated with 2-D Clean-up kit to remove any 
impurities and salts in the sample according to the manufacturer‟s instruction. 
Subsequently, 28 µg of DTT was added into 1 ml of thawed rehydration solution. Then, 
50 µg of sample (protein) were mixed with DTT added rehydration solution to give a 
final volume of 450 µl. 450 µl of rehydration which contained DTT and sample proteins 
was loaded onto slot in the reswelling tray. Any large bubbles were removed. The code 
of the strip gel was recorded and assigned to a specific loaded sample. An Immobiline 
DryStrip was placed in the reswelling tray channel with gel side down. The gel strip was 
gently pressed to remove any trapped bubbles. The strip was then overlaid with 
Immobiline DryStrip Cover Fluid and rehydrated for 18 hours.  
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3.5.3 Methods (Isoelectric Focusing of Proteins): 
 Two electropads were cut to an appropriate width and length. IPG strips were 
taken out of the reswelling tray and excess water was removed with filter paper. The 
strips were then placed into the strip holder and wet electropads were placed on both 
ends of the gel strip.  Immobiline DryStrip cover fluid was then overlaid on the strips. 
The Isoelectric focusing unit, Ettan IPGphor 3 was programmed with the following 
parameters: 
Stage Voltage mode Voltage (V) Time (h:min) kVh 
1 Step and hold 500 1:00 0.5 
2 Gradient 1000 1:00 0.8 
3 Gradient 8000 3:30 13.2 
4 Step and hold 8000 6:52 55.0 
Total   12:22 70.0 
 
 Upon completion of the run, IPG strips were removed from the strip holder and 
rinsed gently with ddH2O. The IPG strips were then stored in screw-cap tubes at -20ºC 
up to 1 month.  At this point, the strips were ready for second-dimension electrophoresis. 
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3.6 Preparation of Homogenous Vertical SDS Slab Gels 
3.6.1 Materials: 
4x Resolving gel buffer (1.5M Tris-HCl at pH 8.8) 
Ammonium persulfate solution (10% w/v) 
Tetramethylethylenediamine, TEMED 
SDS (10% w/v) stock solution 
30% T, 2.6% C monomer stock solution (30%  w/v acrylamide, 0.8% w/v  N,N‟-
mehtylene bis-acrylamide) 
Overlay buffer (0.375M Tris-HCl at pH 8.8, 0.1% w/v SDS) 
Gel-casting apparatus from GE Heathcare, USA 
3.6.2 Methods:  
 Glass plates were rinsed with ddH2O and dried with Kimwipes. They were then 
cleaned with Kimwipes soaked in ethanol and allowed to air dry. The gel-casting unit 
was assembled described by the manufacturer (General Electronic Healthcare).  A 
13%T of resolving gel mixture for two slab gels was prepared as follows:  
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Reagents Volume 
Acrylmide 34.7 mL 
4x resolving gel buffer 20.0  mL 
ddH2O 24.1 mL 
10% SDS 800.0 µL 
10% APS  444.4 µL 
TEMED 21.3 µL 
Total 80 mL 
 
The solution was mixed well prior to the addition of TEMED. The gel solution was then 
slowly poured slowly into the assembled gel tank up to a level ~1.0 – 1.5cm below the 
top of the glass plate. The gel was overlaid with a thin layer of 0.1% SDS solution. The 
gels were allowed to polymerize. Polymerized gels were stored at 4ºC until use. 
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3.7  IPG Strip Equilibration 
3.7.1 Materials: 
SDS equilibration buffer (6M urea, 75mM Tris-HCI pH8.8, 29.3% glycerol, 2% SDS, 
0.002% bromophenol blue, total 200ml) 
Shaker table 
Dithiothreitol (DTT) from Merck, USA 
Iodoacetamide (IAA) from Merck, USA 
3.7.2 Methods: 
 First, 100 mg of DTT was dissolved in 10 ml of SDS equilibration buffer 
resulting in final DTT concentration of 1% w/v. Then, ten milliliter of DTT – SDS 
equilibration buffer solution was delivered into the IPG strip holding tube. The IPG 
strip holding tube was gently shaken for 15 minutes. After 15 minutes of elapsed time, 
0.25 g of iodoacetamide was dissolved in 10 mL of SDS equilibration buffer for a 
second equilibration step. Upon completion of the first equilibration step, the 
equilibration solution was decanted and the second equilibration buffer was delivered 
into the IPG strip holding tube.  The IPG strip was again gently shaken for 15 minutes. 
After completion of the second equilibration step, excess equilibration buffer was 
drained with a filter paper. The IPG strip was now ready for second dimensional gel 
electrophoresis. 
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3.8  The Second Dimension: SDS – Gel Electrophoresis of Proteins 
3.8.1 Materials: 
Agarose sealing solution (25mM Tris Base, 192mM glycine, 0.1% SDS, 0.5% agarose, 
0.002% bromophenol blue, total 100ml). 
10x Running buffer (250mM Tris base, 1.92M glycine, 1% SDS) 
Ettan Dalt II separation unit from Amersham Bioscience 
Forceps 
Focused IPG strip 
3.8.2 Methods: 
 A sufficient amount of agarose sealing stock gel was scooped into a beaker. 
Subsequently, it was melted in microwave oven. Once melted, it was allowed to cool 
down to approximately 45ºC. A pair of forceps was used to position the equilibrated 
IPG strip on the surface of the second-dimension gel. The warmed agarose solution was 
poured onto the vertical second-dimension gel gently. The melted agarose solution was 
allowed to cool and solidify. Second-dimension electrophoresis was the performed 
firstly at constant 2 W for 45 minutes. The wattage was then raised to 110 W. The 
power supply was turned off when the bromophenol blue dye front reached the bottom 
of the gel. Gel fixation was immediately performed upon completion of the run. 
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3.9   Silver Staining 
3.9.1 Materials: 
Fixing solution ( 40% v/v ethanol, 10% v/v acetic acid ) 
Sensitizing solution ( 12.65 mM sodium thiosulfate, 25% w/v glutaraldehyde, 0.83 M 
sodium acetate, 0.3% v/v ethanol ) 
Silver solution ( 14.72 mM silver nitrate, 0.015% v/v formaldehyde ) 
Developing solution ( 0.24 M sodium carbonate, 0.015% v/v formaldehyde ) 
Stopping solution ( 0.05 M EDTA acid ) 
Preserving solution ( 30% v/v ethanol, 4% v/v glycerol) 
Stainless steel tray 
Orbital shaking platform 
3.9.2 Methods: 
 Upon completion of the second dimension SDS-PAGE, gels were transferred 
into a stainless steel tray which was filled with fixing solution. Fixing was performed 
overnight.  
 Fixing solution was then drained. Freshly prepared sensitizing solution was then 
poured into the tray. It was shaken on an orbital shaker for 30 minutes. After 30 minutes, 
sensitizing solution was drained and a sufficient amount of ddH2O was poured into the 
dish. It was then washed on an orbital shaker for 5 minutes and repeated 3 times. 
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 The ddH2O was then drained. Fresh silver solution was poured into the dish and 
shaken on an orbital shaker for 20 minutes. The silver solution was then drained. The 
gels were then washed with ddH2O for one minute twice.  
 The ddH2O was then drained and freshly prepared developing solution was 
poured into tray. Developing was performed for four minutes. Developing solution was 
then drained and fresh stopping solution was poured into the tray. It was shaken on an 
orbital shaker for 10 minutes.  
 Finally, stopping solution was drained and ddH2O was poured into tray for 
washing. It was washed for 10 minutes and repeated 3 times. After washing, ddH2O was 
drained and fresh preserving solution was poured into dish for long term storage of the 
gel. 
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3.10  Analysis of 2D Gel Image 
3.10.1 Materials: 
Gel Scanner from Amersham Biosciences 
ImageMaster 2D v7.0 software from GE Healthcare 
3.10.2 Methods: 
 Gel images were acquired using the gel scanner. The image was edited as 
necessary for orientation and size. Contrast of the gel image was then adjusted to 
visualize the maximum number of spots. Next, spot detection and quantification were 
completed automatically by using the ImageMaster program. Landmark of spots were 
used in spot matching to increase the rate and accuracy of matching. Subsequently, the 
gel images were normalized. Once the spots had been picked and matched, a statistical 
report was generated by the program.  
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3.11 In-gel Digestion (for Silver Staining) and Tryptic Peptide Extraction 
3.11.1 Materials:  
Destaining solution (15 mM potassium ferricyanide(III), 50 mM sodium thiosulphate ) 
Reducing solution (10 mM Dithiothreitol, 40 mM Ammonium bicarbonate ) 
Alkylation solution (55 mM iodoacetamide, 40 mM Ammonium bicarbonate )  
Washing solution (50% Acetonitrile (v/v), 40 mM Ammonium bicarbonate ) 
Absolute acetonitrile (ACN) 
Speed vac concentrator from Thermo Scientific 
Tryption solution (7µg/µL trypsin from Promega, 40 mM Ammonium bicarbonate ) 
 
3.11.2 Methods: 
 Spots of interest were manually were excised (1~2 mm
2
 in size) from 4 or 5 
preparative gels and pooled into a 1.5-mL microcentrifuge tube. Brown colored gel 
plugs were destained with 100 µL destaining solution. After destaining, proteins in gel 
plugs were reduced in 150 uL reducing solution for 30 minutes at 60°C. This was then 
followed by alkylation using 150 uL alkylating solution for 20 minutes, incubation in 
the dark and at room temperature. Subsequently, the gel plugs were washed with 500 uL 
washing solution for 10 minutes on a mini-shaker and extensively washed for 3 times to 
remove any excess iodoacetamide. Fifty micro liters of ACN was used to dehydrate the 
gel plugs by immersing it for 15 minutes until it turned opaque white. Remaining ACN 
was rapidly evaporated by speed vacuum for 15 minutes. Upon drying, 25 µL of trypsin 
solution was added and it was incubated at 37°C overnight. The next day, peptide rich 
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trypsin solution was transferred into a new 1.5-mL microcentrifuge tube. First recovery 
peptide from gel plugs was performed by mixing and shaking with 25 uL of 50% ACN 
solution for 15 minutes. An additional extraction step with 25 uL of absolute ACN was 
performed for 15 minutes. The peptide extraction solution was completely evaporated in 
a speed vacuum centrifuge. Dried peptide was stored at 4°C until spotting on MALDI 
plates. 
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3.12 Spotting on MALDI Plate  
3.12.1 Materials: 
384 - well MALDI plates 
Ziptip µ-C18 (Millipore) 
Trifluoroacetic acid (TFA), 0. 1% (v/v) from Merck, USA 
Absolute acetonitrile  
Matrix α-cyano-4-hydroxycinnamic acid (Sigma) 
3.12.2 Methods: 
 Ziptip was first activated using 100% acetonitrile by flushing the column bed 3 
times. Organic mobile phase of the Ziptip was removed by washing and flushing with 
10 µL of trifluoroacetic acid, 0.1% (v/v) 5 times. The dried peptide mixture was 
reconstituted in 10 µL of trifluoroacetic acid, 0.1% (v/v) and was then applied onto the 
Ziptip by flushing for 10 times to ensure that the tryptic peptides completely bind to the 
C18 column bed. Unbound salt in the mobile phase of column was flushed using 10 µL 
of trifluoroacetic acid, 0.1% (v/v). Bound tryptic peptides were eluted with 1.5 µL 
elution solution. Eluted peptide mixture was then mixed with matrix α-cyano-4-
hydroxycinnamic acid (4-CHCA) 10 mg/mL in 1:1 ratio. Upon thoroughly mixing, 
matrix-peptides mixtures were spotted (7µL) onto 384-well MALDI plates. This was 
allowed to air-dry to allow for the co-crystallization of matrix and tryptic peptides. A 
second spotting was then performed.  
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3.13  Tandem Mass Spectrometry and Database Searching 
3.13.1 Equipment and software: 
4800 Plus MALDI TOF/TOF Analyzer (Agilent Technologies, US) 
GPS Explorer
TM
 (Agilent Technologies, US) 
3.13.2 Methods: 
 All analyses and protein identification were performed using the ABI 4800 Plus 
MALDI TOF/TOF Analyzer from Applied Biosystems. Sample peptides were ionized 
and energized by YAG Laser shot at 355 nm wavelength. The software used for spectra 
acquisition was the 4000 series explorer. Minimum signal to noise ratio (S/N) was set at 
25 for monoisotopic precursor selection in MS/MS. A list of acquired spectrums from 
MS/MS was matched with the theoretical spectrums in Swiss-PROT database. The 
matching task was performed using GPS Explorer
TM
 software. Before database 
searching, several parameters were changed to improve the searching outcomes and 
speeds. The reference proteins database was confined under taxonomy Homo sapiens. 
MS/MS fragment and precursor tolerance was selected at 0.2 Da and 100 ppm 
respectively. Maximum peptide missed cleavage was selected at 1. Methionine 
oxidation and cysteine carbamidomethylation were selected as variable modifications in 
database searching. The search outcomes were returned as protein rank. Protein rank 
was determined by the probability based Mowse score. The highest ranked protein had 
the highest score among other candidates.  
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3.14 In Silico Analysis of Protein Localization and Functions 
3.14.1 Programs: 
SignalP 4.0 server (http://www.cbs.dtu.dk/services/SignalP/) 
SecretomeP 2.0 server (http://www.cbs.dtu.dk/ services/SecretomeP/) 
TMHMM v2.0 server (http:// www.cbs.dtu.dk/services/TMHMM-2.0/) 
Ingenuity Pathway Analysis (Ingenuity® Systems, www.ingenuity.com) 
Exocarta database (http://www.exocarta.org) 
3.14.2 Methods: 
 Canonical sequences of identified proteins were selected for all bioinformatics 
analysis. SignalP 4.0 server was used to predict the location of signal peptide cleavage 
site based on submitted identified protein amino acid sequences. The signal peptide was 
anticipated to be present in protein sequence if it returned D-score exceeding 0.450 
(Petersen et al. 2011). SecretomeP 2.0 server was used to analyze which proteins were 
predicted to be secreted by non-classical secretion. The identified proteins were 
considered as non-classical secreted proteins if the N-N score was above a threshold of 
0.500 (Bendtsen et al. 2004). TMHMM v2.0 server was used to analyze all identified 
proteins for transmembrane plasma protein feature. As its expected number of amino 
acid in transmembrane helixes (ExpAA) exceeded 18.000, it was considered as 
transmembrane plasma protein (Sonnhammer et al. 1998; Krogh et al. 2001; 
Mathivanan et al. 2010). Ingenuity Pathway Analysis was applied to determine the 
localization of identified proteins and their participation in molecular networks 
associated with carcinogenesis according to the well-established Ingenuity Knowledge 
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Base. The identified proteins were categorized as part of secretome if it possessed a 
signal peptide according to SignalP or it is non-classically secreted according to 
SecretomeP or it has transmembrane helix according to TMHMM or its localization is 
in the extracellular space according to Ingenuity Knowledge Base. In addition, all 
identified proteins were also subjected to a query search on Exocarta database to 
determine their presence in microvesicular bodies (Mathivanan et al. 2012). 
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3.15 Real-time PCR Validation 
3.15.1 Materials: 
Primer 3 software from http://simgene.com/Primer3 
PrimerBank from http://pga.mgh.harvard.edu/primerbank/ 
NCBI Primer-Blast from http://www.ncbi.nlm.nih.gov/tools/primer-blast/ 
RNAqueous®-4PCR Kit from Ambion, USA 
High Capacity cDNA Reverse Transcription Kit from Applied Biosystems, CA 
Taqman® Gene Expression Assay from Applied Biosystems, CA 
Fast SYBR Green from Applied Biosystems, CA 
StepOnePlus Real-Time PCR instrument from Applied Biosystems, CA 
StepOne Software v2.2 from Applied Biosystems, CA 
Relative expression software tool (REST) from 
http://www.genequantification.de/rest.html 
3.15.2 Methods: 
 Total mRNA was extracted from cell pellets using RNAqueous®-4PCR Kit. 
High Capacity cDNA Reverse Transcription kit was used to reverse transcribe total 
mRNA into cDNA templates. Owing to the high specificity and accuracy of Taqman® 
Gene Expression Assay, it was employed to validate differential expression of proteins 
of great interest - TIMP1, TIMP2 and MMP7 which mutually coordinate in a favor of 
cancer progression and dissemination. Fast Sybr Green was used to assay the gene 
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expression level of the rest of the protein candidates as a trade-off between result 
specificity and cost incurred. Primers were either designed using Primer3 software or 
retrieved from literature and PrimerBank (He et al. 2005; Spandidos et al. 2008). The 
specificities of targeted primers were examined using NCBI primer-Blast prior to 
primer purchasing. Standard curve and melt curve were plotted for all purchased 
primers from 1
st
 Base Laboratory Sdn Bhd, Malaysia to ensure their efficiency and 
specificity. The details of primer pairs are tabulated in Table 3.3.  
 All PCR reactions were run using StepOnePlus Real-Time PCR instrument. The 
PCR was initially preheated at 95 °C for 20 s to activate Taq polymerase. Subsequently, 
DNA melting step was performed at 95 °C for 3 s followed by an annealing step at 
60 °C for 30 s. A complete PCR cycle consisted of DNA melting and primer annealing 
stage was repeated for 40 rounds. Automatic threshold and baseline were selected to 
calculate Ct value. Gene expression level of different cell lines were comparatively 
analyzed using StepOne software v2.2. Raw data from the experiments were 
recalculated as a mean expression level of cancer and normal group to generalize results 
of comparison between two groups. Student unpaired one tailed t-test and pair wise 
fixed reallocation randomization test were then performed to examine significance of 
results from comparison among varied cell lines (Pfaffl et al. 2002). 
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Table 3.3: Entrez gene name of forward and reverse primer pair sequences or taqman assay ID used in real-time PCR. 
No Entrez Gene Name NCBI RefSeq Taqman Assay ID/ Primer pairs
 a)
 
1 Matrix metallopeptidase 7 NM_002423.3 Hs01042796_m1 
2 TIMP metallopeptidase inhibitor 2 NM_003255.4 Hs00234278_m1 
3 Cystatin- E/M NM_001323.3 sense 5‟- TACTTCCTGACGATGGAGATGG-3‟ 
antisense 5‟- GAGTTCTGCCAGGGAACCAC-3‟ 
Primer bank ID: 325197208c1 
4 Cathepsin D NM_001909.4 sense 5‟-CACCACAAGTACAACAGCGAC-3‟ 
antisense 5‟- CCCGAGCCATAGTGGATGT-3‟ 
Primer bank ID: 332078524c2 
5 Cadherin 2 NM_001792.3 sense 5‟- AGCCAACCTTAACTGAGGAGT-3‟ 
antisense 5‟- GGCAAGTTGATTGGAGGGATG-3‟ 
Primer bank ID: 215422305c2 
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Table 3.3, continued   
6 Heterogeneous nuclear 
ribonucleoprotein A2 
NM_002137.3 sense 5'-GAGTCCGCGATGGAGAGAGA-3'; 
antisense 5'-GATCCCTCATTACCACACAGTCTGT-3' 
Reference: (He et al. 2005) 
7 Heterogeneous nuclear 
ribonucleoprotein B1 
NM_031243.2 sense 5'-GGAGAAAACTTTAGAAACTGTTCCTTTG-3';  
antisense 5'-GCTTTCCCCATTGTTCGTAGTAGT-3' 
Reference:(He et al. 2005) 
8 Reticulocalbin 1 NM_002901.2 sense 5‟- AAGCCCACGGTGCGCAAAGA-3‟ 
antisense 5‟- AGGCCTCGTGGTCGTACTGGAA-3‟ 
9 Peroxiredoxin 1 NM_002574.3 sense 5'-CCACGGAGATCATTGCTTTCA-3' ; 
antisense 5'-AGGTGTATTGACCCATGCTAGAT-3' 
PrimerBank ID: 32455267b1 
10 Proliferating cell nuclear antigen NM_182649.1 sense 5'-ATCAACGAGGCCTGCTGGGA-3' ; 
antisense 5'-TGGACATACTGGTGAGGTTCACGC-3' 
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Table 3.3, continued   
11 Follistatin-like 1 NM_007085.4 sense 5‟- CCCAGTTGTTTGCTATCAGTCC-3‟ 
antisense 5‟- TGTAGTTGCTGCCTTTAGAGAAC-3‟ 
Primer bank ID: 197304788c2 
12 Hepatoma-derived growth factor NM_001126050.1 sense 5'-CTCTTCCCTTACGAGGAATCCA-3' ; 
antisense 5'-CCTTGACAGTAGGGTTGTTCTC-3' 
PrimerBank ID: 186928818b1 
13 Heat shock 10kDa protein 1 NM_002157.2 sense 5‟- AGTCGCTGTTGGATCGGGTTCT-3‟ 
antisense 5‟- TTGGTGCCTCCATATTCTGGGAGA-3‟ 
14 Laminin, beta 3 NM_001017402.1 sense 5'-GCAGCCTCACAACTACTACAG-3' ; 
antisense 5'-CCAGGTCTTACCGAAGTCTGA-3' 
PrimerBank ID: 62868216b2 
15 Interleukin 1 receptor antagonist NM_173842.2 sense 5‟- AGAGGCCTCCGCAGTCACCTA-3‟ 
antisense 5‟- TTTTCTCCCAGAGGGTCGGCA-3‟ 
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Table 3.3, continued   
16 TIMP metallopeptidase inhibitor 1 NM_003254.2 Hs00171558_m1 
17 S100 calcium binding protein A8 NM_002964.4 sense 5'-ATGCCGTCTACAGGGATGAC-3' ; 
antisense 5'-ACACTCGGTCTCTAGCAATTTCT-3' 
PrimerBank ID: 21614543b1 
18 Secreted protein, acidic, cysteine-
rich  
NM_003118.3 sense 5'-TGAGGTATCTGTGGGAGCTAATC-3' ; 
antisense 5'-CCTTGCCGTGTTTGCAGTG-3' 
PrimerBank ID: 48675809b1 
19 Actin, beta* NM_001101.3 Hs99999903_m1 / 
sense 5'-CGTTACACCCTTTCTTGACAAAACC-3' 
antisense 5'-GCTGTCACCTTCACCGTTCCA-3' 
Reference: (He et al. 2005) 
 
Source of reference: He, Y., Brown, M. A., Rothnagel, J. A., Saunders, N. A., & Smith, R. (2005). Roles of heterogeneous 
nuclear ribonucleoproteins A and B in cell proliferation. J Cell Sci 118(Pt 14): 3173-83. 
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Footnotes of Table 3.3: 
a) Taqman gene assay ID was obtained through Applied Biosystem 
TaqMan
®
 Gene Expression Assay Search. Primer pairs were retrieved from 
PrimerBank and literature or designed using Primer 3 software. 
 *    Endogenous gene control 
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4.1  Cancer cell lines proliferation assay (MTT assay) 
 Cancer cell lines are usually cultured under nourishment of 10% FBS for 
optimum condition. However, incubation with serum-free media is a key step for 
secretome preparation. Under such stress environment, cell lines may proliferate slowly 
resulting in a different secretome profile from its original state. Therefore, impact of 
serum deprivation on proliferation rate of cancer cell lines with optimum protein yield 
was assessed by MTT assay for 24 and 48 hours. A longer incubation period of 48 hours 
was believed to give higher protein yield.  
 Cancer cell lines viability in 0% FBS media was significantly equal to 10% FBS 
furnished cancer cell lines (p>0.05). The results also showed that for cell lines H400 
and 48T, there was no significant difference in proliferation rate of 24 and 48 hours 
starvation periods, whereas starvation for 48 hours adversely influenced proliferation 
rate of 153T cell line (62% decline) compared with starvation for 24 hours. In order to 
avoid dramatic inhibition on proliferation of 153T cell line, an incubation period of 24 
hours was determined as the optimum condition for secretome sample preparation 
(Figure 4.1). Normal primary cultures were not subjected to this assay because as was 
maintained in keratinocyte serum-free media (KSFM) optimally without serum additive.  
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Figure 4.1 : Effect of fetal bovine serum concentration on cancer cell lines at different 
incubation period, 24 hours and 48 hours. Graph (A) and (B) are presented as mean 
viability ± standard deviation. (A) cell proliferation rate of H400 and 48T were slightly 
inhibited after 24 hours incubation. (B) cell proliferation rate of 153T was greatly 
reduced after 48 hours incubation.  
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4.2  Cell death rate monitoring using Casy Ton device 
 MTT-based cell viability assay was not employed to assess cell cultures death 
rate as it was susceptible to metabolic interference. Furthermore, total cell death 
percentage of cell lines could not be measured by MTT assay because reduction of 
tetrazolium does not happened in dead cells.  Therefore, cell death of cancer cell lines 
and normal primary cultures were monitored using Casy® Model DT cell counter in 
order to achieve the least amount of cell death (< 20%, as depicted in the Figure 4.2) 
during secretome preparation. This was performed to minimize cytosolic protein 
contamination in the secretome. Cytosolic protein contamination is inevitable in 
secretome preparation as 24 hours of serum deprivation will inevitably induce apoptosis. 
Washing 5× under stringent condition with phosphate buffer saline may also cause 
rupture in cell membrane. However, both steps were necessary to remove abundant 
serum proteins which were present in the media.  
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Figure 4.2: Cell death percentage (%) of cancer cell lines and normal primary cultures 
after 24 hours starvation and 5 times stringent washing with PBS. This histogram is 
presented as mean total cell death percentage + standard deviation. Cell death 
percentage of cancer cell lines was considered optimum, below 20%. Cell death 
percentages of normal primary culture were also considered optimum, below 20%. Low 
cell death percentage suggested minimal cytosolic protein contamination that may arise 
from cell lysis. 
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4.3 Two-dimensional (2D) Gel Images of Oral Cancer Cell Line and Normal 
Primary Culture 
 A total of 35 identified protein spots were labeled in Figure 4.3 and Figure 4.4. 
Their molecular weights ranged from 190 kDa to below 10 kDa and their pI values 
ranged from 3 to 10. The 13%T of 2D gel was good to resolve low molecular weight of 
secreted proteins. These proteins were separated become distinct and sharp spots. In 
addition, there was no protein aggregation near to the dye front. The largest 24 cm gel 
was used to resolve secretome for higher sample loads and better resolution.  
 
Figure 4.3: A representative (20 × 24 cm) gel for normal primary culture. Identified 
spots were labeled with their corresponding spot ID numbers. Down-regulated proteins 
were labeled in this figure. 
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Figure 4.4: A representative (20 × 24 cm) gel for cancer cell lines. Identified spots were 
labeled with their corresponding spot ID number. Up-regulated proteins were labeled in 
this figure. 
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4.4 2D Gel Analysis and Protein Spot Identification 
 Approximately 35 protein spots were identified with significant MOWSE score (p=0.05). Identified spots information was shown in Table 4.1. 
Regulated fold changes of identified proteins were around 2-folds and above. All of the identified protein spots with ANOVA p-value and q-value less 
than 0.05 indicated that their differential expression was significant with less false-negative and false-positive errors. 
Table 4.1:  List of differential expressed proteins in oral cancer secretome. 
Spot 
ID 
Protein Name (Gene 
symbols) 
Swiss-
Prot 
Accession 
Mean volume (%) ± 
dispersion 
Fold 
changes
(a)
 
ANOVA Q-value
(b)
 Mowse
(c)
 
Sequence 
coverage
(d)
 
Cancer Normal 
1 Cadherin-2 precursor 
(CDH2) 
P19022 0.059 ± 0.049 0.000 10
6
 0.020 0.009 110 3 
2 Cathepsin D (CTSD) P07339 0.098 ± 0.092 0.000 10
6
 0.038 0.016 492 47 
3 Tissue inhibitor 
metalloproteinase-2 (TIMP2) 
P16035 0.282 ± 0.182 0.005 ± 0.006 55.543 0.005 0.004 314 32 
4 Follistatin like-1 (FSTL1) Q12841 0.028 ± 0.017 0.002 ± 0.003 17.119 0.004 0.003 206 12 
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Table 4.1, continued        
5 Heterogeneous nuclear  
ribonucleoproteins A2/B1 
(HNRNPA2/B1) 
P22626 0.088 ± 0.025 0.006 ± 0.007 15.231 0.000 0.000 57 7 
6 Peroxiredoxin-1 (PRDX1) Q06830 0.073 ± 0.061 0.009 ± 0.012 8.409 0.039 0.016 187 23 
7 Heat shock 10kDa protein-1 
(HSPE1) 
P61604 0.203 ± 0.110 0.027 ± 0.032 7.614 0.004 0.003 121 40 
8 Acidic nuclear 
phosphoprotein  
32 family member  B 
(ANP32B) 
Q92688 0.100 ± 0.061 0.014 ± 0.008 6.993 0.008 0.005 343 23 
9 Heterogeneous nuclear  
ribonucleoproteins A2/B1 
(HNRNPA2/B1) 
, spliced variant B1 
P22626 0.146 ± 0.069 0.023 ± 0.019 6.447 0.001 0.002 92 15 
10 Proliferating cell nuclear 
antigen (PCNA) 
P12004 0.122 ± 0.038 0.022 ± 0.018 5.556 0.000 0.000 193 20 
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Table 4.1, continued         
11 Matrix metalloproteinase-7 
(MMP7) 
P09237 0.074 ± 0.046 0.016 ± 0.013 4.491 0.018 0.009 359 29 
12 Protein SET (SET) Q01105 0.152 ± 0.055 0.034 ± 0.022 4.426 0.000 0.001 378 20 
13 Guanine nucleotide-binding 
protein subunit beta 2-like 1 
(GNB2L1) 
P63244 0.050 ± 0.022 0.011 ± 0.014 4.416 0.003 0.002 265 23 
14 Proliferating cell nuclear 
antigen (PCNA) 
P12004 0.050 ± 0.019 0.012 ± 0.007 4.259 0.001 0.001 125 13 
15 Protein SET (SET),  
isoform 1/α 
Q01105 0.112 ± 0.033 0.027 ± 0.015 4.208 0.000 0.000 239 27 
16 Ubiquitin (UBB) P62988 0.709 ± 0.266 0.179 ± 0.097 3.957 0.001 0.001 211 50 
17 Single-stranded DNA-
binding protein (SSBP1) 
Q04837 0.059 ± 0.031 0.018 ± 0.016 3.355 0.013 0.007 
279 
43 
18 Hepatoma-derived growth 
factor (HDGF) 
P51858 0.099 ± 0.028 0.038 ± 0.005 2.575 0.000 0.000 159 27 
19 Cyclophilin-A (PPIA) P62937 0.344 ± 0.093 0.156 ± 0.035 2.204 0.001 0.001 439 39 
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Table 4.1, continued        
20 Cofilin-1 (CFL1) P23528 0.062 ± 0.027 0.031 ± 0.022 2.006 0.043 0.018 73 6 
21 Elongation Factor 1-D 
(EEF1D) 
P29692 0.050 ± 0.009 0.025 ± 0.004 1.998 0.000 0.000 126 28 
22 Gamma 
glutamylcyclotransferase 
(GGCT) 
O75223 0.111 ± 0.035 0.056 ± 0.022 1.978 0.006 0.005 156 25 
23 Cyclophilin-A (PPIA) P62937 0.067 ± 0.028 0.036 ± 0.005 1.859 0.032 0.014 116 27 
24 Glutathione transferase 
omega-1 (GSTO1) 
P78417 0.039 ± 0.024 0.111 ± 0.034 -2.892 0.000 0.000 64 12 
25 Cystatin-M (CST6) Q15828 0.078 ± 0.032 0.238 ± 0.071 -3.055 0.000 0.000 264 51 
26 Leukocyte elastase 
inhibitor (SERPINB1) 
P30740 0.048 ± 0.016 0.206 ± 0.061 -4.251 0.000 0.000 475 27 
27 Calmodulin-like protein 3 
(CALML3) 
P27482 0.022 ± 0.028 0.127 ± 0.011 -5.716 0.000 0.000 116 11 
28 Galectin-7 (LGALS7) P47929 0.027 ± 0.028 0.185 ± 0.034 -6.755 0.000 0.000 534 88 
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Table 4.1, continued        
29 Laminin subunit beta-3 
(LAMB3) 
Q13751 0.012 ± 0.009 0.093 ± 0.079 -7.423 0.002 0.002 653 30 
30 Secreted protein acidic and 
rich in cysteine (SPARC) 
P09486 0.018 ± 0.027 0.158 ± 0.082 -8.764 0.000 0.000 250 29 
31 Tissue inhibitor 
metalloproteinase-1 
(TIMP1) 
P01033 0.028 ± 0.041 0.405 ± 0.137 -14.294 0.000 0.000 270 41 
32 S100 calcium binding 
protein A8 (S100A8) 
P05109 0.006 ± 0.009 0.306 ± 0.117 -48.362 0.000 0.000 122 26 
33 Interleukin-1 receptor 
antagonist protein 
precursor (IL1RN) 
P18510 0.000 0.116 ± 0.031 -10
6
 0.000 0.000 322 30 
34 Reticulocalbin-1 (RCN1) Q15293 0.000 0.030 ± 0.048 -10
6
 0.032 0.014 571 37 
35 Laminin subunit alpha-3 
(LAMA3) 
Q16787 0.000 0.114 ± 0.063 -10
6
 0.000 0.000 122 2 
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Footnotes of Table 4.1: 
a) (-) sign represented down-regulated expression of proteins in cancer secretome. Deregulated fold changes at 106 indicated that the protein was 
present in cancer secretome but undetectable in normal secretome. Whereas, fold changes at -10
6
 indicated that the protein was present only in 
normal secretome but undetectable in cancer secretome.   
b) Q-value was employed to control false discovery rate (FDR) by using generated p-value list. Q-value threshold less than 0.05 was selected. 
c) Mowse score was probability based scoring scheme using by MASCOT search engine to evaluate significance of search outcomes from random 
matches with database. Protein with higher score above significant threshold (p<0.05) were recognized as identity of protein spot.  
d) Sequence coverage was a percentage of experimentally identified sequence peptides (MS/MS) against unidentified sequence peptides of same 
protein. 
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4.5 Bioinformatic Analysis of Proteins Localizations 
  By excluding duplicated protein identities, a total of 31 proteins were subjected 
to in silico analysis for protein localizations and functions, as depicted in Table 4.2. 
Distinguishing “bona fide” secreted proteins from intracellular proteins which derived 
from dead cells is important to sort out secreted potential biomarkers.  A total 24 out of 
31 proteins were predicted to be secreted proteins. In other words, 77% of identified 
proteins were secreted via classical signal peptide dependant pathway or non-classical 
mechanism. However, as query search of identified proteins in the Exocarta, the non-
secreted proteins that are predicted by previous programs were matching the exosomal 
protein candidates in the database. These non-secreted proteins may be transported out 
as a cargo into extracellular spaces via exosomal proteins. In summary, this study 
approach was reliable to investigate secreted proteome of cell lines.  
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Table 4.2: Analysis of Proteins Localization Using Different Prediction Programs and Established Databases. 
Spot ID Protein Name  Accession ID Localization
a)
 SignalP
b)
 SecretomeP
c)
 TMHMM
d)
 ExoCarta
e)
 
1 Cadherin-2 precursor P19022 P 0.746 - 23.345 - 
2 Cathepsin D P07339 C 0.781 - 12.287 Yes 
3 Tissue inhibitor metalloproteinase-2 P16035 E 0.938 - 0.240 Yes 
4 Follistatin like-1 Q12841 E 0.939 - 0.803 - 
5 Heterogeneous nuclear 
ribonucleoproteins A2/B1 
P22626 N 0.104 0.081 0.033 Yes 
6 Peroxiredoxin-1 Q06830 C 0.125 0.528 10.047 Yes 
7 Heat shock 10kDa protein-1 P61604 C 0.213 0.570 0.000 Yes 
8 Acidic nuclear phosphoprotein 32 
family member  B 
Q92688 N 0.125 0.068 0.550 Yes 
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Table 4.2, continued       
9 Heterogeneous nuclear 
ribonucleoproteins A2/B1 
P22626 N 0.104 0.081 0.033 Yes 
10 Proliferating cell nuclear antigen 
(PCNA) 
P12004 N 0.139 0.566 0.021 Yes 
11 Matrix metalloproteinase-7 P09237 E 0.887 - 0.538 Yes 
12 Protein SET, isoform 2/ß Q01105 N 0.112 0.106 0.001 Yes 
13 Guanine nucleotide-binding protein 
subunit beta 2-like 1 
P63244 C 0.112 0.465 0.013 Yes 
14 Proliferating cell nuclear antigen 
(PCNA) 
P12004 N 0.139 0.566 0.021 Yes 
15 Protein SET, isoform 1/α  Q01105 N 0.112 0.106 0.001 Yes 
16 Ubiquitin P62988 C 0.118 0.693 0.000 Yes 
17 Single-stranded DNA-binding 
protein 
Q04837 C 0.116 0.850 0.000 Yes 
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Table 4.2,  continued       
18 Hepatoma-derived growth factor 
(HDGF) 
P51858 E 0.120 0.477 0.004 - 
19 Cyclophilin-A P62937 C 0.107 0.339 0.001 Yes 
20 Cofilin-1 P23528 N 0.102 0.628 0.001 Yes 
21 Elongation Factor 1-D P29692 C 0.106 0.529 0.003 Yes 
22 Gamma glutamylcyclotransferase O75223 C 0.108 0.503 0.011 Yes 
23 Cyclophilin-A P62937 C 0.107 0.339 0.001 Yes 
24 Glutathione transferase omega-1 P78417 C 0.106 0.435 0.081 Yes 
25 Cystatin-M Q15828 E 0.845 - 16.014 - 
26 Leukocyte elastase inhibitor P30740 C 0.350 0.516 3.711 Yes 
27 Calmodulin-like protein 3 P27482 C 0.101 0.585 0.000 Yes 
28 Galectin-7 P47929 E 0.117 0.673 0.000 Yes 
29 Laminin subunit beta-3 Q13751 E 0.826 - 0.005 Yes 
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Table 4.2,  continued       
30 Secreted protein acidic and rich in 
cysteine  
P09486 E 0.939 - 0.007 Yes 
31 Tissue inhibitor metalloproteinase-1 P01033 E 0.923 - 0.510 Yes 
32 S100 calcium binding protein A8 P05109 C 0.100 0.280 0.043 Yes 
33 Interleukin-1 receptor antagonist 
protein precursor 
P18510 E 0.726 - 0.595 Yes 
34 Reticulocalbin-1 Q15293 C 0.848 - 13.124 - 
35 Laminin subunit alpha-3 Q16787 E 0.630 - 0.923 Yes 
 
Footnotes of Table 4.2: 
a) Protein localization was determined according to Ingenuity Knowledge Base (IPA), where P denoted as plasma membrane, C denoted as 
cytoplasm, E denoted as extracellular space. 
b) SignalP 4.0 was employed to predict the presence of signal peptide in a sequence of protein based on a combination of several artificial 
neural networks. Protein was identified as classical secreted protein when its D-score exceeded 0.450. Bold number represents a value higher 
than D-score threshold (D > 0.450). 
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c) SecretomeP 2.0 was used to identify non-classical secreted proteins without signal peptides when its N-N score exceeded 0.500. Bold 
number represents a value higher than NN-score threshold (N-N > 0.5).  
d) Transmembrane proteins have higher likelihood to be shed and secreted into extracellular space via exosome and apoptotic blebs 
(Sonnhammer et al. 1998). TMHMM v2.0 was therefore used to predict the presence of transmembrane helix in a protein. A protein was 
anticipated as plasma protein when its expected number of amino acid in transmembrane helixes (ExpAA) exceeded 18.000. Bold number 
represents a value higher than ExpAA threshold (ExpAA > 18.000). 
e) ExoCarta, is an exosome database established based on literatures. All identified proteins were investigated based on this database. Protein 
was identified as an exosomal protein if it was found in the database.   
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4.6 In Silico Pathway Analysis of Protein Molecules 
 Based on the IPA core analysis, the list of identified proteins was highly relevant 
in cancer progression. These proteins were likely involved in tumor growth, metastasis, 
hyperproliferation, tumorigenesis, neoplasia, hyperplasia, and cell transformation. A top 
scored molecular network as depicted in Figure 4.5 in IPA core analysis was 
participated by these identified proteins that are LAMB3, LAMA3, MMP7, LGALS7, 
HDGF, FSTL1, SPARC, IL1RN, TIMP1, TIMP2, CDH2, GNB2L1, S100A8, PRDX1, 
PPIA, CTSD, HSPE1, and CFL1. These identified proteins are also interrelated with 
oncoproteins in the molecular network such as NF-Kß, TGF-ß, α-catenin, AP-1, p38 
MAPK, PDGF, MMPs, estrogen receptor and IL-1. According Ingenuity Knowledge 
Base, expression dynamics of these proteins is highly relevant to cancer development 
and cell motility. 
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Figure 4.5: A top-scored molecular network with 18 identified proteins implicated in 
cancer progression according to IPA (Ingenuity® Systems, www.ingenuity.com). All 
protein molecules in the network were represented as gene symbol labeled nodes. The 
biological relationship between two nodes is represented as an edge. All edges are 
supported by at least one reference from the literature, from a textbook, or from 
canonical information stored in the Ingenuity Knowledge Base. The intensity of the 
node color indicates the degree of up- (red) or down- (green) regulation. Nodes are 
displayed using various shapes that represent the functional class of the gene product. A) 
molecule types, B) relationship types. 
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4.7 Real Time PCR Results Analysis 
 Although protein expression was discrepant with messenger RNA expression 
level due to protein post-modification or proteolytic cleavage, real-time PCR is still 
remain robust and rapid as preliminary validation. The identified proteins were 
subjected to qPCR validation only if they are plausible secreted proteins or higher 
expression fold-change proteins or closely cancer-associated proteins. The results, 
which are shown in Table 4.3 and Figure 4.6, demonstrated that the direction of 
transcript level regulation of all selected proteins was parallel to their protein expression 
except CST6 and RCN. Small differences between efficiency corrected RQ and ΔΔCT 
based RQ of all genes showed that the effect of inequality of amplification efficiency 
was negligible. Some of selected candidates showed insignificant differences (p>0.05) 
of transcript expression level between cancer group (48T, 153T, H400) and normal 
group (316N, 317N, 322N, 326N) due to higher variation among cell lines in a group. In 
summary, significant differentially expressed genes with student‟s t-test ≤ 0.05 were 
MMP7, hnRNP A2, hnRNP B1, PRDX1, LAMB3, TIMP1, IL1RN, S100A8, and 
SPARC. While, significantly differential expressed genes with pair-wise randomization 
test ≤ 0.05 were MMP7, LAMB3, TIMP1, IL1RN, S100A8, and SPARC only. All 
significantly dysregulated genes were regulated in a fold change range from ~1.5 folds 
to as high as ~100 folds. 
 Results 
78 
Chapter 4 
 
Figure 4.6: Base ten Logarithm relative quantity (Log10RQ) of targeted genes in cancer cell lines were measured using qPCR. This histogram is 
presented as mean Log10RQ ± error bars. Error bars indicate Log10RQmin and Log10RQmax. Two asterisks (**) indicates that statically significant of 
differential gene expression by both student t-test (p = 0.05) and pair wise fixed reallocation randomization test (p = 0.05). Single asterisk (*) shows 
that differential gene expression is statically significant by either student t-test or randomization test only.   
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Table 4.3: Differential expression of targeted genes between normal and oral cancer cell lines and their significance was tested with student‟s t-test and 
randomization test. 
No Entrez Gene Name 
Gene 
Symbol 
NCBI RefSeq RQ 
Fold 
change
a)
 
Efficiency 
Corrected 
RQ
b)
 
Log10 
RQ
c)
 
RQ 
Min
d)
 
RQ 
Max
d)
 
t-
test
e)
 
REST 
p-value
f)
 
1 Matrix 
metallopeptidase 7 
MMP7 NM_002423.3 74.254 74.254 74.254 1.871 22.790 241.931 0.007 0.029 
2 TIMP metallopeptidase 
inhibitor 2 
TIMP2 NM_003255.4 3.004 3.004 3.004 0.478 1.759 5.131 0.113 0.190 
3 Cystatin- E/M CST6 NM_001323.3 2.592 2.592 2.416 0.414 0.618 10.879 0.391 0.381 
4 Cathepsin D CTSD NM_001909.4 2.247 2.247 2.262 0.352 1.237 4.082 0.092 0.328 
5 Cadherin 2 CDH2 NM_001792.3 2.187 2.187 2.150 0.340 1.132 4.225 0.237 0.433 
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Table 4.3,  continued          
6 Heterogeneous nuclear 
ribonucleoprotein A2 
HNRNP
A2 
NM_002137.3 1.614 1.614 1.563 0.208 1.102 2.363 0.007 0.214 
7 Heterogeneous nuclear 
ribonucleoprotein B1 
HNRNP
B1 
NM_031243.2 1.561 1.561 1.516 0.193 1.186 2.055 0.030 0.110 
8 Reticulocalbin 1 RCN1 NM_002901.2 1.551 1.551 1.501 0.191 0.660 3.643 0.258 0.581 
9 Peroxiredoxin 1 PRDX1 NM_002574.3 1.525 1.525 1.483 0.183 1.111 2.094 0.029 0.197 
10 Proliferating cell 
nuclear antigen 
PCNA NM_182649.1 1.360 1.360 1.363 0.134 0.727 2.545 0.253 0.799 
11 Follistatin-like 1 FSTL1 NM_007085.4 1.286 1.286 1.268 0.109 0.478 3.460 0.397 0.770 
12 Hepatoma-derived 
growth factor 
HDGF NM_001126050.1 1.108 1.108 1.100 0.044 0.698 1.758 0.314 0.817 
13 Heat shock 10kDa 
protein 1 
HSPE1 NM_002157.2 1.071 1.071 1.069 0.030 0.736 1.560 0.376 0.862 
            
 Results 
81 
Chapter 4 
Table 4.3,  continued           
14 Laminin, beta 3 LAMB3 NM_001017402.1 0.325 -3.080 0.346 -0.489 0.207 0.509 0.007 0.050 
15 TIMP metallopeptidase 
inhibitor 1 
TIMP1 NM_003254.2 0.201 -4.975 0.201 -0.697 0.117 0.346 0.016 0.001 
16 Interleukin 1 receptor 
antagonist 
IL1RN NM_173842.2 0.195 -5.137 0.208 -0.711 0.113 0.335 0.011 0.052 
17 S100 calcium binding 
protein A8 
S100A8 NM_002964.4 0.014 -72.892 0.018 -1.863 0.003 0.072 0.015 0.026 
18 Secreted protein, acidic, 
cysteine-rich 
(osteonectin) 
SPARC NM_003118.3 0.010 -100.640 0.013 -2.003 0.001 0.097 0.041 0.049 
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Footnotes of Table 4.3: 
a) Fold changes was derived from Relative quantity (RQ) by 
1
RQ
 if RQ > 1 or 
RQ
1
 if RQ < 1. (-) sign represents down-regulated expression of 
mRNA copies in cancer cell lines.  
b) Efficiency corrected RQ is adjusted RQ according to efficiency of amplification under the optimal PCR conditions. It is used to assess the effect of 
inequality of amplification efficiency between targeted gene and endogenous control on the expression level of gene transcript. If efficiency 
corrected RQ is closer to RQ, which was calculated based on comparative ∆∆Ct, the effect of inequality of amplification efficiency will be 
considered small and negligible. 
c) Base ten logarithms RQ shows regulated direction of gene expression with relatively smaller numerical value.  
d) The RQ minimum and RQ maximum define statistical boundaries for true RQ value to fall within the RQ Min/Max range with a 95% confidence 
interval. The RQ Min/Max is calculated using the equation: 
2
-(∆∆C
T(s,t)
±T x VAB(C
T(s,t)
)) 
where ΔΔCT(s,t)=ΔCT(s,t) - ΔCT(calibrator,t); s=sample name; t=target detector; T=student‟s T value at the selected confidence setting using a degree of 
freedom that is associated with the test sample ΔCT(s,t); and VAB is the Applied Biosystems‟ variability function for calculating the variability of 
the test sample ΔCT statistic. 
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e) Student t-test (one-tailed, unpaired, equal variance) was performed to hypothetically test significance of differences between two groups. It is 
powerful and higher sensitive test when two groups‟ data points are normally distributed. A p-value cutoff 0.05 was selected. P-values less than or 
equal to 0.05 are bold.  
f) Relative expression software tool (REST) developed by Michael W. Pfaffl et al (Pfaffl et al. 2002) was used to perform pair wise fixed reallocation 
randomization test without making any assumptions about distribution while remaining as powerful as other standard tests. A p-value cutoff 0.05 
was selected. P-values less than or equal to 0.05 are bold. 
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5.1 2DE Proteome Analysis and Protein Identification 
 A total of 35 protein spots with significantly changed abundance (p<0.05 and 
q<0.05) were identified by tandem mass spectrometry. Their deregulated fold changes 
were ranging from around 2 to as high as 10
6
. These identified proteins were 
subsequently subjected to bioinformatics. 
 
5.2 Bioinformatics Analysis of Identified Proteins Localizations and Functions 
Cancer cell secretome encompasses a variety of secreted proteins which may aid 
in carcinogenesis. They can be secreted via the signal peptide dependent pathway or the 
non-classical pathway or exosomal bodies. In signal peptide dependent pathway, 
precursor proteins which possess N-terminal signal peptides are directed to endoplasmic 
reticulum (ER). They are subsequently transported to the golgi apparatus for post-
modification and re-assortment. Ultimately, they are transported to the plasma 
membrane surface in golgi-derived vesicles and liberated into the extracellular spaces 
via exocytosis. This pathway is termed as the classical secretory pathway. However, 
some secreted proteins without signal peptides are secreted through a novel flip-flop 
mechanism and direct translocation into the extracellular region (Karagiannis et al. 
2010). In addition, they can also be secreted via exosomes. Exosomal bodies are 
generated by inward budding of the endosomal membrane within large multivesicular 
bodies (MVBs). The fusion of MVBs with the cellular plasma membrane causes the 
liberation of inner exosomal vesicular bodies into the extracellular space (Mathivanan et 
al. 2010). All golgi independent secretory pathway are termed as non-classical secretory 
pathway. Furthermore, shedding of the ectodomain of transmembrane proteins may also 
contribute to the cancer secretome. Therefore, understanding the secretory pathway of 
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the identified proteins or their localization would help us to sort out “bona fide” secreted 
proteins from the identified proteins for further analysis.  
 Thirty-one unduplicated proteins were subjected to in silico analysis to predict 
their localization using signalP 4.0, secretomeP 2.0, TMHMM, Ingenuity Knowledge 
Base, and Exocarta database. Based on the in silico analysis, 12 proteins were predicted 
to possess N-terminal signal peptides and 11 proteins without signal peptides were 
secreted non-classically. Only one protein was predicted to be a trans-membrane protein. 
Based on the Ingenuity Knowledge Base and Exocarta database searching, 11 proteins 
were recognized as extracellular proteins and 26 proteins were secreted via exosomes. 
In conclusion, all the identified proteins were predicted to be secreted proteins. 
 Expression dynamics of the identified proteins were also subjected to Ingenuity 
Pathway Analysis (IPA) for pathway analysis. A top-scored molecular network (refer to 
Figure 4.5) was generated based on the Ingenuity Knowledge Base. This molecular 
network was closely associated with carcinogenesis and was predicted to mediate other 
recognized oncogenic proteins within the molecular network. Identified proteins that 
were located in the extracellular space of the molecular network were LAMB3, LAMA3, 
LGALS7, HDGF, FSTL1, IL1RN, IL1, SPARC, MMP7, TIMP2, and TIMP1. These 
secreted proteins have higher potential to be oral cancer biomarker candidates. 
 
5.3 Transcript Expression Analysis of Selected Altered Proteins  
 Proteins that were potentially secreted, have potential role(s) in carcinogenesis 
and have the greatest change in abundance were selected for RNA transcript expression 
analysis. Although RNA levels do not always correlate with protein levels, it does 
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provide additional information with regards to whether the expression of the protein 
concerned in regulated at the transcript level.  
 During PCR, amount of a gene is theoretically increased twice with each 
successive PCR cycle. In fact, the number of gene is never double exactly in a real PCR 
run due to imperfect amplification efficiencies. Imperfect amplification efficiencies is 
caused by non-optimal PCR running conditions such as Tm of a primer pair, length of 
the amplicon, GC/AT composition of a primer pair, primer pair concentration, template 
concentration, concentration of Mg
2+
, and sample contaminants. The condition may 
vary from one targeted gene sequence to another. In a comparative real time PCR 
experiment, multiple genes and endogenous control genes are run under the same 
condition. This condition is a general optimum condition for all genes but not specific 
for each gene. This may lead to unequal amplification efficiency for all genes. In a 
comparative genes expression analysis, targeted gene expression is calculated by 
normalized with housekeeping gene expression. Unequal amplification efficiency 
between them may leads to inaccurate relative gene expression calculation results. 
Therefore, a RQ corrected calculation approach was introduced in this experiment to 
examine the effect of inequality of amplification efficiency. The results indicated that 
such effect is negligible for all targeted genes and ∆∆Ct based RQ were reliable to 
reflect their true gene differential expression level. 
 The student‟s t-test of qPCR results with assumption of normal sample 
distribution showed that MMP7, hnRNP A2, hnRNP B1, PRDX1, LAMB3, TIMP1, 
IL1RN, S100A8, and SPARC were significantly deregulated. Without any assumption 
of sample distribution pattern, pair wise randomization test showed that only MMP7, 
LAMB3, TIMP1, IL1RN, S100A8, and SPARC transcript were significantly 
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deregulated. However, the student‟s t-test is much more sensitive than the 
randomization test if the sample distribution is normal. It can however, be a valuable 
reference for short listing potential biomarkers candidates. In addition, these proteins 
were implicated in the top-scored molecular network generated by Ingenuity 
Knowledge Base with the exception of hnRNP A2/B1. These proteins with other known 
cancer associated proteins are reviewed in the following section. 
 
5.4 Identified Proteins Known to Have Roles in Carcinogenesis 
Matrix Metalloproteinase VII (MMP-7) and its natural inhibitors, TIMP-1 and 
TIMP-2 have roles in cancer dissemination. Up-regulation of MMPs accompanied by 
down-regulation of their natural inhibitors is the common expression pattern in 
malignant tumors (Egeblad and Werb 2002). The relative expression of MMP-7 and 
TIMP-1 has also been demonstrated in a study of non-small cell lung cancer (NSCLC)  
(Safranek et al. 2007).    
MMP-7 also known as matrilysin which is a member of the MMP family 
proteases was found to be increased in the oral cancer secretome. Its molecular weight 
was estimated to be above 25 kDa (Figure 4.4, spot ID 11) and part of the propeptide 
sequence RFYLYDSETK, and FFGLPITGMLNSRVIEIMQKPRCGVPDVAE were 
also identified (refer to Appendix A, spot ID. 11). Thus, it was likely to be the latent 
form of MMP-7 or pro-MMP-7 (MW 28 kDa, its active form is 19 kDa). Both latent 
and active forms of MMP-7 have been demonstrated to be implicated in colorectal 
cancer patients who had liver metastases (Zeng et al. 2002). Substrates for MMP-7 are 
commonly implicated in oral carcinogenesis and these include CD95/Fas receptor, Fas 
Ligand (FASL), E-cadherin, and heparin-binding epidermal growth factor (Fingleton 
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2006). By mediating these substrate molecules, MMP-7 is able to regulate cancer cell 
apoptosis, angiogenesis, invasion and metastasis. Studies have demonstrated that CD95 
ligand cleavage product of MMP-7 inhibits apoptosis induced by chemotherapeutic 
drugs and breakdown of Fas receptor by MMP-7 reduces apoptosis sensitivity of 
HepG2 cells (Mitsiades et al. 2001; Strand et al. 2004). Moreover, it enables the 
proteolytic release of membrane-anchored HB-EGF which is a potent proangiogenic 
factor thus promoting cell survival and angiogenesis (Handsley and Edwards 2005). 
With a function of protease, it cleaves E-cadherin which is involved in cell-cell 
adhesion to promote cancer cell invasion and trigger the EMT (Egeblad and Werb 2002). 
As a result, MMP-7 is able to perform multiple functions to facilitate cancer metastasis. 
Over-expression of MMP-7 has been reported in a wide variety of cancers 
particularly those of epithelial origin. Miyata et al reported that overexpression of 
MMP-7 was a strong prognostic marker for poor prognosis in patients with renal cell 
carcinoma (Miyata et al. 2006).  Gene expression of MMP-7 was observed to be highly 
up-regulated in the early stage of oral cancer especially the G allele type of MMP-7 
gene (Vairaktaris et al. 2007). Furthermore, a finding demonstrated that over-expression 
of MMP-7 was common in more aggressive OSCC tissues but absent in mild verrucous 
carcinoma tissues (Impola et al. 2004). Real time PCR results indicated that the 
transcript level of MMP-7 was significantly up-regulated for 74-fold. Thus, MMP-7 is a 
good candidate for further investigation as a potential biomarker candidate or a 
therapeutic target. Its potential as a serum biomarker has been substantiated in 
colorectal cancer patients (Maurel et al. 2007). Several MMP inhibitors are emerging as 
a new regime for cancer therapy such as Marimastat which can inhibit a broad spectrum 
of MMPs including MMP-7 and showed a good survival benefit in clinical trials 
(Hidalgo and Eckhardt 2001; Overall and Lopez-Otin 2002).  
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In contrast to the expression of MMP-7, tissue inhibitor metalloproteinase I 
(TIMP-1) was found significantly down-regulated at the mRNA and protein expression 
level in oral cancer cell lines. TIMP-1 has a molecular weight of 28 kDa and 2 N-
glycosylated sites. It can bind to all MMPs reversibly but poorly inhibits MMP-19 and 
several types of membrane-bound MMPs (Baker et al. 2002). Down-regulation of 
TIMP-1 leads to unlocking of MMPs activities which facilitates cancer invasion by 
degradation of the ECM components (Egeblad and Werb 2002). Furthermore, TIMP-1 
down-regulation reduces contact inhibition of cancer growths as well as confers cancer 
cell lines with resistance towards apoptosis (Hojilla et al. 2003).  
Tissue inhibitor of metalloproteinase II (TIMP-2) was significantly increased in 
cancer secretome. However, its transcript level showed insignificant up-regulation. 
TIMP-2 exhibits dual functions in the MMPs inhibition as well as in the activation of 
matrix metalloproteinase II (MMP-2) which is essential for breaking down of the ECM 
and promoting carcinoma invasion to surrounding tissues (Lu et al. 2004). Over-
expression of TIMP-2 is also associated with poor prognosis in invasive bladder cancer 
(Grignon et al. 1996). Furthermore, TIMP-2 has been substantiated as a valuable 
prognostic marker in tumor staging of colorectal cancer (Ring et al. 1997). An 
immunohistochemical study of 30 random tumor tissue samples by Qu et al 
demonstrated that association of TIMP-2 up-regulation with oral squamous cell 
carcinoma (Qu et al. 2006).  
Besides up-regulation of proteases of the MMP family, a protease of the 
cathepsin family, Cathepsin-D was increase in oral cancer cell line secretome but was 
not significantly different in expression at the transcript level. The 52 kDa pro-
cathepsin-D was identified in this study (Figure 4.4, spot ID 2). Secreted pro-cathepsin-
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D can be endocytosed by cancer cells again or by adjacent fibroblasts. It exhibits 
optimum enzyme activity under acidic conditions. The roles of cathepsin-D in 
carcinogenesis are in facilitating metastasis, proliferation and angiogenesis. Because of 
its activation is only accomplished under an acidic environment, it is believed that 
cathepsin-D is devoid of proteolytic functions and rather acts as a secreted binding 
protein during tumorigenesis (Liaudet-Coopman et al. 2006). In a comparative analysis 
between immunohistochemistry and routine histopathology, intense staining of 
cathepsin-D was apparent in oral SCC (Yogesh et al. 2011). Moreover, cathepsin-D was 
also shown to be a potential serum marker in glioma patients and its up-regulation was 
associated with poor prognosis of gliomas (Fukuda et al. 2005).  
Cell dissociation is a key step towards cancer cell invasion and metastasis. 
Components of the ECM - collagens, glycoproteins(eg. Laminin), and proteoglycans - 
form a scaffold to support cells attachment. However, it hinders cell dissociation and 
migration (Egeblad and Werb 2002). Disruption of this structure is necessary for the 
movement of cancer cells. Our results indicated that laminin subunit beta-3 and alpha-3 
were found to be decreased in abundance in the oral cancer secretome suggesting lower 
secretion or breakdown of laminin 5 (Ln-5) in cancer cell lines.  Transcript levels of 
laminin subunit ß3 were also found to be significantly down-regulated. Ln-5 is 
composed of 3 subchains, alpha-3, beta-3, and gamma-2 forming a heterotrimeric 
protein. It plays a role in the formation of the hemidesmosome and helps to attach 
normal basal cells to the basal lamina (Hao et al. 1996). Suppression of Ln-5 subunit γ-
2 in non-invasive OSCC cell lines indicated that subunit γ-2 modulated expression of 
subunit α/ß-3 and augmented cancer cells motility and invasion (Yuen et al. 2005). 
Furthermore, significant down-regulation of Ln-5 has been reported in breast carcinoma 
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and prostate cancer (Hao et al. 1996; Martin et al. 1998). Hence, breakdown of this 
barrier will likely enhance cancer cell migration and invasion to a distant site.  
By contrast, a classical type of extracellular matrix adhesion molecule N-
cadherin was up-regulated in oral cancer cell lines secretome. A cleaved fragment of N-
cadherin which had an estimated molecular weight of 15 kDa ~ 20 kDa was detected in 
the secretome. A switching from E-cadherin to N-cadherin has been found in carcinoma 
cell lines and is responsible for epithelial to mesenchymal transition (Hajra and Fearon 
2002). The switching of E-cadherin to N-cadherin has also been shown to be manifested 
in an immunohistochemical study of oral SCC tissues which showed a greater down-
regulation of E-cadherin in the positive N-cadherin group (Pyo et al. 2007). Moreover, 
Diamond, et al demonstrated that up-regulation of N-cadherin in OSCC cell lines 
facilitated cancer cell motility. They also revealed that loss of regulatory mechanism of 
TGF-β1 which mediated N-cadherin expression led to malignant transformation of the 
oral epithelium (Diamond et al. 2008). As a result, N-cadherin overexpression may be a 
crucial element for EMT progression of oral cancer cells.  
Increased abundance of heterogeneous nuclear ribonucleoprotein A2/B1 
(hnRNP A2/B1) and their corresponding transcripts was observed. Protein hnRNP 
A2/B1 (Figure 4.4, spot ID. 9) was determined as the B1 spliced variant due to the 
unique B1 variants amino acid sequence, TLETVPLER was identified in MS/MS 
analysis (refer to Appendix A, spot ID. 9). However, the variant of spot ID. 5 was not 
determined. Two identified hnRNP A2/B1 spots have lower molecular mass than the 
theoretical mass of A2 (34 kDa) or B1 (37 kDa) variants. A2/B1 pre-mRNA has been 
reported to undergo alternative splicing to produce two novel isoforms known as B1b 
(which exclude exon 9) and A2b (which exclude exon 2 and 9) resulting in the 
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production of smaller isoforms. Losing exon 9 which encodes part of the glycine rich 
domain (GRD) of hnRNP A2/B1 impairs M9 nuclear localization signal, A2b and B1b 
are therefore no longer restricted to the nucleolus and are able to be easily trafficked 
into the cytoplasm (Pollard et al. 1996; Han et al. 2010). Furthermore, all MS/MS- 
identified peptide sequences of hnRNP A2/B1 lie within the N-terminal region and are 
devoid of identified peptides in GRD. Therefore, it was plausible that these novel 
spliced variants of hnRNP A2/B1 in the oral cancer secretome were likely devoid of 
GRD as well.  
Heterogeneous nuclear ribonucleoproteins A2/B1 is a telomeric-bound protein 
which functions in recruiting the enzyme telomerase for maintenance of telomere length 
and thus preventing tumor from entering the senescence phase (Carpenter et al. 2006). 
Hence, it is believed that hnRNP A2/B1 endows cancer cells with eternal life. 
Furthermore, RNAi suppression of hnRNP A2 variant expression in cancer cells has 
been shown to lead to a non-apoptotic pattern of slow-down in cell proliferation. It 
indicated that these hnRNP proteins play a role in cell proliferation (He et al. 2005). In 
addition, several studies showed that both hnRNP proteins were highly up-regulated in 
human lung cancer (Sueoka et al. 1999; Pino et al. 2003; Wu et al. 2003). Thus, over-
expression of hnRNP A2/B1 is believed to play an important role in oral cancer cells 
unlimited proliferation.  
Galectin-7 (Gal-7) and leukocyte elastase inhibitor (LEI) have been implicated 
in programmed cell death or apoptosis. Both were found to be significantly reduced in 
the oral cancer secretome. Down-regulation of these proteins may confer cancer cells 
with anti-apoptotic properties. Apoptosis induced by p53 has been studied by Polyak et 
al. They showed that Gal-7 was one of the highly expressed primary transcripts in 
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transfected p53-expressing cells (Polyak et al. 1997). Gal-7 overexpression has also 
been observed in UV-induced apoptotic keratinocytes implying that Gal-7 is associated 
with the apoptosis process (Bernerd et al. 1999). Proapoptotic functions of Gal-7 are 
triggered through JNK activation and liberation of mitochondrial cytochrome c 
(Kuwabara et al. 2002). Tumor growth suppression effect has been demonstrated in a 
study showing Gal-7-transfected cells growing slower than normal cells in vitro with a 
marked reduction of tumor formation of Gal-7-transfected cells in severe combined 
immunodeficient mice (Ueda et al. 2004). Another apoptosis-related protein, LEI from 
porcine spleen has been investigated by Torriglia et al. They demonstrated that LEI 
underwent post-translational modification and transformed into L-DNase II which is 
activated during apoptosis (Torriglia et al. 1998). As a result, oral cancer cells may be 
able to escape from p53-induced apoptosis by down-regulation of Gal-7 and LEI. 
Peroxiredoxin 1 protein and its transcripts were significantly increased in oral 
cancer secretome. Peroxiredoxin 1 acts as a peroxide scavenger and protein chaperone 
intracellularly. Its fundamental role as a peroxidase shield cancer cells from peroxide 
damage induced by apoptosis but not by other chemotherapeutic agents (Berggren et al. 
2001). Overexpression of peroxiredoxin 1 has been shown to promote prostate tumor 
growth and increased levels of angiogenic proteins within the tumor microenvironment. 
Additionally, it can also stimulate endothelial cell proliferation, migration, and 
differentiation in a toll-like receptor 4- and VEGF-dependent manner (Riddell et al. 
2011). Extracellular peroxiredoxin 1 has been demonstrated to stimulate TLR4- 
dependent secretion of TNF-α and IL-6 which are proinflammatory cytokines 
implicated in the activation of NF-κB in tumor cells (Riddell et al. 2010). 
Overexpression of peroxiredoxin 1 has also been detected in lung cancer and oral cancer 
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specimens and its potential prognostic values were evident (Yanagawa et al. 2000; Kim 
et al. 2008).    
Proliferating cell nuclear antigen (PCNA) was increased in the oral cancer 
secretome but was not significantly different at the transcript level. PCNA is an 
essential component in DNA replication and cell proliferation. In a study of 114 cases at 
the University of Malaya (UM), Zain et al demonstrated that cancerous tissues had a 
higher percentage of PCNA positive nuclei (R.B.Zain et al. 1995). A 36 kDa acidic 
form of PCNA has been reported to be specifically associated with aggressive breast 
tumors. This acidic cancer associated form of PCNA (caPCNA) was resulted from a 
unique posttranslational modification in cancer cells instead of random genetic mutation 
events (Bechtel et al. 1998). A caPCNA antibody has been developed to study its 
potential value as a biomarker (Malkas et al. 2006). However, a current attempt to 
detect caPCNA in sera using ELISA showed that differences between control and 
cancer groups were insignificant (Swaby 2010). Nevertheless, this acidic form of PCNA 
was also detected in this study (Figure 4.4, spot ID 10 & 14). However, differential gene 
expression of PCNA was found to be insignificant and this may attributed by its unique 
posttranslational modification. 
A cancer cell growth promoting agent, hepatoma-derived growth factor (HDGF) 
was also significantly increased in the secretome. HDGF stimulates the proliferation of 
several types of cells such as fibroblasts and endothelial cells and is involved in the 
early stages of organ grow. Its growth promoting properties in lung cancer cells have 
been extensively studied and indicated that shRNA knock-down expression of HDGF 
suppressed anchorage-independent growth and invasion of lung cancer cells (Zhang et 
al. 2006; Meng et al. 2010). The prognostic significance of HDGF has also been 
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explored in pancreatic cancer and early-stage non-small-cell lung cancer (Ren et al. 
2004; Uyama et al. 2006). A more recent study on HDGF expression in oral cancer cells 
demonstrated that HDGF augmented cancer cell proliferation and high nuclear HDGF 
expression was correlated with tumor stage and poor prognostic outcome (Lin et al. 
2012).  
A hydrolyzing enzyme, gamma glutamyl cyclotransferase (GGCT) was found to 
be increased in the oral cancer secretome. GGCT has been implicated in glutathione 
homeostasis where it hydrolyzes the dipeptide γ-gluatmylcysteine into 5-oxoproline and 
cysteine amino acid (Oakley et al. 2008). It has also been shown to be involved in 
cancer proliferation and invasion (Uejima et al. 2011). Over-expression of GGCT has 
previously been detected in a large-scale integration of cancer microarray data (Xu et al. 
2007). Furthermore, a proteomic profiling of breast cancer demonstrated that GGCT 
was up-regulated and correlated with poor clinical outcome. Gromov et al. also 
suggested GGCT as a potential serological marker as GGCT is secreted into 
extracellular space (Gromov et al. 2010). Expression of GGCT has previously been 
detected only in epithelial tumors such as lung, esophagus, stomach, bile duct, and 
uterine cervix cancer (Amano et al. 2012).  
Two isoforms of extracellular cyclophilin A (CypA) was detected to be 
significantly up-regulated in the oral cancer secretome. Expression of Multiple isoforms 
of CypA has been detected in the secretome of irradiated breast cancer cells and was 
shown to be associated with radiosensitivity of cancer cells (Chevalier et al. 2012). The 
CypA isoform identified in our analysis were similar in terms of pI and MW to those 
previously identified in breast cancer  (Chevalier et al. 2012). Expression of CypA has 
been reported to augment cancer cell proliferation through interaction with the CD147 
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receptor which regulates a series of cell proliferation-related biological processes (Li et 
al. 2006). Furthermore, it is involved in the phosphorylation of ERK1/2 in a cell-
dependant manner and stimulates NF-Kß (Bahmed et al. 2012). CypA also renders 
cancer cells more resistant to hypoxia- and cisplatin- induced apoptosis (Choi et al. 
2007). Over-expression of secreted CypA has been observed in pancreatic cancer, liver 
fluke-associated cholangiocarcinoma, neoplastic and HPV-immortalized oral 
keratinocytes (Rey et al. 1999; Li et al. 2006; Obchoei et al. 2011). 
A ~17 kDa fragment of Acidic leucine-rich nuclear phosphoprotein 32 family 
member B (ANP32B) was found to be increased in the oral cancer secretome. The 
expression of this short ANP32B fragment has been reported to be associated with the 
stimulation of apoptosis (Shen et al.). ANP32B is characterized by its amino-terminal 
leucine-rich repeat domain and a carboxyl-terminal region that is enriched with acidic 
amino acid residues (Huyton and Wolberger 2007). It has been reported as a critical 
nuclear protein which is indispensable for cell cycle progression to S phase thus, 
implying that it is required for cancer cell proliferation (Sun et al. 2001). ANP32B has 
been shown to be a marker for poor prognostic outcome in breast cancer (Reilly et al.). 
This protein has also been associated with cellular apoptosis in a subcellular proteomic 
analysis of NSC606985 induced apoptotic acute myeloid leukemia cells (Yu et al. 2007). 
ANP32B has also been shown to be a novel substrate for caspase-3 (Shen et al. 2010). It 
has recently been shown that ANP32B inhibits ATRA-induced leukemic cell 
differentiation through blocking the retinoic acid receptor signaling (Yu et al. 2012).    
Two isoforms of Protein SET were significantly increased in oral cancer 
secretome. Protein spot ID.15 was recognized as isoform 1 of Protein SET (unique 
sequence KKPRPPPALGPEETSASAGLPKK at position 14 - 35 was identified in 
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MS/MS, refer to Appendix A, spot ID. 15) but other isoform of Protein SET (spot ID. 
12) was not determined. Protein SET is a potent antagonist of protein phosphatase 2A 
(PP2A) which is a critical tumor suppressor gene (Li et al. 1996). PP2A is implicated in 
diverse cellular processes including the modulation of the oncogenic signal transduction 
pathway (Schonthal 2001; Westermarck and Hahn 2008). As a result, inhibition of 
PP2A is believed to be associated with tumor formation. A recent study demonstrated 
that shRNA knock-down of Protein SET expression restored PP2A tumor suppressor 
activities culminating in cancer cell apoptosis by reducing Mcl-1 levels via 
dephosphorylation of Akt and cancer cells cytotoxicity. This study also reported that the 
peptide COG449 which mimics the antagonistic effects of Protein SET inhibited in vivo 
growth of Ramos cell non-Hodgkin lymphoma tumor xenografts in SCID mice 
(Christensen et al. 2011). Undoubtedly, Protein SET over-expression has deleterious 
effects on the survival of cancer patients and it has been reported in chronic 
lymphocytic leukemia, non-Hodgkin lymphoma, acute myeloid leukemia, and Wilm‟s 
tumor (Carlson et al. 1998; Christensen et al. 2011; Cristobal et al. 2012). 
Low molecular weight heat shock protein 10 (Hsp10) was significantly 
increased in oral cancer secretome but up-regulation of its mRNA transcript level was 
not significant. Intracellular Hsp10 is invariably localized to the mitochondria and 
constitute the mitochondrial chaperonin complex which is implicated in mitochondrial 
protein folding. However, extracellular Hsp10 which is also known as early pregnant 
factor (EPF) is released from ovaries into the maternal serum within 24 hours after 
fertilization in several mammalian species (Cavanagh 1996; Morton 1998). Intriguingly, 
extracellular Hsp10/EPF exhibits a very distinct role against intracellular Hsp10 which 
is located in mitochondria. Extracellular Hsp10/EPF is able to modulate cancer cell 
proliferation and facilitate evasion of tumor immune surveillance by suppressing T-cell 
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activities (Corrao et al. 2010). Moreover, normal cellular Hsp10 is preferably localized 
in the matrix of mitochondria but Hsp10 reaches higher levels in the cytosol of tumor 
cells. This suggested that accumulation of Hsp10 in the cytosol of tumor cells is the 
incipient course for secretion into the extracellular space via a non-classical pathway 
(Jia et al. 2011). The extracellular Hsp10/EPF has been found in the serum of testicular 
cancer patients (Rolfe et al. 1983). Several findings also demonstrated that 
overexpression of Hsp10 in exocervix cancer, prostate cancer and large bowel cancer 
(Cappello et al. 2003a; Cappello et al. 2003b; Cappello et al. 2005).    
Secreted follistatin like 1 (FSTL1) was detected to be increased significantly in 
the oral cancer secretome. The common role for follistatin or other follistatin like 
proteins is as an antagonist against activin activities. However, FSTL1 harbors only a 
single follistatin domain and has no antagonistic activity against activin (Kreidl et al. 
2009). It is a novel proinflammatory molecule that induces the secretion of IL-1β, TNF-
α, IL6 cytokines and also promotes revascularization in ischemic tissue (Miyamae et al. 
2006; Ouchi et al. 2008). It has been reported to be up-regulated in gliomas and highly 
metastatic prostate cancer but acts as a potential tumor suppressor in ovarian and 
endometrial carcinomas (Trojan et al. 2005; Chan et al. 2009). In addition, a proteomic 
study on the secretome of HepG2 and Hep3B cells demonstrated that FSTL1 is the 
characteristic of mesenchymal Hep3B cells and may be a potential marker for EMT 
(Slany et al.).  
Cofilin-1 (CFL1) and elongation factor 1-delta (EF-1-delta) were increased in 
the oral cancer secretome. CFL1 plays an important role in cytoskeletal organization by 
regulating F-actin depolymerization activities. It has been reported to be associated with 
cancer invasion, intravasation, and chemoresistance (Wang et al. 2006; Yan et al. 2007). 
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A multivariate analysis of 78 samples demonstrated that overexpression of CFL1 
mRNA level was a significant prognosis marker for advanced epithelial ovarian cancer 
in individuals receiving therapy (Nishimura et al. 2011). In the context of the translation 
process, elongation factor 1-delta is an integral part of the elongation factor-1 protein 
complex that regulates the elongation step of protein synthesis by transferring 
aminoacyl-t RNA to the 80S ribosomes. It has been shown that the expression level of 
elongation factor-1 delta was significantly up-regulated in oesophageal carcinoma and 
associated with lymph node metastases, advanced disease stages and poorer prognosis 
(Ogawa et al. 2004). Thus, up-regulation of CFL1 and EF-1-delta may facilitate oral 
cancer tumorigenesis.  
Guanine nucleotide binding protein subunit beta-2-like-1 (GNB2L1) which is 
also known as receptor for activated C kinase 1 (RACK1) was significantly increased in 
oral cancer secretome. This protein is crucial in cancer angiogenesis and anti-apoptosis 
(Berns et al. 2000). Furthermore, it has been reported to promote breast carcinoma 
migration via RhoA pathway and regulation of VEGF/Flt1-mediated cell migration via 
the PI3-K/Akt pathway (Cao et al. 2011; Wang et al. 2011). Its overexpression has also 
been detected in oral squamous cell carcinoma tissues (Wang et al. 2008). 
A decrease of interleukin-1 receptor antagonist protein (IL-1RN) was observed 
in the oral cancer secretome with its mRNA transcript expression was also found to be 
decreased. IL-1RN inhibits the effect of interleukine-1 by competing for its 
corresponding receptor site. IL-1RN has been suggested as a novel therapeutic agent 
which functions by suppressing the effect of interleukin 1 (Lewis et al. 2006). 
Additionally, it has been reported as an antagonist of interleukin 6 which is implicated 
in the differentiation and growth of tumor cells (Jordan et al. 1995; Oka et al. 1996; 
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Reichner et al. 1996). Elaraj et al reported that recombinant IL-1RN significantly 
inhibited the xenograft growth of interleukin-1 producing tumor in athymic nude mice 
(Elaraj et al. 2006). A study with 80 colorectal cancer patients and tissues demonstrated 
that serum IL-1ra may be a potent index to evaluate colorectal cancer progression (Ito 
and Miki 1999). 
Non-glycosylated form of cystatin M (CST6), ~14 kDa was identified to be 
reduced significantly in the secretome of oral cancer. However, its mRNA expression 
was found to be up-regulated. It primarily functions as an endogenous inhibitor of 
lysosomal cysteine proteinases (Turk and Bode 1991).  Additionally, it renders tumor 
cells more resistant to TNF-α induced apoptosis by inhibiting cathepsin B and also 
facilitates cancer invasion (Zhang et al. 2004; Vigneswaran et al. 2005). Down-
regulation of cystatin M was first reported in breast cancer cells and proved to be a 
novel candidate tumor suppressor gene for breast cancer (Sotiropoulou et al. 1997; 
Zhang et al. 2004). Diminishing of cystatin M in invasive breast cancer cells was 
reported to be associated with the losses of the estrogen receptor, progesterone receptor, 
and HER4 (Ko et al. 2010). Followed by such unprecedented finding in breast cancer, 
significantly differential expression of cystatin M in oral carcinoma cell lines was also 
revealed with the use of oligonucloetide arrays (Zacharias et al. 2001).  It was further 
demonstrated that there was up-regulation of cystatin M during progression from 
primary tumor to its advanced stage (Vigneswaran et al. 2003). A study on carcinogenic 
functions of cystatin M in oral cancer showed that siRNA knock-down expression of 
cystatin M in oral cancer cell lines promoted cell proliferation and in vitro invasion 
(Vigneswaran et al. 2006).  
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Most of the calcium Ca
2+
-binding proteins, secreted protein acidic and rich in 
cysteine (SPARC), S100 calcium-binding protein A8 (S100-A8), Reticulocalbin-1 
precursor (RCN-1), and calmodulin-like protein 3 (CALML3) were found to be 
decreased in the oral cancer secretome. Among them, SPARC and S100-A8 mRNA 
transcript showed similar change in expression. SPARC is a secreted glycoprotein 
which plays an important role in developing bones and teeth, cell differentiation, 
migration, and angiogenesis. It has been reported that SPARC inhibits the proliferation 
of normal and cancer cells as well as induces apoptosis of cancer cells (Yiu et al. 2001). 
Low concentrations of S100-A8 promotes cancer cell invasion and increases cell 
proliferation whereas high concentration of S100-A8 exerts proapoptotic effects on 
cancer cells (Ghavami et al. 2008). The exact function of RCN-1 remains unclear 
although it may play a role in normal cell behavior (Fukuda et al. 2007). Hirano et al 
reported that lower expression of RCN-1 rendered non-small lung cancer cells more 
resistant to platinum cisplatin chemotherapy (Hirano et al. 2005). Calmodulin like 
proteins which are specifically expressed in epithelial cells show some similar functions 
as calmodulin. However, it has a ~8-fold lower affinity towards Ca
2+
 than calmodulin. It 
also functions as a specific light chain of human unconventional myosin X, which is 
implicated in cell signaling and cell motility (Rogers and Strehler 2001).  Rogers et al 
has suggested that human calmodulin like protein 3 (CALML3) is aberrantly regulated 
during terminal epithelial cell differentiation resulting in disrupted control of cell 
differentiation and cell immortalization (Rogers et al. 2001). Down-regulation of 
CALML3 was observed in cancer transformed human mammary epithelial cell lines 
induced by Kirsten sarcoma virus as well as in the majority of breast cancer cells 
(Yaswen et al. 1990; Rogers et al. 1999). Down-regulation of CALML3 in our data is 
further substantiated in a study that demonstrated a down-regulation of CALML3 
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expression in oral malignant transformation compared to expression of CALML3 in 
normal oral mucosa (Brooks et al. 2009).  
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6.0 Conclusion 
The secretome of three cancer cell lines (48T, 153T, H400) were profiled using 
2D gel electrophoresis. By comparing 2D gel images of the secretome of cancer and its 
normal counterpart, thirty one proteins were observed to have changed in abundance in 
cancer cells. Proteins which are highly cancer associated and likely secreted were also 
validated in their transcript level. Among these proteins, differential expression of 
MMP-7, hnRNP-A2/B1 spliced variants, PRDX-1, LAMB3 subunit, TIMP-1, IL-1RN, 
S100-A8 and SPARC were found to be consistent and significant in both proteome and 
gene expression analysis. These proteins were known to be associated with cancer 
migration, immortalization, anti-apoptosis, and proliferation by many studies worldwide.  
Early-detection of oral cancer via serological biomarkers is less invasive and 
more accessible. Therefore, discovery of oral cancer serological biomarkers is an 
ultimate goal for a number of researchers. In our study, MMP7, hnRNP-A2/B1 spliced 
variants, PRDX-1, LAMB3 subunit, TIMP-1, IL-1RN, S100-A8 and SPARC were 
detected to have significantly changed in the oral cancer cell lines secretome suggesting 
these proteins may also be secreted into the blood circulatory system. Thus, this work 
has demonstrated the significance of studying the cancer cell line secretome in 
identifying potential biomarker candidates. 
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SPOT ID. 1 
Mascot Search Results 
Protein View 
Match to: CADH2_HUMAN Score: 110 Expect: 1.6e-007 
Cadherin-2 precursor (Neural-cadherin) (N-cadherin) (CD325 antigen)  
(CDw325) - Homo sapiens (Human) 
 
Nominal mass (Mr): 99747; Calculated pI value: 4.64 
NCBI BLAST search of CADH2_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 3% 
 
Matched peptides shown in Bold Black 
 
     1 MCRIAGALRT LLPLLAALLQ ASVEASGEIA LCKTGFPEDV YSAVLSKDVH  
    51 EGQPLLNVKF SNCNGKRKVQ YESSEPADFK VDEDGMVYAV RSFPLSSEHA  
   101 KFLIYAQDKE TQEKWQVAVK LSLKPTLTEE SVKESAEVEE IVFPRQFSKH  
   151 SGHLQRQKRD WVIPPINLPE NSRGPFPQEL VRIRSDRDKN LSLRYSVTGP  
   201 GADQPPTGIF IINPISGQLS VTKPLDREQI ARFHLRAHAV DINGNQVENP  
   251 IDIVINVIDM NDNRPEFLHQ VWNGTVPEGS KPGTYVMTVT AIDADDPNAL  
   301 NGMLRYRIVS QAPSTPSPNM FTINNETGDI ITVAAGLDRE KVQQYTLIIQ  
   351 ATDMEGNPTY GLSNTATAVI TVTDVNDNPP EFTAMTFYGE VPENRVDIIV  
   401 ANLTVTDKDQ PHTPAWNAVY RISGGDPTGR FAIQTDPNSN DGLVTVVKPI  
   451 DFETNRMFVL TVAAENQVPL AKGIQHPPQS TATVSVTVID VNENPYFAPN  
   501 PKIIRQEEGL HAGTMLTTFT AQDPDRYMQQ NIRYTKLSDP ANWLKIDPVN  
   551 GQITTIAVLD RESPNVKNNI YNATFLASDN GIPPMSGTGT LQIYLLDIND  
   601 NAPQVLPQEA ETCETPDPNS INITALDYDI DPNAGPFAFD LPLSPVTIKR  
   651 NWTITRLNGD FAQLNLKIKF LEAGIYEVPI IITDSGNPPK SNISILRVKV  
   701 CQCDSNGDCT DVDRIVGAGL GTGAIIAILL CIIILLILVL MFVVWMKRRD  
   751 KERQAKQLLI DPEDDVRDNI LKYDEEGGGE EDQDYDLSQL QQPDTVEPDA  
   801 IKPVGIRRMD ERPIHAEPQY PVRSAAPHPG DIGDFINEGL KAADNDPTAP  
   851 PYDSLLVFDY EGSGSTAGSL SSLNSSSSGG EQDYDYLNDW GPRFKKLADM  
   901 YGGGDD 
 
Start - End    Observed  Mr(expt) Mr(calc)   Delta  Miss  Sequence 
    92 - 101    1102.51  1101.50  1101.55    -0.05     0  R.SFPLSSEHAK.F   
   102 - 114    1612.75  1611.74  1611.81    -0.07     1  K.FLIYAQDKETQEK.W   
   150 - 156     834.39   833.38   833.43    -0.04     0  K.HSGHLQR.Q  
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SPOT ID. 2 
Mascot Search Results 
Protein View 
Match to: CATD_HUMAN Score: 492 Expect: 1e-045 
Cathepsin D precursor (EC 3.4.23.5) [Contains: Cathepsin D light chain;  
Cathepsin D heavy chain] -  
 
Nominal mass (Mr): 44524; Calculated pI value: 6.10 
NCBI BLAST search of CATD_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 47% 
 
Matched peptides shown in Bold Black 
 
     1 MQPSSLLPLA LCLLAAPASA LVRIPLHKFT SIRRTMSEVG GSVEDLIAKG  
    51 PVSKYSQAVP AVTEGPIPEV LKNYMDAQYY GEIGIGTPPQ CFTVVFDTGS  
   101 SNLWVPSIHC KLLDIACWIH HKYNSDKSST YVKNGTSFDI HYGSGSLSGY  
   151 LSQDTVSVPC QSASSASALG GVKVERQVFG EATKQPGITF IAAKFDGILG  
   201 MAYPRISVNN VLPVFDNLMQ QKLVDQNIFS FYLSRDPDAQ PGGELMLGGT  
   251 DSKYYKGSLS YLNVTRKAYW QVHLDQVEVA SGLTLCKEGC EAIVDTGTSL  
   301 MVGPVDEVRE LQKAIGAVPL IQGEYMIPCE KVSTLPAITL KLGGKGYKLS  
   351 PEDYTLKVSQ AGKTLCLSGF MGMDIPPPSG PLWILGDVFI GRYYTVFDRD  
   401 NNRVGFAEAA RL 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   24 - 33     1211.74  1210.73  1210.72     0.01     1  R.IPLHKFTSIR.R 
   55 - 72     1898.02  1897.01  1897.02    -0.01     0  K.YSQAVPAVTEGPIPEVLK.N 
  177 - 184     879.46   878.45   878.45    -0.00     0  R.QVFGEATK.Q  
  177 - 194    1906.04  1905.03  1905.04    -0.00     1  R.QVFGEATKQPGITFIAAK.F   
  185 - 194    1045.58  1044.58  1044.60    -0.02     0  K.QPGITFIAAK.F   
  195 - 205    1239.63  1238.62  1238.61     0.01     0  K.FDGILGMAYPR.I   
  195 - 205    1255.62  1254.61  1254.61     0.01     0  K.FDGILGMAYPR.I (M)  
  206 - 222    1975.03  1974.02  1974.02    -0.01     0  R.ISVNNVLPVFDNLMQQK.L (M)  
  223 - 235    1601.84  1600.83  1600.82     0.00     0  K.LVDQNIFSFYLSR.D   
  236 - 253    1787.81  1786.80  1786.80    -0.01     0  R.DPDAQPGGELMLGGTDSK.Y  
  268 - 287    2317.11  2316.10  2316.16    -0.05     0  K.AYWQVHLDQVEVASGLTLCK.E (C)  
  288 - 309    2334.09  2333.08  2333.09    -0.01     0  K.EGCEAIVDTGTSLMVGPVDEVR.E (C)  
  288 - 309    2350.10  2349.09  2349.08     0.01     0  K.EGCEAIVDTGTSLMVGPVDEVR.E(C);(M)  
  314 - 331    1989.01  1988.00  1988.01    -0.01     0  K.AIGAVPLIQGEYMIPCEK.V (C)  
  314 - 331    2005.01  2004.00  2004.01    -0.01     0  K.AIGAVPLIQGEYMIPCEK.V (C);(M) 
  349 - 357    1065.55  1064.54  1064.54     0.00     0  K.LSPEDYTLK.V      
  393 - 399     963.46   962.46   962.45     0.01     0  R.YYTVFDR.D      
  393 - 403    1462.68  1461.67  1461.66     0.01     1  R.YYTVFDRDNNR.V      
  404 - 411     820.44   819.43   819.42     0.00     0  R.VGFAEAAR.L      
  404 - 412     933.52   932.52   932.51     0.01     1  R.VGFAEAARL.-      
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SPOT ID. 3 
Mascot Search Results 
Protein View 
Match to: TIMP2_HUMAN Score: 314 Expect: 6.4e-028 
Metalloproteinase inhibitor 2 precursor (TIMP-2) (Tissue inhibitor of 
metalloproteinases 2) (CSC-21 
 
Nominal mass (Mr): 24383; Calculated pI value: 7.45 
NCBI BLAST search of TIMP2_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 32% 
 
Matched peptides shown in Bold Black 
 
     1 MGAAARTLRL ALGLLLLATL LRPADACSCS PVHPQQAFCN ADVVIRAKAV  
    51 SEKEVDSGND IYGNPIKRIQ YEIKQIKMFK GPEKDIEFIY TAPSSAVCGV  
   101 SLDVGGKKEY LIAGKAEGDG KMHITLCDFI VPWDTLSTTQ KKSLNHRYQM  
   151 GCECKITRCP MIPCYISSPD ECLWMDWVTE KNINGHQAKF FACIKRSDGS  
   201 CAWYRGAAPP KQEFLDIEDP  
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   54 - 68     1676.96  1675.95  1675.82     0.13     1  K.EVDSGNDIYGNPIKR.I       
   85 - 107    2328.21  2327.20  2327.14     0.07     0  K.DIEFIYTAPSSAVCGVSLDVGGK.K   
  148 - 155    1075.48  1074.47  1074.39     0.08     0  R.YQMGCECK.I  2 (C)  
  196 - 205    1257.63  1256.62  1256.54     0.09     1  K.RSDGSCAWYR.G  (C)  
  197 - 205    1101.52  1100.51  1100.43     0.08     0  R.SDGSCAWYR.G  (C)  
  206 - 220    1626.93  1625.92  1625.79     0.13     1  R.GAAPPKQEFLDIEDP.-   
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SPOT ID. 4 
Mascot Search Results 
Protein View 
Match to: FSTL1_HUMAN Score: 206 Expect: 4e-017 
Follistatin-related protein 1 precursor (Follistatin-like 1) - Homo sapiens 
(Human) 
 
Nominal mass (Mr): 34963; Calculated pI value: 5.39 
NCBI BLAST search of FSTL1_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 12% 
 
Matched peptides shown in Bold Black 
 
     1 MWKRWLALAL ALVAVAWVRA EEELRSKSKI CANVFCGAGR ECAVTEKGEP  
    51 TCLCIEQCKP HKRPVCGSNG KTYLNHCELH RDACLTGSKI QVDYDGHCKE  
   101 KKSVSPSASP VVCYQSNRDE LRRRIIQWLE AEIIPDGWFS KGSNYSEILD  
   151 KYFKNFDNGD SRLDSSEFLK FVEQNETAIN ITTYPDQENN KLLRGLCVDA  
   201 LIELSDENAD WKLSFQEFLK CLNPSFNPPE KKCALEDETY ADGAETEVDC  
   251 NRCVCACGNW VCTAMTCDGK NQKGAQTQTE EEMTRYVQEL QKHQETAEKT  
   301 KRVSTKEI 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   28 - 40     1439.64  1438.63  1438.68    -0.05     1  K.SKICANVFCGAGR.E  2 (C)     
   30 - 40     1224.52  1223.52  1223.55    -0.04     0  K.ICANVFCGAGR.E  2 (C)  
  221 - 232    1430.66  1429.65  1429.70    -0.05     1  K.CLNPSFNPPEKK.C  (C)  
  286 - 299    1730.80  1729.79  1729.86    -0.07     1  R.YVQELQKHQETAEK.T   
  293 - 299     842.48   841.47   841.39     0.08     0  K.HQETAEK.T   
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SPOT ID. 5 
Mascot Search Results 
Protein View 
Match to: ROA2_HUMAN Score: 57 Expect: 0.029 
Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP A2 / hnRNP B1) - Homo 
sapiens (Human) 
 
Nominal mass (Mr): 37407; Calculated pI value: 8.97 
NCBI BLAST search of ROA2_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 7% 
 
Matched peptides shown in Bold Black 
 
     1 MEKTLETVPL ERKKREKEQF RKLFIGGLSF ETTEESLRNY YEQWGKLTDC  
    51 VVMRDPASKR SRGFGFVTFS SMAEVDAAMA ARPHSIDGRV VEPKRAVARE  
   101 ESGKPGAHVT VKKLFVGGIK EDTEEHHLRD YFEEYGKIDT IEIITDRQSG  
   151 KKRGFGFVTF DDHDPVDKIV LQKYHTINGH NAEVRKALSR QEMQEVQSSR  
   201 SGRGGNFGFG DSRGGGGNFG PGPGSNFRGG SDGYGSGRGF GDGYNGYGGG  
   251 PGGGNFGGSP GYGGGRGGYG GGGPGYGNQG GGYGGGYDNY GGGNYGSGNY  
   301 NDFGNYNQQP SNYGPMKSGN FGGSRNMGGP YGGGNYGPGG SGGSGGYGGR  
   351 SRY 
  
 
 Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
    23 - 38     1798.95  1797.95  1797.91     0.03     0  K.LFIGGLSFETTEESLR.N   
   204 - 213    1013.46  1012.45  1012.44     0.02     0  R.GGNFGFGDSR.G   
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SPOT ID. 6 
Mascot Search Results 
Protein View 
Match to: PRDX1_HUMAN Score: 187 Expect: 3.2e-015 
Peroxiredoxin-1 (EC 1.11.1.15) (Thioredoxin peroxidase 2) (Thioredoxin 
-dependent peroxide reductase 
 
Nominal mass (Mr): 22096; Calculated pI value: 8.27 
NCBI BLAST search of PRDX1_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 23% 
 
Matched peptides shown in Bold Black 
 
     1 MSSGNAKIGH PAPNFKATAV MPDGQFKDIS LSDYKGKYVV FFFYPLDFTF  
    51 VCPTEIIAFS DRAEEFKKLN CQVIGASVDS HFCHLAWVNT PKKQGGLGPM  
   101 NIPLVSDPKR TIAQDYGVLK ADEGISFRGL FIIDDKGILR QITVNDLPVG  
   151 RSVDETLRLV QAFQFTDKHG EVCPAGWKPG SDTIKPDVQK SKEYFSKQK 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   17 - 27     1164.56  1163.55  1163.56    -0.01     0  K.ATAVMPDGQFK.D   
  121 - 128     894.42   893.41   893.42    -0.01     0  K.ADEGISFR.G   
  141 - 151    1211.66  1210.65  1210.67    -0.02     0  R.QITVNDLPVGR.S   
  152 - 158     819.42   818.41   818.41    -0.00     0  R.SVDETLR.L   
  159 - 168    1196.62  1195.61  1195.62    -0.01     0  R.LVQAFQFTDK.H   
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SPOT ID. 7 
Mascot Search Results 
Protein View 
Match to: CH10_HUMAN Score: 121 Expect: 1.3e-008 
10 kDa heat shock protein, mitochondrial (Hsp10) (10 kDa chaperonin) (CPN10) 
(Early-pregnancy facto 
 
Nominal mass (Mr): 10925; Calculated pI value: 8.89 
NCBI BLAST search of CH10_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 40% 
 
Matched peptides shown in Bold Black 
 
     1 MAGQAFRKFL PLFDRVLVER SAAETVTKGG IMLPEKSQGK VLQATVVAVG  
    51 SGSKGKGGEI QPVSVKVGDK VLLPEYGGTK VVLDDKDYFL FRDGDILGKY  
   101 VD 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
    9 - 15      907.52   906.52   906.50     0.02     0  K.FLPLFDR.V   
   29 - 36      860.46   859.45   859.45     0.00     0  K.GGIMLPEK.S  (M) 
   67 - 80     1475.79  1474.79  1474.80    -0.02     1  K.VGDKVLLPEYGGTK.V   
   71 - 80     1076.61  1075.61  1075.59     0.01     0  K.VLLPEYGGTK.V   
   81 - 92     1529.83  1528.82  1528.79     0.03     1  K.VVLDDKDYFLFR.D   
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SPOT ID. 8 
Mascot Search Results 
Match to: AN32B_HUMAN Score: 343 Expect: 8e-031 
Acidic leucine-rich nuclear phosphoprotein 32 family member B (PHAPI2 protein) 
(Silver-stainable pr 
 
Nominal mass (Mr): 28770; Calculated pI value: 3.94 
NCBI BLAST search of AN32B_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 23% 
 
Matched peptides shown in Bold Black 
 
     1 MDMKRRIHLE LRNRTPAAVR ELVLDNCKSN DGKIEGLTAE FVNLEFLSLI  
    51 NVGLISVSNL PKLPKLKKLE LSENRIFGGL DMLAEKLPNL THLNLSGNKL  
   101 KDISTLEPLK KLECLKSLDL FNCEVTNLND YRESVFKLLP QLTYLDGYDR  
   151 EDQEAPDSDA EVDGVDEEEE DEEGEDEEDE DDEDGEEEEF DEEDDEDEDV  
   201 EGDEDDDEVS EEEEEFGLDE EDEDEDEDEE EEEGGKGEKR KRETDDEGED  
   251 D 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
    6 - 12      936.63   935.62   935.57     0.06     1  R.RIHLELR.N   
   76 - 86     1193.69  1192.69  1192.62     0.07     0  R.IFGGLDMLAEK.L   
   87 - 99     1420.88  1419.87  1419.78     0.09     0  K.LPNLTHLNLSGNK.L   
  117 - 132    1973.03  1972.02  1971.90     0.12     0  K.SLDLFNCEVTNLNDYR.E (C) 
  138 - 150    1566.91  1565.90  1565.81     0.09     0  K.LLPQLTYLDGYDR.E   
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SPOT ID. 9 
Mascot Search Results 
Protein View 
Match to: ROA2_HUMAN Score: 92 Expect: 1e-005 
Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP A2 / hnRNP B1) - Homo 
sapiens (Human) 
 
Nominal mass (Mr): 37407; Calculated pI value: 8.97 
NCBI BLAST search of ROA2_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 15% 
 
Matched peptides shown in Bold Black 
 
     1 MEKTLETVPL ERKKREKEQF RKLFIGGLSF ETTEESLRNY YEQWGKLTDC  
    51 VVMRDPASKR SRGFGFVTFS SMAEVDAAMA ARPHSIDGRV VEPKRAVARE  
   101 ESGKPGAHVT VKKLFVGGIK EDTEEHHLRD YFEEYGKIDT IEIITDRQSG  
   151 KKRGFGFVTF DDHDPVDKIV LQKYHTINGH NAEVRKALSR QEMQEVQSSR  
   201 SGRGGNFGFG DSRGGGGNFG PGPGSNFRGG SDGYGSGRGF GDGYNGYGGG  
   251 PGGGNFGGSP GYGGGRGGYG GGGPGYGNQG GGYGGGYDNY GGGNYGSGNY  
   301 NDFGNYNQQP SNYGPMKSGN FGGSRNMGGP YGGGNYGPGG SGGSGGYGGR  
   351 SRY 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
    4 - 12     1057.52  1056.52  1056.58    -0.06     0  K.TLETVPLER.K   
   16 - 21      836.39   835.38   835.42    -0.04     1  R.EKEQFR.K  
  100 - 112    1338.65  1337.65  1337.69    -0.05     0  R.EESGKPGAHVTVK.K   
  100 - 113    1466.74  1465.74  1465.79    -0.05     1  R.EESGKPGAHVTVKK.L   
  138 - 147    1188.60  1187.59  1187.64    -0.05     0  K.IDTIEIITDR.Q   
  187 - 200    1648.75  1647.75  1647.80    -0.05     1  K.ALSRQEMQEVQSSR.S   
  191 - 200    1221.51  1220.50  1220.55    -0.04     0  R.QEMQEVQSSR.S  
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SPOT ID. 10 
Mascot Search Results 
Protein View 
Match to: PCNA_HUMAN Score: 193 Expect: 1.3e-014 
Proliferating cell nuclear antigen (PCNA) (Cyclin) - Homo sapiens (Human) 
 
Nominal mass (Mr): 28750; Calculated pI value: 4.57 
NCBI BLAST search of PCNA_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 20% 
 
Matched peptides shown in Bold Black 
 
     1 MFEARLVQGS ILKKVLEALK DLINEACWDI SSSGVNLQSM DSSHVSLVQL  
    51 TLRSEGFDTY RCDRNLAMGV NLTSMSKILK CAGNEDIITL RAEDNADTLA  
   101 LVFEAPNQEK VSDYEMKLMD LDVEQLGIPE QEYSCVVKMP SGEFARICRD  
   151 LSHIGDAVVI SCAKDGVKFS ASGELGNGNI KLSQTSNVDK EEEAVTIEMN  
   201 EPVQLTFALR YLNFFTKATP LSSTVTLSMS ADVPLVVEYK IADMGHLKYY  
   251 LAPKIEDEEG S 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   54 - 61      974.47   973.46   973.41     0.05     0  R.SEGFDTYR.C   
   81 - 91     1261.69  1260.68  1260.61     0.07     0  K.CAGNEDIITLR.A  (C)  
   92 - 110    2075.10  2074.09  2073.99     0.10     0  R.AEDNADTLALVFEAPNQEK.V   
  139 - 146     910.45   909.44   909.40     0.04     0  K.MPSGEFAR.I  (M)  
  211 - 217     932.54   931.53   931.48     0.05     0  R.YLNFFTK.A   
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SPOT ID. 11 
Mascot Search Results 
Protein View 
Match to: MMP7_HUMAN Score: 359 Expect: 2e-032 
Matrilysin precursor (EC 3.4.24.23) (Pump-1 protease) (Uterine  
metalloproteinase) (Matrix metallopr 
 
Nominal mass (Mr): 29658; Calculated pI value: 7.74 
NCBI BLAST search of MMP7_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 29% 
 
Matched peptides shown in Bold Black 
 
     1 MRLTVLCAVC LLPGSLALPL PQEAGGMSEL QWEQAQDYLK RFYLYDSETK  
    51 NANSLEAKLK EMQKFFGLPI TGMLNSRVIE IMQKPRCGVP DVAEYSLFPN  
   101 SPKWTSKVVT YRIVSYTRDL PHITVDRLVS KALNMWGKEI PLHFRKVVWG  
   151 TADIMIGFAR GAHGDSYPFD GPGNTLAHAF APGTGLGGDA HFDEDERWTD  
   201 GSSLGINFLY AATHELGHSL GMGHSSDPNA VMYPTYGNGD PQNFKLSQDD  
   251 IKGIQKLYGK RSNSRKK 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   41 - 50     1321.66  1320.65  1320.63     0.01     1  K.RFYLYDSETK.N   
   42 - 50     1165.56  1164.56  1164.53     0.02     0  R.FYLYDSETK.N   
   65 - 77     1452.79  1451.79  1451.76     0.03     0  K.FFGLPITGMLNSR.V   
   65 - 77     1468.79  1467.78  1467.75     0.03     0  K.FFGLPITGMLNSR.V (M) 
   78 - 86     1113.67  1112.66  1112.64     0.02     0  R.VIEIMQKPR.C   
   78 - 86     1129.66  1128.65  1128.63     0.02     0  R.VIEIMQKPR.C (M)  
   87 - 103    1879.92  1878.91  1878.88     0.03     0  R.CGVPDVAEYSLFPNSPK.W (C)  
  119 - 127    1065.59  1064.58  1064.56     0.02     0  R.DLPHITVDR.L   
  139 - 145     911.53   910.52   910.50     0.02     0  K.EIPLHFR.K   
  147 - 160    1535.83  1534.82  1534.80     0.02     0  K.VVWGTADIMIGFAR.G      
  147 - 160    1551.82  1550.81  1550.79     0.02     0  K.VVWGTADIMIGFAR.G (M)   
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SPOT ID. 12 
Mascot Search Results 
Protein View 
Match to: SET_HUMAN Score: 378 Expect: 2.5e-034 
Protein SET (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating 
factor I) (TAF-I) (HLA 
 
Nominal mass (Mr): 33469; Calculated pI value: 4.23 
NCBI BLAST search of SET_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 20% 
 
Matched peptides shown in Bold Black 
 
     1 MAPKRQSPLP PQKKKPRPPP ALGPEETSAS AGLPKKGEKE QQEAIEHIDE  
    51 VQNEIDRLNE QASEEILKVE QKYNKLRQPF FQKRSELIAK IPNFWVTTFV  
   101 NHPQVSALLG EEDEEALHYL TRVEVTEFED IKSGYRIDFY FDENPYFENK  
   151 VLSKEFHLNE SGDPSSKSTE IKWKSGKDLT KRSSQTQNKA SRKRQHEEPE  
   201 SFFTWFTDHS DAGADELGEV IKDDIWPNPL QYYLVPDMDD EEGEGEEDDD  
   251 DDEEEEGLED IDEEGDEDEG EEDEDDDEGE EGEEDEGEDD  
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   76 - 83     1063.58  1062.57  1062.60    -0.03     1  K.LRQPFFQK.R   
   78 - 84      950.49   949.48   949.51    -0.03     1  R.QPFFQKR.S   
   84 - 90      816.47   815.46   815.49    -0.02     1  K.RSELIAK.I   
  123 - 132    1208.57  1207.56  1207.60    -0.04     0  R.VEVTEFEDIK.S   
  123 - 136    1671.77  1670.77  1670.82    -0.05     1  R.VEVTEFEDIKSGYR.I   
  137 - 150    1840.76  1839.75  1839.80    -0.05     0  R.IDFYFDENPYFENK.V   
  151 - 167    1873.87  1872.86  1872.92    -0.06     1  K.VLSKEFHLNESGDPSSK.S   
  155 - 167    1446.60  1445.60  1445.64    -0.05     0  K.EFHLNESGDPSSK.S   
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SPOT ID. 13 
Mascot Search Results 
Protein View 
Match to: GBLP_HUMAN Score: 265 Expect: 5.1e-023 
Guanine nucleotide-binding protein subunit beta 2-like 1 (Guanine nucleotide-
binding protein subuni 
 
Nominal mass (Mr): 35055; Calculated pI value: 7.60 
NCBI BLAST search of GBLP_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 23% 
 
Matched peptides shown in Bold Black 
 
     1 MTEQMTLRGT LKGHNGWVTQ IATTPQFPDM ILSASRDKTI IMWKLTRDET  
    51 NYGIPQRALR GHSHFVSDVV ISSDGQFALS GSWDGTLRLW DLTTGTTTRR  
   101 FVGHTKDVLS VAFSSDNRQI VSGSRDKTIK LWNTLGVCKY TVQDESHSEW  
   151 VSCVRFSPNS SNPIIVSCGW DKLVKVWNLA NCKLKTNHIG HTGYLNTVTV  
   201 SPDGSLCASG GKDGQAMLWD LNEGKHLYTL DGGDIINALC FSPNRYWLCA  
   251 ATGPSIKIWD LEGKIIVDEL KQEVISTSSK AEPPQCTSLA WSADGQTLFA  
   301 GYTDNLVRVW QVTIGTR 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   39 - 44      807.40   806.39   806.44    -0.04     0  K.TIIMWK.L  (M) 
   48 - 57     1192.57  1191.57  1191.55     0.01     0  R.DETNYGIPQR.A   
  107 - 118    1309.66  1308.65  1308.63     0.02     0  K.DVLSVAFSSDNR.Q   
  131 - 139    1033.52  1032.52  1032.54    -0.03     0  K.LWNTLGVCK.Y   
  140 - 155    1981.89  1980.89  1980.86     0.02     0  K.YTVQDESHSEWVSCVR.F (C)  
  246 - 257    1309.66  1308.65  1308.65    -0.00     0  R.YWLCAATGPSIK.I   
  246 - 257    1366.69  1365.68  1365.68     0.01     0  R.YWLCAATGPSIK.I (C)  
  309 - 317    1059.61  1058.60  1058.59     0.02     0  R.VWQVTIGTR.-   
    
 
 
 
 
 
 
 
 
 
 Appendix A 
137 
 
SPOT ID. 14 
Mascot Search Results 
Protein View 
Match to: PCNA_HUMAN Score: 125 Expect: 5.1e-009 
Proliferating cell nuclear antigen (PCNA) (Cyclin) - Homo sapiens (Human) 
 
Nominal mass (Mr): 28750; Calculated pI value: 4.57 
NCBI BLAST search of PCNA_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 13% 
 
Matched peptides shown in Bold Black 
 
     1 MFEARLVQGS ILKKVLEALK DLINEACWDI SSSGVNLQSM DSSHVSLVQL  
    51 TLRSEGFDTY RCDRNLAMGV NLTSMSKILK CAGNEDIITL RAEDNADTLA  
   101 LVFEAPNQEK VSDYEMKLMD LDVEQLGIPE QEYSCVVKMP SGEFARICRD  
   151 LSHIGDAVVI SCAKDGVKFS ASGELGNGNI KLSQTSNVDK EEEAVTIEMN  
   201 EPVQLTFALR YLNFFTKATP LSSTVTLSMS ADVPLVVEYK IADMGHLKYY  
   251 LAPKIEDEEG S 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   54 - 61      974.51   973.50   973.41     0.08     0  R.SEGFDTYR.C   
   92 - 110    2075.18  2074.18  2073.99     0.19     0  R.AEDNADTLALVFEAPNQEK.V   
  211 - 217     932.56   931.56   931.48     0.08     0  R.YLNFFTK.A      
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SPOT ID. 15 
Mascot Search Results 
Protein View 
Match to: SET_HUMAN Score: 239 Expect: 2e-020 
Protein SET (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating 
factor I) (TAF-I) (HLA 
 
Nominal mass (Mr): 33469; Calculated pI value: 4.23 
NCBI BLAST search of SET_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 27% 
 
Matched peptides shown in Bold Black 
 
     1 MAPKRQSPLP PQKKKPRPPP ALGPEETSAS AGLPKKGEKE QQEAIEHIDE  
    51 VQNEIDRLNE QASEEILKVE QKYNKLRQPF FQKRSELIAK IPNFWVTTFV  
   101 NHPQVSALLG EEDEEALHYL TRVEVTEFED IKSGYRIDFY FDENPYFENK  
   151 VLSKEFHLNE SGDPSSKSTE IKWKSGKDLT KRSSQTQNKA SRKRQHEEPE  
   201 SFFTWFTDHS DAGADELGEV IKDDIWPNPL QYYLVPDMDD EEGEGEEDDD  
   251 DDEEEEGLED IDEEGDEDEG EEDEDDDEGE EGEEDEGEDD  
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   14 - 35     2228.26  2227.26  2227.23     0.02     1  K.KKPRPPPALGPEETSASAGLPK.K   
   15 - 35     2100.17  2099.16  2099.14     0.02     0  K.KPRPPPALGPEETSASAGLPK.K   
   15 - 36     2228.26  2227.26  2227.23     0.02     1  K.KPRPPPALGPEETSASAGLPKK.G   
   76 - 83     1063.62  1062.61  1062.60     0.01     1  K.LRQPFFQK.R      
   78 - 84      950.53   949.52   949.51     0.01     1  R.QPFFQKR.S   
  123 - 132    1208.62  1207.62  1207.60     0.02     0  R.VEVTEFEDIK.S   
  137 - 150    1840.83  1839.83  1839.80     0.03     0  R.IDFYFDENPYFENK.V   
  155 - 167    1446.66  1445.65  1445.64     0.01     0  K.EFHLNESGDPSSK.S   
  183 - 192    1106.56  1105.56  1105.55     0.01     1  R.SSQTQNKASR.K     
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SPOT ID. 16 
Mascot Search Results 
Protein View 
Match to: UBIQ_HUMAN Score: 211 Expect: 1.3e-017 
Ubiquitin - Homo sapiens (Human) 
 
Nominal mass (Mr): 8560; Calculated pI value: 6.56 
NCBI BLAST search of UBIQ_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 50% 
 
Matched peptides shown in Bold Black 
 
     1 MQIFVKTLTG KTITLEVEPS DTIENVKAKI QDKEGIPPDQ QRLIFAGKQL  
    51 EDGRTLSDYN IQKESTLHLV LRLRGG 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   12 - 27     1787.86  1786.85  1786.92    -0.07     0  K.TITLEVEPSDTIENVK.A   
   30 - 42     1523.72  1522.71  1522.77    -0.06     1  K.IQDKEGIPPDQQR.L   
   34 - 42     1039.49  1038.49  1038.51    -0.02     0  K.EGIPPDQQR.L   
   64 - 72     1067.58  1066.57  1066.61    -0.04     0  K.ESTLHLVLR.L   
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SPOT ID. 17 
Mascot Search Results 
Protein View 
Match to: SSB_HUMAN Score: 279 Expect: 2e-024 
Single-stranded DNA-binding protein, mitochondrial precursor (Mt-SSB) (MtSSB) 
(PWP1-interacting pro 
 
Nominal mass (Mr): 17249; Calculated pI value: 9.59 
NCBI BLAST search of SSB_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 43% 
 
Matched peptides shown in Bold Black 
 
     1 MFRRPVLQVL RQFVRHESET TTSLVLERSL NRVHLLGRVG QDPVLRQVEG  
    51 KNPVTIFSLA TNEMWRSGDS EVYQLGDVSQ KTTWHRISVF RPGLRDVAYQ  
   101 YVKKGSRIYL EGKIDYGEYM DKNNVRRQAT TIIADNIIFL SDQTKEKE 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   39 - 46      883.55   882.54   882.49     0.05     0  R.VGQDPVLR.Q  
   52 - 66     1794.92  1793.91  1793.88     0.03     0  K.NPVTIFSLATNEMWR.S (M)  
   67 - 81     1611.84  1610.83  1610.74     0.09     0  R.SGDSEVYQLGDVSQK.T   
   87 - 95     1044.68  1043.68  1043.62     0.05     0  R.ISVFRPGLR.D       
   96 - 103     985.55   984.54   984.49     0.05     0  R.DVAYQYVK.K      
  114 - 122    1133.54  1132.53  1132.47     0.06     0  K.IDYGEYMDK.N   
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SPOT ID. 18 
Mascot Search Results 
Protein View 
Match to: HDGF_HUMAN Score: 159 Expect: 2e-012 
Hepatoma-derived growth factor (HDGF) (High-mobility group protein 1-like 2) 
(HMG-1L2) - Homo sapie 
 
Nominal mass (Mr): 26772; Calculated pI value: 4.70 
NCBI BLAST search of HDGF_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 27% 
 
Matched peptides shown in Bold Black 
 
     1 MSRSNRQKEY KCGDLVFAKM KGYPHWPARI DEMPEAAVKS TANKYQVFFF  
    51 GTHETAFLGP KDLFPYEESK EKFGKPNKRK GFSEGLWEIE NNPTVKASGY  
   101 QSSQKKSCVE EPEPEPEAAE GDGDKKGNAE GSSDEEGKLV IDEPAKEKNE  
   151 KGALKRRAGD LLEDSPKRPK EAENPEGEEK EAATLEVERP LPMEVEKNST  
   201 PSEPGSGRGP PQEEEEEEDE EEEATKEDAE APGIRDHESL  
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   12 - 21     1127.59  1126.58  1126.55     0.03     1  K.CGDLVFAKMK.G  (M)  
   22 - 29      983.54   982.53   982.48     0.05     0  K.GYPHWPAR.I   
   62 - 70     1127.59  1126.58  1126.52     0.06     0  K.DLFPYEESK.E  
   73 - 79      846.52   845.51   845.49     0.02     1  K.FGKPNKR.K   
   81 - 96     1819.99  1818.98  1818.88     0.10     0  K.GFSEGLWEIENNPTVK.A   
  181 - 197    1941.12  1940.11  1939.99     0.12     0  K.EAATLEVERPLPMEVEK.N   
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SPOT ID. 19 
Mascot Search Results 
Protein View 
Match to: PPIA_HUMAN Score: 439 Expect: 2e-040 
Peptidyl-prolyl cis-trans isomerase A (EC 5.2.1.8) (PPIase A) (Rotamase A) 
(Cyclophilin A) (Cyclosp 
 
Nominal mass (Mr): 18001; Calculated pI value: 7.68 
NCBI BLAST search of PPIA_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 39% 
 
Matched peptides shown in Bold Black 
 
     1 MVNPTVFFDI AVDGEPLGRV SFELFADKVP KTAENFRALS TGEKGFGYKG  
    51 SCFHRIIPGF MCQGGDFTRH NGTGGKSIYG EKFEDENFIL KHTGPGILSM  
   101 ANAGPNTNGS QFFICTAKTE WLDGKHVVFG KVKEGMNIVE AMERFGSRNG  
   151 KTSKKITIAD CGQLE 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   20 - 28     1055.59  1054.58  1054.53     0.05     0  R.VSFELFADK.V       
   20 - 31     1379.82  1378.81  1378.75     0.06     1  R.VSFELFADKVPK.T   
   56 - 69     1598.83  1597.82  1597.74     0.08     0  R.IIPGFMCQGGDFTR.H (C)  
   56 - 69     1614.82  1613.82  1613.73     0.08     0  R.IIPGFMCQGGDFTR.H (C);(M)  
   77 - 91     1832.00  1831.00  1830.90     0.09     1  K.SIYGEKFEDENFILK.H   
   83 - 91     1154.63  1153.62  1153.57     0.05     0  K.FEDENFILK.H   
  132 - 144    1505.82  1504.81  1504.74     0.08     1  K.VKEGMNIVEAMER.F   
  132 - 144    1521.82  1520.81  1520.73     0.08     1  K.VKEGMNIVEAMER.F (M) 
  134 - 144    1278.65  1277.64  1277.57     0.06     0  K.EGMNIVEAMER.F  
  134 - 144    1294.64  1293.63  1293.57     0.06     0  K.EGMNIVEAMER.F (M) 
  155 - 165    1247.69  1246.68  1246.62     0.06     1  K.KITIADCGQLE.- (C)  
  156 - 165    1119.57  1118.56  1118.53     0.03     0  K.ITIADCGQLE.- (C)  
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SPOT ID. 20 
Mascot Search Results 
Protein View 
Match to: COF1_HUMAN Score: 73 Expect: 0.0009 
Cofilin-1 (Cofilin, non-muscle isoform) (18 kDa phosphoprotein) (p18) - Homo 
sapiens (Human) 
 
Nominal mass (Mr): 18491; Calculated pI value: 8.22 
NCBI BLAST search of COF1_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 6% 
 
Matched peptides shown in Bold Black 
 
     1 MASGVAVSDG VIKVFNDMKV RKSSTPEEVK KRKKAVLFCL SEDKKNIILE  
    51 EGKEILVGDV GQTVDDPYAT FVKMLPDKDC RYALYDATYE TKESKKEDLV  
   101 FIFWAPESAP LKSKMIYASS KDAIKKKLTG IKHELQANCY EEVKDRCTLA  
   151 EKLGGSAVIS LEGKPL 
 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   82 - 92     1337.69  1336.69  1336.62     0.07     0  R.YALYDATYETK.E   
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SPOT ID. 21 
Mascot Search Results 
Protein View 
Match to: EF1D_HUMAN Score: 126 Expect: 4e-009 
Elongation factor 1-delta (EF-1-delta) (Antigen NY-CO-4) - Homo sapiens 
(Human) 
 
Nominal mass (Mr): 31103; Calculated pI value: 4.90 
NCBI BLAST search of EF1D_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 28% 
 
Matched peptides shown in Bold Black 
 
     1 MATNFLAHEK IWFDKFKYDD AERRFYEQMN GPVAGASRQE NGASVILRDI  
    51 ARARENIQKS LAGSSGPGAS SGTSGDHGEL VVRIASLEVE NQSLRGVVQE  
   101 LQQAISKLEA RLNVLEKSSP GHRATAPQTQ HVSPMRQVEP PAKKPATPAE  
   151 DDEDDDIDLF GSDNEEEDKE AAQLREERLR QYAEKKAKKP ALVAKSSILL  
   201 DVKPWDDETD MAQLEACVRS IQLDGLVWGA SKLVPVGYGI RKLQIQCVVE  
   251 DDKVGTDLLE EEITKFEEHV QSVDIAAFNK I 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   18 - 24      924.41   923.40   923.41    -0.01     1  K.YDDAERR.F   
   25 - 38     1526.70  1525.69  1525.70    -0.01     0  R.FYEQMNGPVAGASR.Q   
   60 - 83     2185.05  2184.04  2184.04    -0.00     0  K.SLAGSSGPGASSGTSGDHGELVVR.I   
   84 - 95     1358.72  1357.72  1357.72    -0.00     0  R.IASLEVENQSLR.G   
  124 - 136    1423.71  1422.70  1422.70    -0.00     0  R.ATAPQTQHVSPMR.Q   
  233 - 241     973.58   972.57   972.58    -0.01     0  K.LVPVGYGIR.K   
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SPOT ID. 22 
Mascot Search Results 
Protein View 
Match to: CG024_HUMAN Score: 156 Expect: 4e-012 
Uncharacterized protein C7orf24 - Homo sapiens (Human) 
 
Nominal mass (Mr): 20994; Calculated pI value: 5.07 
NCBI BLAST search of CG024_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 25% 
 
Matched peptides shown in Bold Black 
 
     1 MANSGCKDVT GPDEESFLYF AYGSNLLTER IHLRNPSAAF FCVARLQDFK  
    51 LDFGNSQGKT SQTWHGGIAT IFQSPGDEVW GVVWKMNKSN LNSLDEQEGV  
   101 KSGMYVVIEV KVATQEGKEI TCRSYLMTNY ESAPPSPQYK KIICMGAKEN  
   151 GLPLEYQEKL KAIEPNDYTG KVSEEIEDII KKGETQTL 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   35 - 45     1239.61  1238.61  1238.59     0.02     0  R.NPSAAFFCVAR.L (C)  
   46 - 59     1596.82  1595.82  1595.79     0.02     1  R.LQDFKLDFGNSQGK.T   
  149 - 159    1319.66  1318.66  1318.64     0.02     0  K.ENGLPLEYQEK.L 
  172 - 182    1302.65  1301.64  1301.71    -0.07     1  K.VSEEIEDIIKK.G  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix A 
146 
 
SPOT ID. 23 
Mascot Search Results 
Protein View 
Match to: PPIA_HUMAN Score: 116 Expect: 4e-008 
Peptidyl-prolyl cis-trans isomerase A (EC 5.2.1.8) (PPIase A) (Rotamase A) 
(Cyclophilin A) (Cyclosp 
 
Nominal mass (Mr): 18001; Calculated pI value: 7.68 
NCBI BLAST search of PPIA_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 27% 
 
Matched peptides shown in Bold Black 
 
     1 MVNPTVFFDI AVDGEPLGRV SFELFADKVP KTAENFRALS TGEKGFGYKG  
    51 SCFHRIIPGF MCQGGDFTRH NGTGGKSIYG EKFEDENFIL KHTGPGILSM  
   101 ANAGPNTNGS QFFICTAKTE WLDGKHVVFG KVKEGMNIVE AMERFGSRNG  
   151 KTSKKITIAD CGQLE 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   56 - 69     1598.84  1597.83  1597.74     0.09     0  R.IIPGFMCQGGDFTR.H (C)  
   56 - 69     1614.83  1613.82  1613.73     0.09     0  R.IIPGFMCQGGDFTR.H (C);(M)    
   83 - 91     1154.63  1153.63  1153.57     0.06     0  K.FEDENFILK.H     
  134 - 144    1278.68  1277.68  1277.57     0.10     0  K.EGMNIVEAMER.F   
  155 - 165    1247.71  1246.71  1246.62     0.08     1  K.KITIADCGQLE.- (C)  
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SPOT ID. 24 
Mascot Search Results 
Protein View 
Match to: GSTO1_HUMAN Score: 64 Expect: 0.006 
Glutathione transferase omega-1 (EC 2.5.1.18) (GSTO 1-1) - Homo sapiens  
(Human) 
 
Nominal mass (Mr): 27548; Calculated pI value: 6.23 
NCBI BLAST search of GSTO1_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 12% 
 
Matched peptides shown in Bold Black 
 
     1 MSGESARSLG KGSAPPGPVP EGSIRIYSMR FCPFAERTRL VLKAKGIRHE  
    51 VININLKNKP EWFFKKNPFG LVPVLENSQG QLIYESAITC EYLDEAYPGK  
   101 KLLPDDPYEK ACQKMILELF SKVPSLVGSF IRSQNKEDYA GLKEEFRKEF  
   151 TKLEEVLTNK KTTFFGGNSI SMIDYLIWPW FERLEAMKLN ECVDHTPKLK  
   201 LWMAAMKEDP TVSALLTSEK DWQGFLELYL QNSPEACDYG L 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   12 - 25     1320.69  1319.68  1319.68    -0.00     0  K.GSAPPGPVPEGSIR.I   
   31 - 37      869.38   868.38   868.39    -0.01     0  R.FCPFAER.T  
   31 - 37      926.41   925.41   925.41    -0.01     0  R.FCPFAER.T (C) 
  123 - 132    1074.63  1073.62  1073.62    -0.00     0  K.VPSLVGSFIR.S  
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SPOT ID. 25 
Mascot Search Results 
Protein View 
Match to: CYTM_HUMAN Score: 264 Expect: 6.4e-023 
Cystatin-M precursor (Cystatin-6) (Cystatin-E) - Homo sapiens (Human) 
 
Nominal mass (Mr): 16500; Calculated pI value: 8.31 
NCBI BLAST search of CYTM_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 51% 
 
Matched peptides shown in Bold Black 
 
     1 MARSNLPLAL GLALVAFCLL ALPRDARARP QERMVGELRD LSPDDPQVQK  
    51 AAQAAVASYN MGSNSIYYFR DTHIIKAQSQ LVAGIKYFLT MEMGSTDCRK  
   101 TRVTGDHVDL TTCPLAAGAQ QEKLRCDFEV LVVPWQNSSQ LLKHNCVQM 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   34 - 50     1926.87  1925.86  1925.95    -0.09     1  R.MVGELRDLSPDDPQVQK.A   
   34 - 50     1942.86  1941.85  1941.95    -0.09     1  R.MVGELRDLSPDDPQVQK.A (M)  
   51 - 70     2183.93  2182.92  2183.01    -0.09     0  K.AAQAAVASYNMGSNSIYYFR.D   
   87 - 99     1610.60  1609.59  1609.66    -0.07     0  K.YFLTMEMGSTDCR.K (C)  
   87 - 100    1738.68  1737.67  1737.75    -0.08     1  K.YFLTMEMGSTDCRK.T (C) 
  101 - 123    2468.10  2467.10  2467.21    -0.12     1  K.TRVTGDHVDLTTCPLAAGAQQEK.L (C)    
  103 - 123    2210.99  2209.98  2210.06    -0.08     0  R.VTGDHVDLTTCPLAAGAQQEK.L (C) 
  103 - 125    2480.13  2479.12  2479.25    -0.13     1  R.VTGDHVDLTTCPLAAGAQQEKLR.C (C)  
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SPOT ID. 26 
Mascot Search Results 
Protein View 
Match to: ILEU_HUMAN Score: 475 Expect: 5.1e-044 
Leukocyte elastase inhibitor (LEI) (Serpin B1) (Monocyte/neutrophil  
elastase inhibitor) (M/NEI) (EI 
 
Nominal mass (Mr): 42715; Calculated pI value: 5.90 
NCBI BLAST search of ILEU_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 27% 
 
Matched peptides shown in Bold Black 
 
     1 MEQLSSANTR FALDLFLALS ENNPAGNIFI SPFSISSAMA MVFLGTRGNT  
    51 AAQLSKTFHF NTVEEVHSRF QSLNADINKR GASYILKLAN RLYGEKTYNF  
   101 LPEFLVSTQK TYGADLASVD FQHASEDARK TINQWVKGQT EGKIPELLAS  
   151 GMVDNMTKLV LVNAIYFKGN WKDKFMKEAT TNAPFRLNKK DRKTVKMMYQ  
   201 KKKFAYGYIE DLKCRVLELP YQGEELSMVI LLPDDIEDES TGLKKIEEQL  
   251 TLEKLHEWTK PENLDFIEVN VSLPRFKLEE SYTLNSDLAR LGVQDLFNSS  
   301 KADLSGMSGA RDIFISKIVH KSFVEVNEEG TEAAAATAGI ATFCMLMPEE  
   351 NFTADHPFLF FIRHNSSGSI LFLGRFSSP 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   57 - 69     1602.77  1601.77  1601.76     0.01     0  K.TFHFNTVEEVHSR.F   
   70 - 80     1305.69  1304.69  1304.68     0.00     1  R.FQSLNADINKR.G   
   97 - 110    1686.87  1685.86  1685.87    -0.00     0  K.TYNFLPEFLVSTQK.T   
  111 - 129    2052.93  2051.92  2051.92     0.00     0  K.TYGADLASVDFQHASEDAR.K   
  111 - 130    2181.03  2180.02  2180.01     0.01     1  K.TYGADLASVDFQHASEDARK.T   
  178 - 186    1006.49  1005.48  1005.49    -0.00     0  K.EATTNAPFR.L 
  204 - 213    1218.61  1217.60  1217.60     0.00     0  K.FAYGYIEDLK.C   
  276 - 290    1785.90  1784.90  1784.89     0.00     1  R.FKLEESYTLNSDLAR.L 
  364 - 375    1287.68  1286.67  1286.67    -0.00     0  R.HNSSGSILFLGR.F   
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SPOT ID. 27 
Mascot Search Results 
Protein View 
Match to: CALL3_HUMAN Score: 116 Expect: 4e-008 
Calmodulin-like protein 3 (Calmodulin-related protein NB-1) (CaM-like  
protein) (CLP) - Homo sapiens 
 
Nominal mass (Mr): 16880; Calculated pI value: 4.30 
NCBI BLAST search of CALL3_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 11% 
 
Matched peptides shown in Bold Black 
 
     1 MADQLTEEQV TEFKEAFSLF DKDGDGCITT RELGTVMRSL GQNPTEAELR  
    51 DMMSEIDRDG NGTVDFPEFL GMMARKMKDT DNEEEIREAF RVFDKDGNGF  
   101 VSAAELRHVM TRLGEKLSDE EVDEMIRAAD TDGDGQVNYE EFVRVLVSK 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
  128 - 144    1885.80  1884.79  1884.81    -0.02     0  R.AADTDGDGQVNYEEFVR.V   
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SPOT ID. 28 
Mascot Search Results 
Protein View 
Match to: LEG7_HUMAN Score: 534 Expect: 6.4e-050 
Galectin-7 (Gal-7) (HKL-14) (PI7) (p53-induced protein 1) - Homo sapiens  
(Human) 
 
Nominal mass (Mr): 15066; Calculated pI value: 7.03 
NCBI BLAST search of LEG7_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 88% 
 
Matched peptides shown in Bold Black 
 
     1 MSNVPHKSSL PEGIRPGTVL RIRGLVPPNA SRFHVNLLCG EEQGSDAALH  
    51 FNPRLDTSEV VFNSKEQGSW GREERGPGVP FQRGQPFEVL IIASDDGFKA  
   101 VVGDAQYHHF RHRLPLARVR LVEVGGDVQL DSVRIF 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
    8 - 21     1481.87  1480.86  1480.84     0.03     0  K.SSLPEGIRPGTVLR.I  
   22 - 32     1179.63  1178.62  1178.69    -0.07     1  R.IRGLVPPNASR.F   
   24 - 32      910.53   909.52   909.50     0.02     0  R.GLVPPNASR.F       
   33 - 54     2511.22  2510.21  2510.18     0.04     0  R.FHVNLLCGEEQGSDAALHFNPR.L(C)     
   55 - 65     1238.64  1237.63  1237.62     0.01     0  R.LDTSEVVFNSK.E   
   66 - 72      819.39   818.38   818.37     0.01     0  K.EQGSWGR.E   
   66 - 75     1233.59  1232.58  1232.55     0.03     1  K.EQGSWGREER.G   
   73 - 83     1271.67  1270.66  1270.64     0.02     1  R.EERGPGVPFQR.G   
   76 - 83      857.47   856.46   856.46     0.01     0  R.GPGVPFQR.G   
   84 - 99     1735.91  1734.90  1734.88     0.02     0  R.GQPFEVLIIASDDGFK.A   
  100 - 111    1399.71  1398.70  1398.68     0.02     0  K.AVVGDAQYHHFR.H   
  100 - 113    1692.87  1691.86  1691.84     0.03     1  K.AVVGDAQYHHFRHR.L   
  121 - 134    1485.82  1484.81  1484.78     0.03     0  R.LVEVGGDVQLDSVR.I      
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SPOT ID. 29 
Mascot Search Results 
Protein View 
Match to: LAMB3_HUMAN Score: 653 Expect: 8e-062 
Laminin subunit beta-3 precursor (Laminin 5 beta 3) (Laminin B1k chain)  
(Kalinin B1 chain) - Homo s 
 
Nominal mass (Mr): 129489; Calculated pI value: 7.14 
NCBI BLAST search of LAMB3_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 30% 
 
Matched peptides shown in Bold Black 
 
     1 MRPFFLLCFA LPGLLHAQQA CSRGACYPPV GDLLVGRTRF LRASSTCGLT  
    51 KPETYCTQYG EWQMKCCKCD SRQPHNYYSH RVENVASSSG PMRWWQSQND  
   101 VNPVSLQLDL DRRFQLQEVM MEFQGPMPAG MLIERSSDFG KTWRVYQYLA  
   151 ADCTSTFPRV RQGRPQSWQD VRCQSLPQRP NARLNGGKVQ LNLMDLVSGI  
   201 PATQSQKIQE VGEITNLRVN FTRLAPVPQR GYHPPSAYYA VSQLRLQGSC  
   251 FCHGHADRCA PKPGASAGPS TAVQVHDVCV CQHNTAGPNC ERCAPFYNNR  
   301 PWRPAEGQDA HECQRCDCNG HSETCHFDPA VFAASQGAYG GVCDNCRDHT  
   351 EGKNCERCQL HYFRNRRPGA SIQETCISCE CDPDGAVPGA PCDPVTGQCV  
   401 CKEHVQGERC DLCKPGFTGL TYANPQGCHR CDCNILGSRR DMPCDEESGR  
   451 CLCLPNVVGP KCDQCAPYHW KLASGQGCEP CACDPHNSLS PQCNQFTGQC  
   501 PCREGFGGLM CSAAAIRQCP DRTYGDVATG CRACDCDFRG TEGPGCDKAS  
   551 GRCLCRPGLT GPRCDQCQRG YCNRYPVCVA CHPCFQTYDA DLREQALRFG  
   601 RLRNATASLW SGPGLEDRGL ASRILDAKSK IEQIRAVLSS PAVTEQEVAQ  
   651 VASAILSLRR TLQGLQLDLP LEEETLSLPR DLESLDRSFN GLLTMYQRKR  
   701 EQFEKISSAD PSGAFRMLST AYEQSAQAAQ QVSDSSRLLD QLRDSRREAE  
   751 RLVRQAGGGG GTGSPKLVAL RLEMSSLPDL TPTFNKLCGN SRQMACTPIS  
   801 CPGELCPQDN GTACGSRCRG VLPRAGGAFL MAGQVAEQLR GFNAQLQRTR  
   851 QMIRAAEESA SQIQSSAQRL ETQVSASRSQ MEEDVRRTRL LIQQVRDFLT  
   901 DPDTDAATIQ EVSEAVLALW LPTDSATVLQ KMNEIQAIAA RLPNVDLVLS  
   951 QTKQDIARAR RLQAEAEEAR SRAHAVEGQV EDVVGNLRQG TVALQEAQDT  
  1001 MQGTSRSLRL IQDRVAEVQQ VLRPAEKLVT SMTKQLGDFW TRMEELRHQA  
  1051 RQQGAEAVQA QQLAEGASEQ ALSAQEGFER IKQKYAELKD RLGQSSMLGE  
  1101 QGARIQSVKT EAEELFGETM EMMDRMKDME LELLRGSQAI MLRSADLTGL  
  1151 EKRVEQIRDH INGRVLYYAT CK 
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SPOT ID 29, continued 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   73 - 81     1201.65  1200.64  1200.54     0.10     0  R.QPHNYYSHR.V   
  145 - 159    1791.98  1790.97  1790.83     0.14     0  R.VYQYLAADCTSTFPR.V (C)  
  162 - 172    1356.79  1355.78  1355.67     0.11     0  R.QGRPQSWQDVR.C  
  173 - 183    1269.72  1268.71  1268.64     0.07     0  R.CQSLPQRPNAR.L      
  208 - 218    1271.80  1270.79  1270.69     0.10     0  K.IQEVGEITNLR.V   
  231 - 245    1708.97  1707.97  1707.84     0.13     0  R.GYHPPSAYYAVSQLR.L   
  246 - 258    1544.77  1543.76  1543.64     0.12     0  R.LQGSCFCHGHADR.C  2 (C) 
  358 - 364    1023.56  1022.56  1022.48     0.08     0  R.CQLHYFR.N  (C)  
  403 - 409     854.47   853.46   853.40     0.06     0  K.EHVQGER.C   
  504 - 517    1439.80  1438.79  1438.67     0.12     0  R.EGFGGLMCSAAAIR.Q  (C)  
  523 - 532    1099.57  1098.56  1098.48     0.09     0  R.TYGDVATGCR.A  (C)  
  553 - 563    1172.70  1171.69  1171.60     0.10     0  R.CLCRPGLTGPR.C     
  553 - 563    1286.75  1285.74  1285.64     0.10     0  R.CLCRPGLTGPR.C  2 (C)  
  629 - 635     873.58   872.57   872.51     0.06     1  K.SKIEQIR.A      
  681 - 687     847.49   846.48   846.41     0.07     0  R.DLESLDR.S   
  688 - 698    1329.77  1328.76  1328.65     0.11     0  R.SFNGLLTMYQR.K    
  688 - 699    1473.87  1472.87  1472.74     0.12     1  R.SFNGLLTMYQRK.R  (M) 
  706 - 716    1107.64  1106.63  1106.54     0.09     0  K.ISSADPSGAFR.M   
  717 - 737    2258.24  2257.23  2257.03     0.21     0  R.MLSTAYEQSAQAAQQVSDSSR.L   
  772 - 786    1708.97  1707.97  1707.84     0.13     0  R.LEMSSLPDLTPTFNK.L  (M)  
  825 - 840    1618.96  1617.96  1617.83     0.13     0  R.AGGAFLMAGQVAEQLR.G   
  841 - 848     933.57   932.56   932.48     0.08     0  R.GFNAQLQR.T   
  855 - 869    1562.89  1561.88  1561.73     0.14     0  R.AAEESASQIQSSAQR.L   
  879 - 887    1149.63  1148.62  1148.52     0.10     1  R.SQMEEDVRR.T   
  888 - 896    1126.65  1125.65  1125.70    -0.05     1  R.TRLLIQQVR.D   
  890 - 896     869.62   868.61   868.55     0.06     0  R.LLIQQVR.D   
  932 - 941    1116.67  1115.66  1115.58     0.09     0  K.MNEIQAIAAR.L   
  942 - 953    1326.82  1325.81  1325.76     0.05     0  R.LPNVDLVLSQTK.Q   
  962 - 970    1016.59  1015.59  1015.49     0.09     0  R.LQAEAEEAR.S   
  973 - 988    1693.01  1692.00  1691.86     0.14     0  R.AHAVEGQVEDVVGNLR.Q   
 1015 - 1027   1466.95  1465.95  1465.83     0.12     0  R.VAEVQQVLRPAEK.L   
 1092 - 1104   1333.77  1332.77  1332.65     0.12     0  R.LGQSSMLGEQGAR.I  
 1126 - 1135   1277.76  1276.76  1276.65     0.11     1  R.MKDMELELLR.G   
 1126 - 1135   1309.76  1308.75  1308.64     0.11     1  R.MKDMELELLR.G  2 (M)  
 1136 - 1143    875.55   874.54   874.47     0.07     0  R.GSQAIMLR.S   
 1136 - 1143    891.47   890.46   890.46    -0.00     0  R.GSQAIMLR.S  (M) 
 1153 - 1158    800.53   799.52   799.47     0.06     1  K.RVEQIR.D   
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SPOT ID. 30 
Mascot Search Results 
Protein View 
Match to: SPRC_HUMAN Score: 250 Expect: 1.6e-021 
SPARC precursor (Secreted protein acidic and rich in cysteine)  
(Osteonectin) (ON) (Basement-membran 
 
Nominal mass (Mr): 34610; Calculated pI value: 4.73 
NCBI BLAST search of SPRC_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 29% 
 
Matched peptides shown in Bold Black 
 
     1 MRAWIFFLLC LAGRALAAPQ QEALPDETEV VEETVAEVTE VSVGANPVQV  
    51 EVGEFDDGAE ETEEEVVAEN PCQNHHCKHG KVCELDENNT PMCVCQDPTS  
   101 CPAPIGEFEK VCSNDNKTFD SSCHFFATKC TLEGTKKGHK LHLDYIGPCK  
   151 YIPPCLDSEL TEFPLRMRDW LKNVLVTLYE RDEDNNLLTE KQKLRVKKIH  
   201 ENEKRLEAGD HPVELLARDF EKNYNMYIFP VHWQFGQLDQ HPIDGYLSHT  
   251 ELAPLRAPLI PMEHCTTRFF ETCDLDNDKY IALDEWAGCF GIKQKDIDKD  
   301 LVI 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
  118 - 129    1447.59  1446.58  1446.62    -0.04     0  K.TFDSSCHFFATK.C (C)  
  141 - 150    1215.58  1214.58  1214.61    -0.04     0  K.LHLDYIGPCK.Y  (C) 
  151 - 166    1949.92  1948.91  1948.96    -0.05     0  K.YIPPCLDSELTEFPLR.M (C)  
  167 - 172     848.41   847.40   847.44    -0.03     1  R.MRDWLK.N   
  173 - 181    1106.58  1105.57  1105.61    -0.04     0  K.NVLVTLYER.D      
  173 - 191    2278.10  2277.10  2277.15    -0.05     1  K.NVLVTLYERDEDNNLLTEK.Q   
  205 - 218    1575.82  1574.81  1574.85    -0.04     1  K.RLEAGDHPVELLAR.D   
  206 - 218    1419.72  1418.72  1418.75    -0.04     0  R.LEAGDHPVELLAR.D   
  257 - 268    1425.66  1424.65  1424.69    -0.04     0  R.APLIPMEHCTTR.F (C)  
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SPOT ID. 31 
Mascot Search Results 
Protein View 
Match to: TIMP1_HUMAN Score: 270 Expect: 1.6e-023 
Metalloproteinase inhibitor 1 precursor (TIMP-1) (Erythroid-potentiating 
activity) (Chevalier et al.) (Tissue in 
 
Nominal mass (Mr): 23156; Calculated pI value: 8.46 
NCBI BLAST search of TIMP1_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 41% 
 
Matched peptides shown in Bold Black 
 
     1 MAPFEPLASG ILLLLWLIAP SRACTCVPPH PQTAFCNSDL VIRAKFVGTP  
    51 EVNQTTLYQR YEIKMTKMYK GFQALGDAAD IRFVYTPAME SVCGYFHRSH  
   101 NRSEEFLIAG KLQDGLLHIT TCSFVAPWNS LSLAQRRGFT KTYTVGCEEC  
   151 TVFPCLSIPC KLQSGTHCLW TDQLLQGSEK GFQSRHLACL PREPGLCTWQ  
   201 SLRSQIA 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   71 - 82     1233.60  1232.59  1232.61    -0.02     0  K.GFQALGDAADIR.F   
   83 - 98     1963.86  1962.85  1962.88    -0.02     0  R.FVYTPAMESVCGYFHR.S (C) 
   83 - 98     1979.85  1978.85  1978.87    -0.02     0  R.FVYTPAMESVCGYFHR.S (C);(M) 
  142 - 161    2250.05  2249.05  2248.99     0.06     0  K.TYTVGCEECTVFPCLSIPCK.L (C) 
  162 - 180    2201.05  2200.05  2200.06    -0.01     0  K.LQSGTHCLWTDQLLQGSEK.G  (C)  
  186 - 192     866.45   865.44   865.46    -0.02     0  R.HLACLPR.E  (C)  
  193 - 203    1346.64  1345.63  1345.64    -0.02     0  R.EPGLCTWQSLR.S  (C)  
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SPOT ID. 32 
Mascot Search Results 
Protein View 
Match to: S10A8_HUMAN Score: 122 Expect: 1e-008 
Protein S100-A8 (S100 calcium-binding protein A8) (Calgranulin-A) (Migration 
inhibitory factor-rela 
 
Nominal mass (Mr): 10828; Calculated pI value: 6.51 
NCBI BLAST search of S10A8_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 26% 
 
Matched peptides shown in Bold Black 
 
     1 MLTELEKALN SIIDVYHKYS LIKGNFHAVY RDDLKKLLET ECPQYIRKKG  
    51 ADVWFKELDI NTDGAVNFQE FLILVIKMGV AAHKKSHEES HKE 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   24 - 31      963.51   962.51   962.47     0.04     0  K.GNFHAVYR.D   
   24 - 35     1434.78  1433.78  1433.71     0.07     1  K.GNFHAVYRDDLK.K   
   36 - 47     1549.86  1548.85  1548.80     0.05     1  K.KLLETECPQYIR.K (C) 
   37 - 47     1421.76  1420.75  1420.70     0.05     0  K.LLETECPQYIR.K  (C)  
   37 - 48     1549.86  1548.85  1548.80     0.05     1  K.LLETECPQYIRK.K (C)  
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SPOT ID. 33 
Mascot Search Results 
Protein View 
Match to: IL1RA_HUMAN Score: 322 Expect: 1e-028 
Interleukin-1 receptor antagonist protein precursor (IL-1ra) (IRAP) (IL1 
inhibitor) (IL-1RN) (ICIL- 
 
Nominal mass (Mr): 20042; Calculated pI value: 5.83 
NCBI BLAST search of IL1RA_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 30% 
 
Matched peptides shown in Bold Black 
 
     1 MEICRGLRSH LITLLLFLFH SETICRPSGR KSSKMQAFRI WDVNQKTFYL  
    51 RNNQLVAGYL QGPNVNLEEK IDVVPIEPHA LFLGIHGGKM CLSCVKSGDE  
   101 TRLQLEAVNI TDLSENRKQD KRFAFIRSDS GPTTSFESAA CPGWFLCTAM  
   151 EADQPVSLTN MPDEGVMVTK FYFQEDE 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   52 - 70     2100.09  2099.08  2099.06     0.01     0  R.NNQLVAGYLQGPNVNLEEK.I   
   71 - 89     2012.14  2011.13  2011.13     0.00     0  K.IDVVPIEPHALFLGIHGGK.M   
  103 - 117    1714.90  1713.90  1713.89     0.01     0  R.LQLEAVNITDLSENR.K  
  103 - 118    1842.98  1841.98  1841.98    -0.01     1  R.LQLEAVNITDLSENRK.Q   
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SPOT ID. 34 
Mascot Search Results 
Protein View 
Match to: RCN1_HUMAN Score: 571 Expect: 1.3e-053 
Reticulocalbin-1 precursor - Homo sapiens (Human) 
 
Nominal mass (Mr): 38866; Calculated pI value: 4.86 
NCBI BLAST search of RCN1_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 37% 
 
Matched peptides shown in Bold Black 
 
     1 MARGGRGRRL GLALGLLLAL VLAPRVLRAK PTVRKERVVR PDSELGERPP  
    51 EDNQSFQYDH EAFLGKEDSK TFDQLTPDES KERLGKIVDR IDNDGDGFVT  
   101 TEELKTWIKR VQKRYIFDNV AKVWKDYDRD KDDKISWEEY KQATYGYYLG  
   151 NPAEFHDSSD HHTFKKMLPR DERRFKAADL NGDLTATREE FTAFLHPEEF  
   201 EHMKEIVVLE TLEDIDKNGD GFVDQDEYIA DMFSHEENGP EPDWVLSERE  
   251 QFNEFRDLNK DGKLDKDEIR HWILPQDYDH AQAEARHLVY ESDKNKDEKL  
   301 TKEEILENWN MFVGSQATNY GEDLTKNHDE L 
 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
   71 - 83     1565.73  1564.72  1564.74    -0.01     1  K.TFDQLTPDESKER.L   
   87 - 105    2136.03  2135.02  2135.04    -0.02     1  K.IVDRIDNDGDGFVTTEELK.T   
   91 - 105    1652.75  1651.75  1651.76    -0.01     0  R.IDNDGDGFVTTEELK.T   
  114 - 122    1125.59  1124.58  1124.60    -0.01     1  K.RYIFDNVAK.V   
  123 - 129     981.45   980.44   980.47    -0.03     1  K.VWKDYDR.D   
  135 - 141     954.44   953.43   953.45    -0.02     0  K.ISWEEYK.Q   
  177 - 188    1217.60  1216.59  1216.60    -0.01     0  K.AADLNGDLTATR.E   
  189 - 204    2020.90  2019.89  2019.90    -0.01     0  R.EEFTAFLHPEEFEHMK.E   
  189 - 204    2036.90  2035.89  2035.90    -0.00     0  R.EEFTAFLHPEEFEHMK.E (M)  
  250 - 256     969.44   968.43   968.44    -0.00     0  R.EQFNEFR.D   
  250 - 260    1439.67  1438.67  1438.68    -0.02     1  R.EQFNEFRDLNK.D 
  264 - 270     888.46   887.46   887.47    -0.02     1  K.LDKDEIR.H      
  271 - 286    1949.92  1948.92  1948.92    -0.00     0  R.HWILPQDYDHAQAEAR.H   
  287 - 294     990.48   989.47   989.48    -0.01     0  R.HLVYESDK.N   
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SPOT ID. 35 
Mascot Search Results 
Protein View 
Match to: LAMA3_HUMAN Score: 122 Expect: 1e-008 
Laminin subunit alpha-3 precursor (Epiligrin 170 kDa subunit) (E170) (Nicein 
subunit alpha) - Homo  
 
Nominal mass (Mr): 189187; Calculated pI value: 8.41 
NCBI BLAST search of LAMA3_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 2% 
 
Matched peptides shown in Bold Black 
 
     1 MGWLWIFGAA LGQCLGYSSQ QQRVPFLQPP GQSQLQASYV EFRPSQGCSP  
    51 GYYRDHKGLY TGRCVPCNCN GHSNQCQDGS GICVNCQHNT AGEHCERCQE  
   101 GYYGNAVHGS CRACPCPHTN SFATGCVVNG GDVRCSCKAG YTGTQCERCA  
   151 PGYFGNPQKF GGSCQPCSCN SNGQLGSCHP LTGDCINQEP KDSSPAEECD  
   201 DCDSCVMTLL NDLATMGEQL RLVKSQLQGL SASAGLLEQM RHMETQAKDL  
   251 RNQLLNYRSA ISNHGSKIEG LERELTDLNQ EFETLQEKAQ VNSRKAQTLN  
   301 NNVNRATQSA KELDVKIKNV IRNVHILLKQ ISGTDGEGNN VPSGDFSREW  
   351 AEAQRMMREL RNRNFGKHLR EAEADKRESQ LLLNRIRTWQ KTHQGENNGL  
   401 ANSIRDSLNE YEAKLSDLRA RLQEAAAQAK QANGLNQENE RALGAIQRQV  
   451 KEINSLQSDF TKYLTTADSS LLQTNIALQL MEKSQKEYEK LAASLNEARQ  
   501 ELSDKVRELS RSAGKTSLVE EAEKHARSLQ ELAKQLEEIK RNASGDELVR  
   551 CAVDAATAYE NILNAIKAAE DAANRAASAS ESALQTVIKE DLPRKAKTLS  
   601 SNSDKLLNEA KMTQKKLKQE VSPALNNLQQ TLNIVTVQKE VIDTNLTTLR  
   651 DGLHGIQRGD IDAMISSAKS MVRKANDITD EVLDGLNPIQ TDVERIKDTY  
   701 GRTQNEDFKK ALTDADNSVN KLTNKLPDLW RKIESINQQL LPLGNISDNM  
   751 DRIRELIQQA RDAASKVAVP MRFNGKSGVE VRLPNDLEDL KGYTSLSLFL  
   801 QRPNSRENGG TENMFVMYLG NKDASRDYIG MAVVDGQLTC VYNLGDREAE  
   851 LQVDQILTKS ETKEAVMDRV KFQRIYQFAR LNYTKGATSS KPETPGVYDM  
   901 DGRNSNTLLN LDPENVVFYV GGYPPDFKLP SRLSFPPYKG CIELDDLNEN  
   951 VLSLYNFKKT FNLNTTEVEP CRRRKEESDK NYFEGTGYAR VPTQPHAPIP  
  1001 TFGQTIQTTV DRGLLFFAEN GDRFISLNIE DGKLMVRYKL NSELPKERGV  
  1051 GDAINNGRDH SIQIKIGKLQ KRMWINVDVQ NTIIDGEVFD FSTYYLGGIP  
  1101 IAIRERFNIS TPAFRGCMKN LKKTSGVVRL NDTVGVTKKC SEDWKLVRSA  
  1151 SFSRGGQLSF TDLGLPPTDH LQASFGFQTF QPSGILLDHQ TWTRNLQVTL  
  1201 EDGYIELSTS DSGGPIFKSP QTYMDGLLHY VSVISDNSGL RLLIDDQLLR  
  1251 NSKRLKHISS SRQSLRLGGS NFEGCISNVF VQRLSLSPEV LDLTSNSLKR  
  1301 DVSLGGCSLN KPPFLMLLKG STRFNKTKTF RINQLLQDTP VASPRSVKVW  
  1351 QDACSPLPKT QANHGALQFG DIPTSHLLFK LPQELLKPRS QFAVDMQTTS  
  1401 SRGLVFHTGT KNSFMALYLS KGRLVFALGT DGKKLRIKSK EKCNDGKWHT  
  1451 VVFGHDGEKG RLVVDGLRAR EGSLPGNSTI SIRAPVYLGS PPSGKPKSLP  
  1501 TNSFVGCLKN FQLDSKPLYT PSSSFGVSSC LGGPLEKGIY FSEEGGHVVL  
  1551 AHSVLLGPEF KLVFSIRPRS LTGILIHIGS QPGKHLCVYL EAGKVTASMD  
  1601 SGAGGTSTSV TPKQSLCDGQ WHSVAVTIKQ HILHLELDTD SSYTAGQIPF  
  1651 PPASTQEPLH LGGAPANLTT LRIPVWKSFF GCLRNIHVNH IPVPVTEALE  
  1701 VQGPVSLNGC PDQ 
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SPOT ID. 35, continued 
 
 
 Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
 
  991 - 1012    2404.24  2403.23  2403.25    -0.02     0 R.VPTQPHAPIPTFGQTIQTTVDR.G   
 1013 - 1023    1238.61  1237.60  1237.61    -0.01     0  R.GLLFFAENGDR.F   
 1267 - 1283    1883.89  1882.89  1882.90    -0.01     0  R.LGGSNFEGCISNVFVQR.L (C) 
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A representative gel image for each different studied cell lines and primary cultures: 
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